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Voxel-level absorbed dose (VLAD) is rarely calculated for nuclear medicine
(NM) procedures involving unsealed sources or

90 Y

microspheres (YM). The

current standard of practice for absorbed dose calculations in NM utilizes MIRD
S-values, which 1) assume a uniform distribution in organs, 2) do not use patient
specific geometry, and 3) lack a tumor model. VLADs overcome these limitations.
One reason VLADs are not routinely performed is the difficulty in obtaining
accurate absorbed doses in a clinically accept able time. The deterministic gridbased Boltzmann solver (GBBS) was recently applied to radiation oncology where
it was reported as fast and accurate for both megavoltage photons and high dose
rate nuclide-based photon brachytherapy.

This dissertation had two goals. The first was to demonstrate that the
general GBBS code ATTILA™ can be used for VLADs in NM, where primary
photon and electron sources are distributed throughout a patient. The GBBS was
evaluated in voxel-S-value geometries where agreement with Monte Carlo (MC)
in the source voxel was 6% for

90 Y

and

131 I;

v

20% differences were seen for mono-

energetic 10 keV photons in bone. An adaptive tetrahedral mesh (ATM)
generation procedure was developed using information from both the SPECT and
CT for

90 Y

and

131 I

patients. The ATM with increased energy transport cutoffs,

enabled GBBS transport to execute in under 2 ( 90 Y) and 10 minutes ( 131 I). GBBS
absorbed doses to tumors and organs were within 4.5% of MC. Dose v olume
histograms were indistinguishable from MC.

The second goal was to demonstrate VLAD value using 21 YM patients.
Package insert dosimetry was not able to predict mean VLAD tumor absorbed
doses. Partition model had large bias (factor of 0.39) and uncertainty (±128 Gy).
Dose-response curves for hepatocellular carcinoma tumors were generated using
logistic regression. The dose covering 70% of volume (D70) predicted binary
modified RECIST response with an area under the curve of 80.3%. A D70 88 Gy
threshold yielded 89% specificity and 69% sensiti vity.

The GBBS was shown to be fast and accurate, flaws in clinical dosimetry
models were highlighted, and dose-response curves were generated. The
findings in this dissertation support the adoption of VLADs in NM.
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Chapter 1: Introduction
1.1 Purpose Statement

The goal of the research presented in this dissertation is to improve the state of
voxel-level dosimetry for radiopharmaceutical therapies which include
radioimmunotherapy, targeted radionuclide therapy (TRT), peptide receptor radiation
therapy (PRRT), and radioactive microsphere therapies. Microspheres are technically a
sealed source, but in clinical practice they are administered and handled as if they were
an unsealed source; the main difference between the other nuclear medicine (NM)
therapies and 90Y microspheres is that the former are metabolized, whereas
microspheres become mechanically trapped in arterioles. Broadly speaking, this
research focuses on translating methods commonly practiced in radiation oncology,
where voxel-level absorbed doses have been used regularly over the last two decades,
to the nuclear medicine regime, where improvements in emission imaging,
nanotechnology, and targeted drug development, including radiopharmaceuticals,
continue to further the understanding, diagnosis, and control of cancer and other
diseases.

This dissertation addresses several issues for both applying a grid-based
Boltzman solver (GBBS) in the nuclear medicine regime and the value of voxel level
absorbed doses in nuclear medicine. The first part of the research investigates using
the general GBBS code ATTILA™1 for nuclear medicine absorbed dose calculations.
ATTILA was the precursor to the hexahedral-based GBBS Acuros that is used for
1

clinical absorbed dose calculations in radiation oncology.2–10 The GBBS ATTILA, which
has been studied for both high energy sealed source photon brachytherapy11–13 and
megavoltage photon beams12,14 is benchmarked against Monte Carlo in the nuclear
medicine energy regime in the familiar voxel-S-value geometry15. The GBBS is also
applied to patient scans with a relaxation of the geometry matching constraint imposed
during the voxel-S-value study; an adaptive tetrahedral meshing scheme is devised to
use on the patient SPECT/CT’s to generate source, material, and density distribution
inputs to make full scan absorbed dose calculations with the GBBS clinically practical
with regards to calculation time and memory.
An important second goal of the research is to demonstrate the value of voxellevel absorbed doses in the NM regime. Using post-therapy bremsstrahlung SPECT/CT
scans for patients treated with 90Y glass microspheres, this work 1) reports differences
in voxel-level absorbed dose calculations (Monte Carlo, dose kernel, dose kernel with
density scaling, local deposition) in the liver, lung, and at the liver-lung interface; 2)
generates absorbed dose response curves for HCC tumors; 3) quantifies biases and
uncertainties in standard of practice dosimetry models by transforming single
compartment MIRD and three compartment partition model absorbed doses to voxellevel absorbed doses calculated by Monte Carlo.
1.2 Background
1.2.1 Therapeutic Nuclear Medicine

Ionizing radiation has a long history of therapeutic success in medicine for many
diseases16. Shortly after the cyclotron was invented by Ernest Lawrence, unsealed
2

sources (and eventually radiopharmaceuticals) were made available for therapeutic
procedures. In 1936, John Lawrence treated the first patient with an internal emitter: a
patient with polycythemia vera was treated using the beta emitter

32P.17

The first

instance of targeted radionuclide therapy with radioactive iodine in a human was
performed by Seidlin et. al18.; they documented the successful application of
radioactive iodine for treating metastatic adenocarcinoma of the thyroid.18 Today, there
are guidelines and practice parameters in place for administering such unsealed source
therapies that range from alpha and beta emitters for metastatic bone disease to beta
emitters for non-Hodgkins lymphoma19–21.

The Committee on Medical Internal Radiation Dose (MIRD) of the Society of
Nuclear Medicine and Molecular Imaging (SNMMI) has been integral to the
development and implementation of dosimetric aspects of nuclear medicine therapy,
with dedicated pamphlets to aid the nuclear medicine community with collecting image
data, pharmacokinetics, and applying dosimetry models15,22–29. The European
Association of Nuclear Medicine (EANM) also provides dosimetry recommendations
and practice guidelines19,30–41 for several common NM procedures.

Voxel-level absorbed dose calculation methods for nuclear medicine, which
require at least one tomographic emission image, have been around for decades 15,42–
44,

but they have yet to be incorporated into routine clinical practice. There are several

reasons for this, including: reimbursement; referral biases; competing therapies; the
need to acquire tomographic emission scans at multiple time points; lack of dedicated
personnel (equivalent to dosimetrists in radiation oncology); treatment planning tools;
3

inadequate activity quantification and image quality in reconstructed emission images;
and long computation times for Monte Carlo voxel-level absorbed dose calculations.

Figure 1 provides an overview of nuclear medicine absorbed dose and biological
effective dose (BED) calculations45,46. The first objective when calculating voxel-level
absorbed doses is to estimate the activity as a function of space and time: 𝐴(𝑥, 𝑦, 𝑧, 𝑡).
The acquisition process for planning can yield data from multiple time-points, consisting
of various combinations of blood and tissue samples, planar images, and tomographic
images. After spatially registering activity distributions from multiple time-points, the
next step is a temporal integration to yield the total number of disintegrations
∞

(cumulated activity) at each spatial location: 𝑁(𝑥, 𝑦, 𝑧) = ∫0 𝐴(𝑥, 𝑦, 𝑧, 𝑡)𝑑𝑡. This
distribution can then be input into a Monte Carlo dose calculation or convolved with a
point dose kernel to compute absorbed doses15, but accurate radiation transport
methods like Monte Carlo are preferred because they account for the different
materials and densities throughout the patient, as opposed to kernels that are precalculated in a uniform medium.

4

5

Figure 1. A schematic for planning voxel-based absorbed doses or biological
effective doses incorporating dose rate, repair, and radiosensitiviity for TRT.

For planning purposes, the goal is to deliver absorbed doses to tumors while
minimizing toxicity in normal tissues, which are usually kidneys, bone marrow, liver and
lungs in therapeutic nuclear medicine. The physician would prescribe a target tumor
absorbed dose, and then this absorbed dose would be used to determine the amount
of activity to administer for therapy. A similar prescription can be created using the BED
model, which is potentially useful for comparing with external beam radiotherapy
absorbed doses.
1.2.2 Voxel-level Absorbed Dose Calculations

Voxel-level absorbed doses have been used extensively in radiation oncology
for external beam megavoltage photon treatments as well as, sealed source photon
brachytherapy treatments with 192Ir, 125I, 103Pd, and other radionuclides. The current
standard of practice for voxel-level absorbed doses with external photon beams relies
on superposition/convolution methods such as the anisotropic analytical algorithm 47–49
and collapsed cone convolution50. These have limitations stemming from the
approximation of transport imposed by scaling a water or tissue based kernel.
However, there continues to be a need for more accurate calculations as radiation
oncologists attempt to treat smaller targets in low density and interface regions.
Consequently, full radiation transport methods including both Monte Carlo 51 and
GBBS8,52 are being made available for clinical external photon beam calculations.
6

For sealed source brachytherapy, the current standard of practice relies on the
American Association of Physicists in Medicine Task Group 43 formalism53,54 which
parameterizes an absorbed dose kernel from a single source at the center of a sphere
of water. This formalism enables voxel-level absorbed doses, but disregards
boundaries, tissue heterogeneities, and brachytherapy implant applicator materials.
However, the recent introduction of model-based dose calculations in brachytherapy for
clinical absorbed dose calculations is again emphasizing the importance of more
realistic radiation transport in patients for therapeutic procedures55,56. The GBBS2,5
Acuros BrachyVision and advanced collapsed engine ACE Oncentra57 are now
available from vendors for 192Ir sealed source brachytherapy.

Similar to external beam and sealed source brachytherapy there is an on-going
evolution in absorbed dose calculations for nuclear medicine therapy. The current
standard of practice is not patient-specific and utilizes generic S-values for organ-level
absorbed dose estimates58,59. MIRD and other researchers have published voxel-Svalues (dose kernels), but these are approximations to full transport with known
limitations regarding material and tissue heterogeneity. Collapsed cone convolution
methods, common in radiation oncology, were recently implemented for nuclear
medicine60,61, and have improved handling of heterogeneities compared to
conventional published dose kernels. However, there is still a push toward full transport
as witnessed by the many research codes based on Monte Carlo that have been used
to demonstrate the potential of patient-specific voxel-level absorbed doses42–44,62–65.
Unfortunately, Monte Carlo methods are computationally intensive and require much
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computation time to reduce statistical noise inherent to the stochastic process of
tracking/simulating individual particles. However, a potential solution to the
computational time, is to extend the deterministic GBBS that has been shown to be fast
and accurate in external beam and sealed source brachytherapy12,14.

Deterministic solvers of the linear Boltzmann transport equation (LBTE) have
become more practical over the last decade as computers shifted to 64-bit
architectures; this has allowed larger amounts of the phase-space variables (space,
energy, angle) to reside in main memory allowing for more efficient solvers. The
embarrassingly parallel nature of Monte Carlo has also benefitted from multiple cores
and graphical processing units. GBBS is also commonly known as the discreteordinates method in the nuclear engineering field. It directly solves the LBTE for the
steady-state distribution of neutral particles as a function of space, angle, and energy
(i.e. angular flux) and the linear Boltzmann-Fokker-Plank (BFP) equation for the
angular flux of charged particles66,67.

The GBBS ATTILA solves the transport equations in three-dimensions through
discretization of the phase-space variables consisting of energy, angle, and space. The
solution is defined throughout the entire space represented by the problem. Discrete
ordinates differencing is used for discretizing angles. Spatial discretization utilizes
linear discontinuous finite element spatial differencing on an unstructured tetrahedral
mesh, and standard multi-group energy discretization is employed to represent energy.
The scattering sources are represented as a finite number of terms in a spherical
harmonics expansion, which is limited by the number of discrete ordinates. The GBBS
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requires cross-sections to be in a multi-group Legendre form and are obtained through
an external program68–70. As the GBBS refines the phase-space to finer and finer
discretizations, and Monte Carlo simulates an increasing number of particles, the
GBBS and Monte Carlo, in theory, will converge to the same solution.
1.2.3 Radioembolization for hepatocellular carcinoma and metatstatic colorectal
cancers

Liver cancer accounts for 748,000 new cancer cases every year making it the
sixth most common cancer throughout the world71,72. It is almost always fatal, with
survival rates on the order of a few percent; liver cancers are estimated to cause
696,000 deaths per year globally - trailing only the number of deaths from lung
(1,380,000) and stomach (738,000) cancers.72 Consequently, investigations to improve
the efficacy of liver-directed therapies is of the utmost importance for the global
population.
There are many options for treating HCC, as well as, liver metastases from
colorectal cancer73,74. The therapy chosen depends on a multitude of factors, including:
patient stage; previous therapy; institutional resources and preference; and patient
resources and preference. Bland embolization, transarterial chemoembolization,
radioembolization, radiofrequency ablation, sealed source brachytherapy75, stereotactic
body radiation therapy76, proton therapy, kinase inhibition (sorafenib), and others are
treatment options.
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Radioembolization (90Y radiolabeled microspheres) liver-directed therapy is
multidisciplinary, often including personnel from radiation oncology, interventional
radiology, nuclear medicine, and nuclear medicine and radiation physics.77,78 90Y
microspheres are classified as a sealed source used for permanent implantation by the
Nuclear Regulatory Commission,79 but in practice they are handled and delivered
similar to unsealed sources. There are currently two options for

90Y

radioembolization

with microspheres. Resin microspheres (SIR-Spheres®, Sirtex SIR-Spheres Pty Ltd.)
are FDA approved for the treatment of colorectal cancer liver metastases. Glass
microspheres (Therasphere®, Theragenics Corporation) can only be used under a
humanitarian device exemption from the FDA for hepatocellular carcinoma (HCC) - to
treat other diseases in the liver with glass spheres the user’s institutional review board
must approve it. The package insert for glass microspheres

80uses

a simple MIRD style

mean absorbed to the target (segmental, lobar or whole liver) region, whereas the
package insert for resin microspheres details both an empiric body surface area, and a
three compartment partition model approach that separates tumor from non-tumoral
(i.e. normal) liver81. Compared to treatment planning in radiation oncology, these are
very simple absorbed dose calculation methods that only report mean absorbed doses.
HCC has been shown to be radiosensitive, but unfortunately, so is the nontumoral liver74. Radioembolization with 90Y microspheres exploits the fact that HCC
tumors exhibit hypervascularity and receive most of their blood supply from the hepatic
artery, while normal liver parenchyma receives blood supply predominantly from the
portal vein82. This allows an interventional radiologist to guide a catheter from the
femoral artery into the hepatic artery or one of its branches, where the microspheres
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can be slowly released and delivered to the target volume. Such a delivery and
subsequent trapping of microspheres in the arterioles allows a large increase in the
absorbed dose in and around the tumor while minimizing absorbed dose in surrounding
non-tumoral liver tissue.
1.3 Significance and Rationale

The general GBBS code ATTILA™ has not been benchmarked in the voxellevel nuclear medicine energy regime where absorbed dose gradients can change by
orders of magnitude over a few millimeters, compared to smaller gradients found in
sealed source brachytherapy and external beam. Primary electron sources (betas,
auger electrons, internal conversion electrons) are common in nuclear medicine, but
the study of the GBBS for electron transport in patients is limited to partial-coupling
(photon interactions are allowed to generate electrons, but electron interactions are not
allowed generate photons) from megavoltage photon beams with an electron source
component from the linear accelerator head that only affects the absorbed dose near
the patient’s surface. Relative to Monte Carlo transport codes, three-dimensional
electron transport is fairly new to the GBBS83. Consequently, an investigation of the
GBBS ATTILA in a well-known geometry for therapeutic nuclear medicine with relevant
energy spectra and radionuclides is required.

A major driving force behind this research is the realization that biologists and
chemists continue to identify more biomarkers and develop corresponding targeting
agents that can be labeled with a radionuclide. In parallel to these molecular
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developments, advances in detector technologies and reconstruction methods are
improving emission image quality, sensitivity, and resolution; and they are providing
more accurate quantifications84. As a result, the therapeutic options available to nuclear
medicine are likely to increase. Radioimmunotherapy (e.g. monoclonal antibodies),
peptide receptor radionuclide therapy (PRRT), and other receptor-based targeting
agents can be labeled with radionuclides for therapeutic purposes to target thyroid
carcinoma, neuroendocrine tumors, solid tumors, lymphomas, and bone metastases.
153Sm-ethylene

diamine tetramethylene phosphonate (153Sm EDTMP) (Quadramet®,

EUSA Pharma, Inc.) and 89SrCl2 (Metastron™, GE Healthcare) are used to target bone
metastases.85,86 131I-tositumomab (Bexxar®, GlaxoSmithKline) and 90Y-ibritumomab
tiuxetan (Zevalin®, Spectrum Pharmaceuticals, Inc.) are both approved by the FDA for
the treatment of CD20+ transformed non-Hodgkins lymphoma, although BEXXAR was
commercially withdrawn in 2013. The alpha emitter 223RaCl2 (Xofigo™, Bayer
Aktiengesellschaft) has been FDA approved for bone metastases from castrate
resistant prostate cancer.87 131I metaiodobenzylguanidine (MIBG) has been used to
treat neuroblastomas88–90, and PRRT with both 90Y and 177Lu DOTA have been used to
target somatostatin receptors on neuroendocrine tumors91–93. More recently, prostatespecific membrane antigen, which is overexpressed on prostate cancer cells, has been
targeted with peptides labeled with

68Ga

for PET imaging and 177Lu for therapy

purposes.94–96 Given the increasing number of nuclear medicine therapies and
advances in imaging, providing voxel-level absorbed doses and biological effective
doses will be important for properly planning patient treatments and interpreting or
predicting their response to therapy97.
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Therapeutic procedures should strive to be as patient-specific as possible and
utilize the individual patient’s anatomy and biodistribution. The University of Michigan
performed a study using patient-specific 3D imaging with voxel-level absorbed doses
and showed a clear separation in progression free survival based on tumor absorbed
doses for Non-Hodgkins lymphoma patients treated with

131I-tositumomab.98

This

patient-specific approach is the one utilized in radiation oncology, where a patient’s CT
scans are used to plan and calculate absorbed doses. Unfortunately, the current
standard of practice for nuclear medicine absorbed dose calculations is not patient
specific. It utilizes stylized mathematical phantoms to represent patient geometry to
calculate S-values. The ubiquitous S-values (mean absorbed dose to a target region
per unit cumulated activity in a source region) for nuclear medicine organ-level
dosimetry are a result of efforts from individuals associated with the MIRD
Committee.99 These S-values were calculated primarily for occupational and
diagnostic safety purposes, not therapeutic procedures.

In practice, treatment planning for nuclear medicine consists of 1) an empirical
one-size-fits-all activity prescription (e.g. 200 mCi Na131I), 2) prescribing activity based
on body surface area, or 3) prescribing activity based on patient mass. These
prescription methods have the advantage of simplicity, but they fail to tailor therapies
for individual patients. In practice, the S-values are routinely used for determining
patient absorbed doses from therapy as well.58 However, S-values have the following
known limitations: 1) they assume a uniform distribution of activity throughout an organ
and thus only report the mean absorbed dose to organs; 2) they are not patient-specific
because they are based on a stylized phantom; and 3) they do not include a tumor
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model consistent with the patient geometry, but simple spherical tumor models for nonpenetrating radiations are available. Figure 2 shows the progression of phantoms over
the years from quadric surfaces100 to the recent non-uniform rational B-splines
(NURBS)

101,102,

but even the advanced NURBS phantoms fail to capture variations in

an individual patient as shown on a coronal slice of the SPECT/CT from a patient
treated with 153Sm-EDTMP for metastatic breast cancer osteosarcoma.

(a)

(b)

(c)

Figure 2 Virtual Phantoms and an individual patient. Early S-values were
calculated using patient geometry defined with quadric surfaces (a), while newer
ones have used non-uniform rational B-splines (NURBS) (b). Although the level
of realism is improved with NURBS, it is still not patient-specific as shown by the
coronal SPECT/CT image (c). The quadric surfaces and NURBS image are from
research originally published in JNM. Stabin. Uncertainties in internal dose
calculations for radiopharmaceuticals. J Nucl Med. 2008; 49: 853-860. © by the
Society of Nuclear Medicine and Molecular Imaging, Inc. The clinical SPECT/CT
image (c) was provided courtesy of William D. Erwin at MD Anderson Cancer
Center, Houston, TX.
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1.4 Hypothesis and Aims
1.4.1 Central Hypothesis

The central hypothesis of this dissertation is that a deterministic grid-based
Boltzmann solver can calculate voxel-level absorbed doses for nuclear medicine
applications within 5% of Monte Carlo.

1.4.2 Specific Aim 1

Benchmark GBBS against MC calculations of voxel-level absorbed doses for the
nuclear medicine regime.
Rationale: The GBBS has been studied for megavoltage photon beams and high
energy sealed source photons. Partial coupling has been investigated for external
beam where absorbed dose was scored. For sealed source brachytherapy, only photon
transport was considered and KERMA was reported, not absorbed dose. There is a
gap in knowledge using the GBBS for voxel-level absorbed doses in the nuclear
medicine energy regime. Thus, this aim quantifies the differences between GBBS and
Monte Carlo. Several studies have shown that differences between modern Monte
Carlo radiation transport codes are on the order of a few to ten percent when
comparing electron and photon sources, with electron sources yielding larger
differences relative to photons.103–108 The differences between GBBS and Monte Carlo
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are contextualized by comparing them with the magnitude of differences encountered
among Monte Carlo generated voxel-S-values in the literature.
1.4.3 Specific Aim 2

Extend the GBBS to voxel-level absorbed dose calculations on clinical data and
show GBBS is comparable to MC.
Rationale: The low-level benchmarking of the GBBS against MC in voxel-Svalue geometry required numerous (>= 6) tetrahedrons per voxel. This is an inefficient
use of the spatial discretization used by the GBBS, and forcing tetrahedrons to match
voxels unnecessarily increases the computational burden for the GBBS. Thus, in this
aim we show that fast and accurate absorbed dose can be calculated by executing the
GBBS with an adaptive tetrahedral mesh derived from the patient’s emission and
transmission scans, while also adjusting the transport cut off energy and the angular
quadrature order (number of angles).
1.4.4 Specific Aim 3

Retrospectively assess the value of voxel-level absorbed dose calculations for
90Y

microsphere patients.
Rationale: Dosimetry models currently used in the clinic (empirical body surface

area (BSA), single compartment MIRD (STD), three compartment partition model (PM))
have serious limitations. Voxel-level dosimetry overcomes some of these limitations,
but interpretation of voxel-level absorbed doses requires care. Using a UT MD
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Anderson Cancer Center institutional review board approved retrospective analysis
(“Improved radiation absorbed dose estimates for tumor and normal liver tissues
following trans-hepatic arterial radioembolic therapy using patient-specific liver volumes
and tumor-to-normal liver uptake ratios”, DR09-0025, PI:SCK), we investigated the
following to demonstrate the value of voxel-level dosimetry: 1) limitations, biases, and
variability in current clinical dosimetry models; 2) differences in voxel-level absorbed
dose methods and the effect of spatial resolution; and 3) modeling of tumor response
using voxel-level dosimetry. Finally, it is important to recognize that although voxellevel dosimetry is theoretically technically superior, the vast majority of clinical data to
date has been reported using STD or PM; as a result great care must be taken to
ensure the community can properly use voxel-level dosimetry to improve or maintain
outcomes, and not produce worse clinical results. Understanding the best ways to use
new methods takes time109.

1.5 Organization

The main body of this dissertation consists of five chapters. Each chapter is
written in manuscript form and includes the following five sections: introduction,
methods and materials, results, discussion, and conclusion. Chapter two specifically
addresses specific aim 1. It is a low-level benchmarking of the GBBS in the nuclear
medicine energy regime using voxel-S-value geometry in multiple materials and an
interface. The tetrahedrons used by the GBBS are not allowed to cross voxel
boundaries defined by Monte Carlo, and groupings of tetrahedrons are used to create
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regions corresponding to the voxel geometry used by Monte Carlo. This approach
ensures that differences between GBBS and Monte Carlo are not due to source,
material, or scoring geometry. Previous comparisons of the GBBS with Monte Carlo for
medical physics applications have relied heavily on gamma index analysis 110, which
combines distance to agreement and dose differences. Given the large absorbed dose
gradients in nuclear medicine, distance to agreement will cause most of the gamma
indices to pass, and thus will not be a discriminating metric. A more rigorous voxel-tovoxel matched geometry allows quantitative comparisons using percent difference
relative to Monte Carlo and other published voxel-S-values. Differences between the
GBBS and Monte Carlo are contextualized by comparing them with the magnitude of
differences encountered among other published voxel-S-values in the
literature15,103,104,111. Furthermore, multiple discretizations of the phase-space variables
were carried out to show that the GBBS was converged in phase-space variables in
and around the source voxel.

Specific aim 2 is detailed in chapter three, which extends the GBBS to clinical
patient SPECT/CT datasets and shows that fast and accurate, relative to Monte Carlo,
absorbed dose calculations are possible. Maintaining the geometry matching
performed in specific aim 1 would result in at least six tetrahedrons per voxel. Such
matching is not practical for a patient scan and the GBBS ATTILA, with its use of
unstructured tetrahedrons and linear discontinuous finite element method, was not
designed for such a grid. To reduce the number of spatial elements to make
computations clinically practical (memory- and speed-wise) the geometry matching is
relaxed. This is accomplished by generating adaptive tetrahedral meshes based on
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both the SPECT and CT. The methodology presented is readily extended to other
radiopharmaceutical scans for generating such meshes by incorporating the activity,
material, and material gradients. The accuracy, relative to Monte Carlo, and calculation
times are recorded for different number of outer iterations, angular quadrature orders,
and increasing the transport energy cutoffs for electrons.

Specific aim 3 is spread throughout chapters 4, 5, and 6. In chapter 4, clinical
dosimetry models used for glass microspheres (single compartment MIRD and three
compartment partition model MIRD) are compared with voxel-level Monte Carlo
absorbed doses for post-therapy 90Y bremsstrahlung imaging. The partition model
requires a tumor-to-normal ratio (TNR) for the absorbed dose calculation; a portion of
this chapter quantifies the variability in TNR and tumor and non-tumoral (i.e. normal )
liver doses when using a single sphere to estimate the normal uptake. Linear
regressions are performed to show the mean voxel-level absorbed to tumor or normal
liver as a function of the single compartment or three compartment dosimetry models.
A propagation of errors is also included to estimate the uncertainty in absorbed doses
using the clinical dosimetry models. It should be noted that MC calculations and not
GBBS calculations were performed in specific aim 3. However, the results from specific
aims one and two demonstrate that we expect to find similar results when using either
MC or GBBS for 90Y microspheres.

The fifth chapter investigates multiple voxel-level absorbed dose calculation
methods using post-therapy 90Y bremsstrahlung images. This is an important study
because there are many different implementations of voxel-level dosimetry for 90Y
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microspheres. Monte Carlo, soft tissue kernel, soft tissue kernel with density correction,
and local deposition are all investigated in the liver, lung, and at the liver-lung interface.
As the field moves toward voxel-level dosimetry, this work 1) highlights the issue of
using a simple soft tissue kernel without density correction in the lung; and 2) shows
sensitivity of reported lung absorbed doses to segmentation given the spatial resolution
limitations of emission imaging. A simple simulation study is also performed that
examines the accuracy of the different methods at the liver-lung interface for multiple
lung shunt fractions and spatial resolutions.

In chapter 6, absorbed dose response is investigated for HCC tumors. An
interventional radiologist analyzed patient follow-up imaging data for tumor response
using RECIST, WHO, and modified RECIST criteria. Tumors were classified as
complete response, partial response, stable disease, or progressive disease; and these
were grouped into responders (complete response & partial response) and nonresponders (stable disease & progressive disease). Absorbed doses were calculated
with Monte Carlo and transformed to biological effective dose. Logistic regression was
then performed to generate response probability curves as a function of various dose
volume histogram quantities for both absorbed dose and biological effective dose.
Finally, the last chapter is a summary and discussion of the work performed for
this dissertation. It also provides future research opportunities for the GBBS and voxellevel absorbed dose calculations for 90Y microspheres and other nuclear medicine
therapies.
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Chapter 2: Evaluation of a deterministic Grid-Based Boltzmann Solver (GBBS) for
voxel-level absorbed dose calculations in nuclear medicine.
2.1 Introduction
Voxel-based dosimetry models (VBDM) are the norm in radiation oncology
practice where external beam and sealed source brachytherapy procedures are
performed. Several nuclear medicine researchers have implemented their own
VBDM,42–44,112–117 but unfortunately such VBDM are not widely used within nuclear
medicine departments. Nuclear medicine instead continues to rely on anthropomorphic
phantoms that are not patient-specific, assume uniform activity distributions throughout
organs, and do not include tumor models,118 although some have added simple tumor
models. 58,64,65 Studies have shown that VBDMs, sometimes coupled with
radiobiological modeling, operating on patient-specific anatomy including tumors
improves treatment planning and refines predictions of response and toxicities. 98,119–121
Implementation of VBDMs in therapeutic nuclear medicine range from simplified
complete local absorption/deposition models for 90Y,122,123 voxel dose
kernels,15,104,111,112,122,123 and collapsed-cone convolution60 to solutions of the fully
coupled transport equations for electrons, positrons, and photons. 42–44,122,124 Solutions to
the linear Boltzmann transport equation (LBTE) have traditionally been obtained
stochastically through Monte Carlo (MC) techniques, however deterministic methods
also exist to solve the LBTE.125
Deterministic solvers of the LBTE are relatively new to the radiotherapy
community. Only recently have grid-based Boltzmann solvers (GBBS) been adapted for
clinical use in external photon beams and

192Ir
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sealed source brachytherapy,5–14,52 and

have been investigated for use in magnetic fields.126 ATTILA® (Varian Medical
Systems, Palo Alto, CA) is a general purpose GBBS code, and it has been investigated
for applications to megavoltage photon beams and high energy sealed source gamma
emitters (137Cs, 192Ir).11–14 It has not been studied for nuclear medicine applications of
unsealed sources where electron sources (beta, auger, and internal conversion
electrons) are responsible for most of the energy deposition, and gamma-ray and x-ray
sources are common. When compared to external beam and sealed source
brachytherapy, unsealed sources produce absorbed doses with much larger gradients
and increased heterogeneity. It is important to evaluate the GBBS at the lower (relative
to external beam) energies found in nuclear medicine to ensure that its transport and
cross sections are sufficient for unsealed source voxel-level dosimetry.
The goal of this investigation was to perform a low-level evaluation of the GBBS
ATTILA for voxel-level dosimetry in clinical nuclear medicine. To accomplish this, MC
voxel-S-values were calculated with DOSXYZnrc and benchmarked against published
tabulations of voxel-S-values. It should be noted that MC is often taken as the gold
standard in medical physics radiation transport calculations; then, taking MC as truth,
absorbed dose distributions estimated using the GBBS were compared to those from
MC in the nuclear medicine energy regime for photons and electrons in the following
configurations: 1) the well-studied single source voxel (voxel-S-values) in uniform soft
tissue, bone, and lung; and 2) a single source voxel at the interface of materials (lung
 soft tissue, soft tissue  lung, bone  soft tissue, and soft tissue  bone).
Our goal was not to calculate voxel-S-values with the GBBS for clinical use, but
rather to use voxel-S-values as a benchmark for GBBS in the therapeutic nuclear
medicine regime. The use of voxel-S-values allows us to match source and scoring
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geometry and materials exactly and perform quantitative comparisons with published
data. We want to emphasize this is a difficult transport problem with very large
gradients, and it does not represent a true in-vivo clinical activity distribution acquired
via PET or SPECT. However, voxel-S-values are well known in the nuclear medicine
community and, most importantly, they have been tabulated by several authors using
modern radiation transport codes. Given that voxel-S-values are well known and
quantitative comparisons are possible due to tabulation, we chose to perform a lowlevel benchmarking of the GBBS against MC using the voxel-S-value geometry to
elucidate potential differences between GBBS and other modern radiation transport
codes for therapeutic nuclear medicine. This work represents the first step in
demonstrating the potential value of GBBS for absorbed dose calculations in nuclear
medicine.
2.2 Materials and Methods
2.2.1. DOSXYZnrc Monte Carlo Simulations
MC was used as the gold standard for comparisons with the GBBS code. MC
simulations were performed using DOSXYZnrc127 which is a user code of EGSnrc
(version 4.2.4.0).128 EGSnrc is a general purpose radiation transport code with
improved low energy support compared with EGS4,129 and DOSXYZnrc allows scoring
in the familiar Cartesian voxel geometry ubiquitous in medical imaging.
The simulation geometry employed was the 3 mm voxel-S-value geometry found
in MIRD Report 17.15 Briefly, this phantom geometry consisted of a three-dimensional
infinite distribution of soft tissue discretized into 3 mm isotropic voxels, where the
center voxel was uniformly filled with activity. The absorbed dose to each target voxel
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from the source voxel was then reported as a function of radial distance; source voxel
center to target voxel center was defined as a radial distance 𝑟𝑖 =
√(Δ ⋅ 𝑖 ′ )2 + (Δ ⋅ 𝑗 ′ )2 + (Δ ⋅ 𝑘 ′ )2, where Δ = 3 mm and 𝑖 ′ , 𝑗 ′ , 𝑘′ represent 0-based indices
relative to the source voxel.
Radionuclide spectra were obtained from RADTABS software.130 Independent
simulations were performed for the following emission components: 1) photons: gamma
and x-ray; 2) continuous beta spectra (β− ); and 3) mono-energetic electrons: auger
and internal conversion (auger + IC). The simulated auger component was the
collapsed auger electrons listed in the *.RAD file output by RADTABS. The continuous
beta spectrum is often the dominant energy supplier in the source voxel, but auger and
conversion electrons can also provide substantial contributions. Beyond the range of
beta, auger, and conversion electrons, the gamma and x-ray emissions are dominant.
We did not simulate the gamma and x-ray emissions or auger and conversion electrons
for 90Y because their contributions are negligible for dosimetry.
Several publications exist for voxel-S-values using MC.15,103,104,111,112 As an initial
check we compared our MC simulations with published data. For soft tissue we
compared our MC simulation results with published data for
99mTc

131I, 90Y, 153Sm, 177Lu,

and

taken from Lanconelli et al,104 Amato et al,111 or Bolch et al.15 For bone we

compared our MC simulation results with published data for 131I, 90Y, 153Sm, and 177Lu
using tabulations from Lanconelli et al104. Lanconelli et al104 data were generated using
DOSXYZnrc. Amato et al111 data were generated using Geant4, and Bolch et al15 data
were from EGS4. We tabulated the emission contributions (gamma + x-ray, beta, auger
+ IC) as a percentage of the total voxel-S-value at each voxel for the radionuclides
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investigated.
For quantitative comparisons we followed the analysis of Pacilio et al103 and
investigated differences in the source voxel (000), nearest neighbor (001), and along
the diagonal (011). To put the differences in perspective, we compared our MC
simulations with published values 15,103,104,111 from other modern radiation transport
codes.
For qualitative comparisons we plotted the voxel-S-values by collapsing them to
one dimension as a function of their radius 𝑟𝑖 . The voxel-S-values were sorted by radial
distance (𝑟𝑖 ) such that 𝑟0 ≤ 𝑟1 ≤ ⋯ ≤ 𝑟𝑛 ; for example, 𝑟0 corresponds to the source
voxel (𝑖 ′ = 0, 𝑗 ′ = 0, 𝑘 ′ = 0). In addition to the absolute voxel-S-values, we plotted
percent differences of MC relative to published data as a function of 𝑟𝑖 .
For comparisons with ATTILA we investigated three different materials
generated using the preprocessor PEGS4: soft tissue131 (ρ = 1.04 g/cc), cortical bone100
(ρ = 1.85 g/cc), and lung100 (ρ = 0.26 g/cc). The sources simulated were 90Y and 131I,
which are the two radionuclides most commonly used in internal radionuclide therapy;
mono-energetic 1MeV, 0.1MeV, and 0.01MeV electrons and photons were also
simulated to span the energy range found in typical nuclear medicine procedures.
For our MC simulations, all electrons and photons were tracked down to kinetic
energies of 1 keV. The simulation parameters were set to all the advanced options
including bound Compton scattering, Rayleigh scattering, atomic relaxations, electron
impact ionization, XCOM photon cross sections132, spin effects, exact boundary
crossing, and PRESTA-II128,129.
Our MC simulations were performed using 1E+09 source particles for each
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emitted radiation: 1) gamma + x-ray, 2) beta, and 3) auger + IC. This yielded statistical
uncertainty ≤ 0.05% in the source voxel for all sources in soft tissue. The full voxel-Svalues were constructed by adding the individual emitted radiation components
together with weightings taken from RADTABS.
2.2.2. ATTILA GBBS Code
ATTILA® (version 8.0.0) was the GBBS code evaluated in this work. ATTILA
has been used to calculate absorbed doses from external megavoltage photon
beams12,14, as well as high energy gamma emitting (137Cs, 192Ir) sealed sources.12,13
ATTILA discretizes space, angle, and energy to solve the LBTE for photons and the
Linear Boltzmann-Fokker-Planck Transport Equation (LBFPTE) for charged particles. It
̂ ) throughout space,
solves for the energy and angular dependent particle flux Ψ(𝑟⃗, 𝐸, Ω
and it has the following properties: 1) support for electrons, positrons, photons, and
neutrons; 2) fully-coupled transport where electrons and positrons generate photons,
and photons generate electrons and positrons; 3) unstructured tetrahedral mesh to
represent geometry; 4) linear discontinuous finite element in space; 5) multi-group
discretization in energy; 6) discrete ordinates differencing in angle; and 7) spherical
harmonics expansion of scattering source.12,14,133
The energy dependent scalar flux, Φ(𝑟⃗, 𝐸), is computed by ATTILA and used to
calculate reaction rates corresponding to absorbed dose (energy reaction rate) for
electron groups or kinetic energy released in material (KERMA) for photons; the energy
dependent reaction rate cross sections were calculated by the cross section generator
described later. Details of the LBTE, LBFPTE, and calculating reaction rates as post-
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processing steps are not replicated here because they have been listed and described
in previous publications.11–14
ATTILA requires multi-group energy cross sections, which were generated
using ZERKON (Varian Medical Systems, Palo Alto, CA), which is an extension of
CEPXS.68 CEPXS has been benchmarked against several other codes suggesting it
sufficiently accounts for electron and photon interactions.69 For cross section
generation, full-coupling was used for both photon and electron sources with a
Legendre expansion of order 7. Cross sections were generated for soft tissue, lung,
and bone matching the atomic composition and densities used in the MC simulations.
Cross section files were generated for each radionuclide emission component and
each energy group discretization.
2.2.3. Voxel-S-Value Simulations
For the initial evaluation of ATTILA in the nuclear medicine regime, we chose to
calculate voxel-S-values, as published by the Society of Nuclear Medicine and
Molecular Imaging’s Medical Internal Radiation Dosimetry (MIRD) committee.15 VoxelS-values are well known in the nuclear medicine community, and publications offer
tabulated results for quantitative comparisons.15,104,111 Most work and publications to
date have reported voxel-S-values only in soft tissue. In this work, we performed
calculations in soft tissue, cortical bone, and lung. The MC simulations used were
described earlier. The ATTILA settings and parameters selection are described below.
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2.2.3.1. ATTILA Solver Settings
We used square Chebychev Legendre quadrature sets, with Galerkin scattering
treatment, and diagonal transport correction. For photon sources, we set the diffusion
synthetic acceleration (DSA) to simplified_WLA. DSA was turned off for the electron
sources. Further detail on DSA can be found in the literature.134 All electron and photon
energy cutoffs were 1 keV.
2.2.3.2. Sensitivity Analysis for ATTILA
The GBBS requires sufficient discretization in space, angle, energy, and scatter
source to converge on a solution. In this work, we wanted to ensure that the space,
angle, energy, and scatter source (also known as phase-space variables) converged
sufficiently in and near the source; this was the rationale behind the sensitivity analysis.
To evaluate the effect of these parameters, we generated calculations for three
tetrahedral meshes (𝑀0 , 𝑀1 , 𝑀2 ); three energy group structures (𝐸0 , 𝐸1 , 𝐸2 ); three
angular quadrature orders (𝑆4 , 𝑆8 , 𝑆16) corresponding to 32, 128, and 512 angles over
the unit sphere respectively for the Square-Chebychev quadrature set; and up to a 7th
order spherical harmonics polynomial expansion of the scattering source (𝑃0 to 𝑃6 ).
Higher numbers on the subscripts indicate finer discretizations.
To quantify the convergence in terms of the four discretization parameters, we
calculated the ratio in the source voxel absorbed dose along each variable of the finest
discretization to the next finest for each variable: Δ𝑀 = 𝑀2 𝐸2 𝑃6 𝑆16 /𝑀1 𝐸2 𝑃6 𝑆16 , ΔE =
𝑀2 𝐸2 𝑃6 𝑆16 /𝑀2 𝐸1 𝑃6 𝑆16 , ΔP = 𝑀2 𝐸2 𝑃6 𝑆16 /𝑀2 𝐸2 𝑃5 𝑆16, and ΔS = 𝑀2 𝐸2 𝑃6 𝑆16 /𝑀2 𝐸2 𝑃6 𝑆8 . We
qualitatively showed convergence by plotting the coarsest (𝑀0 𝐸0 𝑃0 𝑆4 ), intermediate
(𝑀1 𝐸1 𝑃1 𝑆8), and finest (𝑀2 𝐸2 𝑃6 𝑆16) discretizations.
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2.2.3.2.1. Tetrahedral Meshes
We matched the voxel geometry from MC simulations exactly with ATTILA by
decomposing each voxel into tetrahedrons. An 11× 11× 11 octant of 3 mm voxels was
generated in Solidworks® (Dassault Systèmes SolidWorks Corporation, Waltham,
MA) and then exported in Parasolid™ format which was imported into ATTILA.
Tetrahedral meshes were generated with the built-in meshing utility in ATTILA. The
coarsest mesh (𝑀0 ) had ≈6 tetrahedrons per voxel resulting in ≈8,000 tetrahedrons.
We increased the number of tetrahedrons in and around the source voxel by reducing
the maximum tetrahedral edge length in the source voxel and its neighbors for both
intermediate and fine meshes. A maximum tetrahedral edge length of 1 mm was
specified to generate the intermediate mesh (𝑀1 ) with ≈16,000 tetrahedrons, and a
maximum tetrahedral edge length of 0.5 mm was selected to create the fine mesh (𝑀2 )
with ≈64,000 tetrahedrons (Figure 3).

a)

c)

b)

Figure 3. The three meshes of the octant are shown with increasing number of
tetrahedrons in and around the source voxel, which is identified by the arrow. a)
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𝑴𝟎 with ≈8,000 tetrahedrons b) 𝑴𝟏 with ≈16,000 tetrahedrons, c) 𝑴𝟐 with ≈64,000
tetrahedrons.
2.2.3.2.2. Energy Groups
We investigated three energy group discretizations for each radionuclide/source
component. The coarse (𝐸0 ), intermediate (𝐸1 ), and fine (𝐸2 ) had approximately 30, 60,
and 90 groups for each particle respectively, yielding approximately 60, 120, and 180
total groups for photons and electrons. Energy groups were distributed logarithmically
using an approximately constant number of groups per decade down to 1 keV. The
energy group widths are described in Table 1.
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1 keV < 10 keV
Coarse (𝑬𝟎 )
Intermediate (𝑬𝟏 )
Fine (𝑬𝟐 )

1 keV
0.5 keV
0.333 keV

10 keV < 100
keV
10 keV
5 keV
3.33 keV

100 keV < 1
MeV
100 keV
50 keV
33.3 keV

> 1 MeV
200 keV
100 keV
66.7 keV

Table 1. Summary of approximate energy group widths for different energy
discretizations as a function of energy. Group widths were the same for both
electrons and photons. Significant mono-energetic radiations were
accommodated by adding additional narrow groups.

Photon energy group structure was adjusted for gamma and x-ray emission
photo-peaks contributing >99% of the total gamma + x-ray emission energy for 131I
(80.2, 284, 326, 364, 503, 637, 643, and 723 keV); 1 keV width energy groups centered
on the photo-peaks (e.g. 363.5 to 364.5 keV) were added to the photon group
structure. Similar adjustments to the group structure were made for the

131I

auger + IC

emission component. Group structures for the mono-energetic electron and photon
sources were also similarly adjusted using 1 keV group widths for 1 MeV and 0.1MeV,
while a 0.1 keV group width was used for 0.01 MeV sources.
2.2.3.3. Comparison Metrics
Similar to the validation of our MC, we performed quantitative comparisons of
ATTILA (coarsest and finest discretizations) in and around the source (000,001,011)
by calculating percent differences of the GBBS relative to MC and published data. The
ground truth in the comparisons was MC or the published data. Qualitative
comparisons of percent differences were performed graphically using radial plots of the
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voxel-S-values.

2.2.4. Single source voxel at interface simulations
To evaluate the GBBS with non-uniform materials, we performed simulations at
an interface of two materials with a single voxel of activity on one side of the interface.
The interfaces studied were lungsoft tissue (L_S), soft tissuelung (S_L), bonesoft
tissue (B_S), and soft tissuebone (S_B); the first material represents the material
containing the source voxel. The simulation geometry is illustrated in Figure 4; the
scoring geometry (voxels) matched MC exactly by not allowing tetrahedrons to cross
voxel boundaries. The same cross sections and source spectra were used as in the
voxel-S-value simulations. However, a full voxel geometry (not octant) and tetrahedral
mesh consisting of ≈120,000 tetrahedrons were generated as shown in Figure 5. The
energy groups, scatter expansion, and angular quadrature set order were identical to
the finest discretization in the uniform material simulations.
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Figure 4. Illustration of the interface simulation geometry with 3 mm voxels. The
source material was defined for voxel centers with z ≤ 0, whereas the other
material was defined for voxel centers having z ≥ +1. The source voxel is at the
center of the z = 0 plane. We evaluated the voxel-S-values and percent
differences for radii confined to the planes z = 0 and z = +1. The ordering of radii
in each planar comparison is shown as ordered subscripts.

Similar to the procedure for uniform voxel-S-values, we performed quantitative
comparisons of ATTILA using tabulations near the source voxel. On the source side,
we investigated the source voxel (000), its neighbor (001), and along the diagonal
(011). On the other side we investigated immediately across from the source (001*)
and diagonally across from the source (011*). Local percent differences were evaluated
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with the ground truth set to our MC. A notable difference in this analysis was that we
only investigated voxels at the interface, meaning the voxel has to exist in the plane
defined by z = 0 or z = +1; we only used the 𝑟𝑖 in the two planes on either side of the
interface as shown in Figure 4. Qualitative comparisons were performed graphically
using radial plots of voxel-S-values and percent differences for voxels in the z = 0 or z
= +1 plane.

Figure 5. The tetrahedral mesh used for the interface simulation seen at the
interface surface between the planes of voxels. The red voxel in the center is the
source. This mesh has ≈ 𝟏𝟐𝟎, 𝟎𝟎𝟎 tetrahedrons.
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2.3. Results
2.3.1. DOSXYZnrc MC Comparison with Published Data
Figure 6 shows 131I and 153Sm plots comparing our DOSXYZnrc MC simulations
with published data in soft tissue. Qualitatively, the absolute voxel-S-value graphs are
in good agreement viewed on the logarithmic scale, where the absorbed dose can
changes by 4 orders of magnitude from the source voxel to the bremsstrahlung tail.
The local percent differences in Figure 6 indicate excellent agreement with both
Lanconelli et al104 and Amato et al111 for 131I – values near the source (listed in Table 2)
were within 3% and the differences at distance are within 5%. Compared to the older
EGS4 used by Bolch et al15, the source voxel had good agreement with differences
around 25% for 001, and 011. At distances further from the source, the differences
were within about 20%.
For 153Sm, which has significant auger and conversion electrons, our MC
overestimated the Lanconelli et al104 source voxel by 23.4%, but these differences
reduced to ≈5% at distances further from the source voxel. MC differed from Amato et
al111 by -5.3% in the source voxel, however differences at distance were larger. The
differences ranged from -40% to -20% with the maximum difference occurring near the
transition region where the gamma and x-ray component becomes dominant.
For the source voxel, differences between MC and published data were within
4.3% for 131I, 90Y, and 99mTc. However, MC differences with Lanconelli et al104 were
≈8% and ≈23% for 177Lu and 153Sm, respectively, whereas MC differences with Amato
et al111 were only ≈4% and ≈6%, respectively.
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Similar levels of agreement were found for 90Y, 131I, 153Sm, 177Lu, and 99mTc in
soft tissue, bone, and lung.

b)

a)

d)

c)

Figure 6. Differences between DOSXYZnrc MC (this work) and published data in soft
tissue. Radial plots of a) voxel-S-values for 131I, b) %difference of MC vs published data
for 131I, c) voxel-S-values for 153Sm, and d) %difference of MC vs published data for 153Sm.
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90Y

131I

177Lu

153Sm

99mTc

-0.7
-0.5
-0.1
2.2
1.4
1.1
8.7
1.1
1.2
23.4
-2.3
-4.8
NA
NA
NA

-4.0
-4.3
-4.1
1.6
2.2
-0.2
-3.0
-3.8
-15.7
-5.3
-6.5
-12.6
4.3
-4.2
-5.7

-1.9
-0.8
-2.7
-0.1
-13.5
-25.0
NA
NA
NA
NA
NA
NA
2.6
-12.6
-1.4

MC vs Lanconelli et al104

Bone

MC vs Bolch et al15

MC vs Amato et al111

ijk
000
001
011
000
001
011
000
001
011
000
001
011
000
001
011

MC vs Lanconelli et al104

Soft Tissue

-0.9
0.0
1.0
2.1
2.0
0.9
8.2
2.1
6.9
20.8
0.4
13.0
NA
NA
NA

Table 2. Percent difference values for our DOSXYZnrc MC versus published data
for 3 mm voxel-S-values in soft tissue. The percent difference in 000 is within
4.3% for 90Y, 131I, and 99mTc indicating excellent agreement. For 000 differences
>8% occur when compared with Lanconelli et al for 177Lu and 153Sm; both
radionuclides have significant auger and conversion electron contributions to
the source voxel. NA indicates the published data did not contain published
voxel-S-values for the given radionuclide.
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2.3.2. ATTILA Voxel-S-Value Simulations
2.3.2.1. Sensitivity Results

Figure 7 illustrates convergence of the GBBS voxel-S-values for a 1 MeV
electron source as the space (𝑀0 , 𝑀1 , 𝑀2 ), energy (𝐸0 , 𝐸1 , 𝐸2 ), angle (𝑆4 , 𝑆8 , 𝑆16), and
scattering source expansion (𝑃0 to 𝑃6 ) was refined. The effect of the angular
discretization was apparent at larger radii with increased angular quadrature order
leading to reduced spreading (Figure 7a). Negative fluxes were occasionally returned
by the coarsest discretization which resulted in negative voxel-S-values; negative
values are an indication that the phase-space variables have not been refined enough.
A few negative values still existed with the intermediate discretization, but the negative
values disappeared for the finest discretization.
Effects of the mesh, energy and scatter source expansion discretizations for 𝑆16
were observed as changes in the source voxel-S-value for 1 MeV electron (Figure 7c
and Figure 7d). Increasing the energy group discretization (Figure 7c and Figure 7d)
did affect the solution, but given 𝑃3 or higher then the difference between 𝐸1 and 𝐸2
was ≈0.5%; the difference between 𝐸0 and 𝐸1 given 𝑃3 or higher was ≈2%. The spatial
discretization differences between 𝑀1 and 𝑀2 were less than 0.1%. However,
differences between 𝑀1 and 𝑀0 ranged from 4.5% for 𝑃0 to 1.5% for 𝑃3 and higher
(Figure 7c and Figure 7d).
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a)

c)

b)

d)

Figure 7. Illustration showing convergence through refinement of phase space
variables for mono-energetic 1 MeV electron voxel-S-values in soft tissue on a)
log scale and b) linear scale near the source to show changes in source voxel,
where red = finest, green = intermediate, orange = coarsest, and MC = black line.
The values around 10-8 in (a) were originally negative values, but have been set
positive for display. Convergence as a function of scatter source expansion 𝑷𝑵
for the 1 MeV electron source voxel-S-value (square = 𝑴𝟐 , triangle = 𝑴𝟏 , circle =
𝑴𝟎 , red = 𝑬𝟐 , green =𝑬𝟏 , orange = 𝑬𝟎 ) is shown in c) with a zoomed view in d). In
(d) notice that moving from 𝑴𝟏 to 𝑴𝟐 makes little difference (<<1%), moving from
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5 to 6 in 𝑷𝑵 makes little difference (<<1%) for 𝑬𝟏 and 𝑬𝟐 , and moving from 𝑬𝟏 to
𝑬𝟐 results in about a 0.5% difference; this tells us that our GBBS solution, at
least in the source voxel, is converged.
For the finest discretizations, most GBBS absorbed doses in the source voxel
changed by less than 1% compared with the next finest discretization along each
phase-space variable; this indicated that our finest discretization was sufficiently
refined. In the source voxel for all sources and materials investigated Δ𝑀 and Δ𝑆
ranged from 0.999 to 1.005. Δ𝐸 ranged from 0.964 to 1.001; most Δ𝐸 were from 0.990
to 1.001 with worse values for photons in bone and for 100 keV photons in lung. Δ𝑃
ranged from 1.000 to 1.005 with the exception of 1 MeV photon in lung which was
1.015.
2.3.2.2 Comparison with DOSXYZnrc MC
Qualitatively, the finest discretization of GBBS and MC in Figure 8 exhibited
good agreement. The agreement worsened at larger radii, most likely due to ray effects
that are known to exist with GBBS methods12. However, it should be noted that these
effects can be overcome through the use of a first scattered distributed source
calculation or further increasing the number of angles,13,133 but this was not performed
in the current study.
There was an incorrect artificial dip in the GBBS voxel-S-values for 1 MeV
mono-energetic electrons near the end of the electron range in lung (Figure 8e); this
occurred because the solution was changing too quickly at that spatial location. The dip
became wider and deeper (including negative values) for the next coarsest mesh with
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other phase-space variables held constant. Thus, we expect further mesh refinement to
resolve this dip.
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Figure 8. Comparison of GBBS finest discretization (𝑴𝟐 𝑬𝟐 𝑷𝟔 𝑺𝟏𝟔 ) voxel-S-values
with MC for electron sources (a,c,e) and photon sources (b,d,f) in soft tissue (a,b),
bone (c,d) and lung (e,f). MC solutions are lines and GBBS solutions are symbols
(1 MeV = red circles, 0.1 MeV = green diamonds, 0.01 MeV = purple squares, 90Y =
orange pentagons, 131I augeric + IC electrons = blue triangles with dashed MC
line, 131I beta or gamma +x-rays = blue X’s)

Figure 9 illustrates quantitative differences between GBBS and our DOSXYZnrc
MC by plotting local percent differences for the finest GBBS calculations assuming MC
as the truth. The overall trend is for the GBBS to produce absorbed doses 7-15% less
than MC. In general, the agreement with photon sources is better than electron
sources. For electron sources, larger differences (>20%) are seen near the end of the
beta range for 90Y in soft tissue and bone, and for both auger + IC electrons and betas
for 131I in lung. The 10 keV sources show the largest percent differences, but the MC
uncertainty at 4.42 mm (011) and beyond for 10 keV electrons was ≥ 10%. The
magnitude of differences also tends to increase as the radius increases.
Table 3 supplements Figure 9 by listing GBBS percent differences from MC for
the source voxel in soft tissue, bone, and lung for the coarsest (𝑀0 𝐸0 𝑃0 𝑆4 ) and finest
(𝑀2 𝐸2 𝑃6 𝑆16) discretizations. At lower energies (≤ 100 keV), the difference between
using the coarsest and finest discretization had little effect on the source voxel
absorbed dose. The local percent differences show that the converged GBBS
consistently underestimates MC in the source voxel; the bias is approximately -7% for
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1.0 MeV photons & electrons and worsens to approximately -15% for 10 keV photons &
electrons across all materials studied.
In addition to absorbed dose values, for the photon sources, Table 3 lists GBBS
KERMA and its percent difference from MC absorbed dose. The GBBS KERMA
calculations exhibited much better agreement with MC absorbed doses than the GBBS
absorbed doses for the 100 keV (0.3% vs -9.9%)and 10 keV (-1.4% vs -15.3%) photon
sources in soft tissue. For low energy photon sources (0.1 MeV, 0.01 MeV), the GBBS
agreement with MC absorbed dose in the source voxel was improved to be within 3.5%
when using KERMA reaction rate instead of the absorbed dose from the energy
deposition reaction rate.

Table 4 lists GBBS percent differences from MC for voxel-S-values near the
source (000,001,011) in soft tissue for the mono-energetic electrons and photons.
Table 4 also lists differences reported by Pacilio et al 103 between modern radiation
transport codes. In the source voxel, the magnitude of differences we report for the
GBBS are slightly larger in magnitude than those reported by Pacilio. For 1 MeV
electrons and photons, the magnitude of GBBS percent differences reported in 001 and
011 are comparable to the percent differences reported by Pacilio et al. For the 100
keV electrons, the magnitude of GBBS percent differences is much improved while the
100 keV photons have slightly worse agreement with the differences reported by
Pacilio et al in modern radiation transport codes Geant4 and MCNP4C.

The GBBS percent differences from MC and published data for
131I

90Y

and the full

spectra by summing the 3 simulated components (beta + auger & IC electrons +
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gamma & x-rays) are listed in Table 5. The coarse GBBS 90Y calculation was within
6.5% for 000, 001, and 011, while the finest GBBS

90Y

calculation was within 9.5% of

all published and MC data. Excluding Bolch et al, the coarsest and finest GBBS

131I

were within 7.1% and 6.0%, respectively, of published and MC data for 000, 001, and
011.
To provide additional context for differences from the GBBS, the differences
between published values and MC can be calculated from Table 5. The spread in MC
and published values was ≈4% for 90Y in 000, 001, and 011. For 131I, the spread in MC
and published values was ≈2%, ≈15%, and ≈ 25% for 000,001, and 011, respectively.
Excluding Bolch et al, the spread in 131I published and MC data was ≈2%, ≈2%, and ≈
7% for 000,001, and 011, respectively.
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Figure 9. GBBS vs MC % differences for the finest (𝑴𝟐 𝑬𝟐 𝑷𝟔 𝑺𝟏𝟔 ) GBBS voxel-Svalues for electron sources (a,c,e) and photon sources (b,d,f) in soft tissue (a,b),
bone (c,d) and lung (e,f). 1 MeV = red circles, 0.1 MeV = green diamonds, 0.01
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MeV = purple squares, 90Y = orange pentagons, and 131I = blue. Blue triangles are
the 131I auger + IC electron component and blue x’s are used for the
gamma+xray component.
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131I

beta and

(KERMA)
discrete

𝜷

photons
electrons

1.7729
0.5504
0.0570
0.0475
1.5797
0.8625
0.0128
0.0020
0.0243
0.0092
NA
NA
NA
NA
1.6894
0.3142
0.0321
0.0288
1.3875
0.5257
0.0164
0.0038
0.0290
0.0101
NA
NA
NA
NA
1.4390
1.9748
0.2276
0.1135
1.6445

1.8079
0.5062
0.0491
0.0430
1.5898
0.8021
0.0171
0.0018
0.0200
0.0090
0.0240
0.0020
0.0235
0.0101
1.5939
0.2879
0.0276
0.0258
1.3619
0.4864
0.0187
0.0034
NA
0.0097
0.0228
0.0037
NA
0.0108
1.5278
1.7937
0.1961
0.1082
1.6535
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2.0
-8.0
-13.8
-9.5
0.6
-7.0
33.6
-9.4
-17.5
-1.7
87.1
-0.0
-3.3
9.8
-5.7
-8.3
-14.1
-10.4
-1.8
-7.5
14.4
-10.4
NA
-3.6
39.2
-1.5
NA
6.5
6.2
-9.2
-13.8
-4.7
0.5

1.6588
0.5090
0.0494
0.0434
1.4879
0.8125
0.0119
0.0018
0.0205
0.0085
0.0245
0.0020
0.0239
0.0101
1.5799
0.2888
0.0277
0.0263
1.3247
0.4940
0.0152
0.0034
0.0233
0.0094
0.0232
0.0037
0.0290
0.0107
1.3920
1.8262
0.1972
0.1025
1.5551

Finest GBBS vs MC (%)

Finest GBBS (mGy/MBq-s)

Coarsest GBBS vs MC (%)

Coarsest GBBS (mGy/MBq-s)

MC (mGy/MBq-s)
discrete

𝜷
(KERMA)
discrete

𝜷

electrons
photons
electrons

Soft Tissue
Bone
Lung

1.0 MeV
0.1 MeV
0.01 MeV
131I
90Y
131I
1.0 MeV
0.1 MeV
0.01 MeV
131I
1.0 MeV
0.1 MeV
0.01 MeV
131I
1.0 MeV
0.1 MeV
0.01 MeV
131I
90Y
131I
1.0 MeV
0.1 MeV
0.01 MeV
131I
1.0 MeV
0.1 MeV
0.01 MeV
131I
1.0 MeV
0.1 MeV
0.01 MeV
131I
90Y

-6.4
-7.5
-13.3
-8.5
-5.8
-5.8
-7.2
-9.9
-15.3
-7.8
91.2
0.3
-1.4
10.4
-6.5
-8.1
-13.6
-8.7
-4.5
-6.0
-6.9
-9.5
-19.7
-7.3
41.6
-0.1
-0.2
5.3
-3.3
-7.5
-13.4
-9.6
-5.4

(KERMA)

photons

131I

1.0 MeV
0.1 MeV
0.01 MeV
131I
1.0 MeV
0.1 MeV
0.01 MeV
131I

2.0445
0.0041
0.0020
0.0359
0.0073
NA
NA
NA
NA

1.9405
0.0074
0.018
0.0294
0.0079
0.0238
0.0020
0.0345
0.0103

-5.1
83.0
-9.1
-18.1
8.5
488.2
1.0
-3.9
40.6

1.9173
0.0038
0.0018
0.0303
0.0064
0.0245
0.0020
0.0353
0.0104

-6.2
-6.6
-9.9
-15.6
-12.2
503.8
1.9
-1.6
42.2

Table 3. Absorbed dose values by emission type (discrete electrons (monoenergetics, auger + IC, continuous electron (beta), discrete photons) in the
source voxel (000) for MC and GBBS for the coarsest (𝑴𝟎 𝑬𝟎 𝑷𝟎 𝑺𝟒) and finest
(𝑴𝟐 𝑬𝟐 𝑷𝟔 𝑺𝟏𝟔 ) discretizations. MC absorbed dose is taken as the truth in the
percent difference comparisons. The table also includes GBBS approximated
absorbed dose for photon sources via KERMA cross sections. Comparisons
were not performed for the coarse GBBS 10 keV photon because the solution did
not converge.
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MCNP4C vs MC* (%)

Geant4 vs MC* (%)

Fine GBBS vs MC (%)

Coarse GBBS vs MC
(%)

MC 𝝈 (%)

Energy (MeV)

Photons

Electrons

ijk
1.0
000 <0.1
2.0
-6.4
-3
-2
001 <0.1
-9.0
-6.8
5
5
011 <0.1
-7.4
-5.5
7
5
0.1
000 <0.1
-8.0
-7.5
-4
-4
001 <0.1 15.0
2.2
70
55
011
0.4
-39.0
6.7
110
130
0.01
000 <0.1 -13.8 -13.3
NA
NA
001
0.3
6.7
4.0
NA
NA
011 10.0 -43.0 -40.0
NA
NA
1.0
000 <0.1 33.6
-7.2
-7
-3
001 <0.1 14.0
-6.6
-5
7
011 <0.1
4.8
-6.1
-5
2
0.1
000 <0.1
-9.4
-9.9
-4
-3
001 <0.1
-6.7
-10.0
-4
-4
011 <0.1
-4.6
-10.3
-3
8
0.01
000 <0.1 -17.5 -15.3
NA
NA
001 <0.1 -13.0 -14.5
NA
NA
011 <0.1
-8.1
-13.2
NA
NA
*Values estimated from Pacilio et al Figures 3a and Figure 3b. NA values were not
calculated by Pacilio et al.
Table 4. Summary of differences between GBBS and MC absorbed doses near
the source voxel for mono-energetic electron and photon sources. For reference,
we also list differences for Geant4 vs MC and MCNP4C vs MC taken from Pacilio
et al.
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vs MC

vs Bolch et al15

vs Amato et al111

vs Lanconelli et al104

Finest GBBS

vs MC

vs Bolch et al15

vs Amato et al111

vs Lanconelli et al104

Coarsest GBBS

ijk
000 0.0
-3.4 -1.3
0.6
-6.4
-9.5
-7.6
-5.8
001 1.2
-2.7
0.8
1.7
-2.7
-6.4
-3.0
-2.2
011 -2.6 -6.5 -5.2 -2.5
1.2
-2.8
-1.5
1.3
131I
000 -5.0 -5.6 -7.2 -7.1
-3.8
-4.5
-6.0
-6.0
001 5.9
6.6
-9.7
4.3
-1.3
-0.6
-15.8
-2.8
011 6.0
4.7 -21.4 -1.7
-0.4
-1.7
-26.2
4.6
Table 5. Percent differences for the coarsest and finest GBBS voxel-S-values
90Y

(000, 001, and 011) relative to published data for the full radionuclide spectra
(beta + auger & IC electrons + gamma & x-rays) and our DOSXYZnrc MC.

2.3.3. ATTILA and MC Interface Simulations

The MC and finest GBBS absorbed doses to voxels in both planes along the
interface were in good qualitative agreement (Figure 10 and Figure 11). The artifact
previously explained for 1MeV electrons in uniform material is also seen in Figure 10.
Local percent differences in Figure 12 and Figure 13 show that differences at the
interface were similar to differences observed in the uniform material simulations. The
differences are quantified near the source in Table 6, which are similar to the
differences reported for uniform material.
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Figure 10. Lung-soft tissue interface planes showing finest discretized GBBS
(circles or triangles) with MC (lines). a) L_S electrons. b) L_S photons. c) S_L
electrons. d) S_L photons. Left of the dashed line indicates the source plane (z =
0) and right of the line indicates (z = +1). Legend identical to Figure 8.
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Figure 11. Bone-soft tissue interface planes showing finest discretized GBBS
(circles or triangles) with MC (lines). a) B_S electrons. b) B_S photons. c) S_B
electrons. d) S_B photons. Left of the dashed line indicates the source plane (z =
0) and right of the line indicates (z = +1). Legend identical to Figure 8.
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Figure 12. Lung-soft tissue interface planes showing percent difference for each
plane. a) L_S electrons. b) L_S photons. c) S_L electrons. d) S_L photons. Left of
the dashed line indicates the source plane (z = 0) and right of the line indicates (z
= +1). Legend identical to Figure 8 with1 MeV = red, 0.1 MeV = green, 0.01 MeV =
purple, 90Y = orange, and 131I = blue. Triangles and dashed line represent the 131I
auger + IC electrons.
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Figure 13. Bone-soft tissue interface planes showing percent difference for each
plane. a) B_S electrons. b) B_S photons. c) S_B electrons. d) S_B photons. Left
of the dashed line indicates the source plane (z = 0) and right of the line indicates
(z = +1). Legend identical to Figure 8 with1 MeV = red, 0.1 MeV = green, 0.01 MeV
= purple, 90Y = orange, and 131I = blue. Triangles and dashed line represent the 131I
auger + IC electrons.
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GBBS vs MC (%)
1 MeV

Electrons

Discrete

0.1 MeV

0.01 MeV

131I

Continuous

131I

90Y

Photons

1 MeV

0.1 MeV

ijk
000
001
011
001*
011*
000
001
011
001*
011*
000
001
011
001*
011*
000
001
011
001*
011*
000
001
011
001*
011*
000
001
011
001*
011*
000
001
011
001*
011*
000
001
011
001*
011*

L_S
-3.8
-4.8
-5.6
-7.0
-6.3
-8.2
-1.9
11.8
3.4
5.5
-13.4
4.6
-54.2
4.3
-50.4
-9.9
-7.1
-6.4
-5.5
-3.0
-6.8
-5.4
-4.1
-2.9
0.2
-5.9
-6.1
-5.2
-4.4
-2.7
-7.4
-7.4
-7.3
-7.0
-6.5
-10.2
-9.7
-9.8
-10.0
-9.9

S_L
-6.7
-6.8
-4.7
-6.2
-5.7
-7.7
9.1
-20.6
3.7
4.3
-13.3
4.2
-55.6
4.6
-46.0
-8.9
-3.9
6.1
-5.2
-3.3
-6.2
-0.4
8.1
-2.6
-0.1
-5.9
-3.0
-0.9
-3.2
-1.6
-7.5
-6.5
-6.0
-6.6
-6.1
-10.1
-9.8
-9.8
-10.2
-9.9
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B_S
-6.8
-6.6
-5.3
-6.6
-5.0
-8.2
20.1
-22.6
15.2
-23.5
-13.6
14.6
-76.3
9.9
-59.3
-9.5
0.7
17.5
-0.9
9.4
-6.6
4.5
19.1
2.7
11.6
-5.0
-1.4
1.7
-2.2
0.2
-7.4
-6.4
-6.1
-6.2
-5.8
-9.7
-9.4
-9.5
-9.4
-9.7

S_B
-6.8
-6.9
-4.7
-6.6
-4.7
-7.8
9.1
-20.4
14.0
-19.5
-13.3
4.2
-55.4
9.2
-49.8
-9.0
-4.2
5.8
-2.0
9.6
-6.3
-0.6
7.7
1.6
11.3
-6.0
-3.0
-0.9
-2.0
0.5
-7.5
-6.5
-5.9
-6.5
-6.2
-10.0
-9.7
-9.8
-9.6
-9.6

0.01 MeV

131I

000
001
011
001*
011*
000
001
011
001*
011*

-15.7
-15.3
-15.0
-14.9
-14.2
-12.6
-7.1
-6.2
-6.5
-6.1

-15.4
-14.2
-13.1
-14.8
-14.1
-8.1
-6.2
-6.2
-6.3
-6.0

-19.7
-17.3
-20.2
-13.3
-12.4
-7.7
-6.6
-6.6
-6.2
-6.1

-15.4
-14.3
-13.1
-18.3
-17.6
-8.1
-6.2
-6.0
-6.6
-6.5

Table 6. GBBS absorbed dose percent differences from MC by emission type
(discrete-energy electrons (mono-energetics, auger + IC), continuous-energy
electron (beta), discrete-energy photons) near the source voxel in the source
material (000,001,011) and across the interface in the other material (001*,011*).

2.4. Discussion
To benchmark our MC models, we first compared our DOSXYZnrc MC voxel-Svalues with published data generated using DOSXYZnrc, Geant4, and EGS4. Pacilio et
al 103 characterized differences of a few percent (-3.5% to +4%) for mono-energetic
electrons and differences up to 7% for mono-energetic photons in a 3 mm source
voxel. In general, our comparisons agreed with Pacilio et al, but we did note
discrepancies between our data and Lanconelli et al for radionuclides with nonnegligible auger or internal conversion electron emissions (153Sm, 177Lu). This was
surprising because both used DOSXYZnrc. A possible explanation for the difference is
that Lanconelli et al may not have included the auger and conversion electron
component in their voxel-S-values. This reasoning is supported by the fact that our
differences in the source voxel are approximately the percentage contribution of auger
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and internal conversion electrons to the beta + auger + IC energy released per
disintegration. From RADTABS, values for the 153Sm (177Lu, 131I, 90Y) average energy
per disintegration released by betas and auger plus conversion electrons were 223.6
(133.3, 181.9, 933.0) keV and 46.3 (14.7, 10.0, 0.2) keV, respectively. Assuming all
electron energy is deposited locally and all x-rays and gammas escape, then the auger
and internal conversion electrons contribute ≈17% (46.3/(46.3 + 223.6)) for 153Sm,
≈10% for 177Lu, ≈5% for 131I, and 0% for 90Y. Applying this correction to the source
voxel would improve agreement to within ≈5%.
For voxel-S-values, the range of absorbed doses can span several orders of
magnitude over a few millimeters. Our percent difference figures show large
differences, but these are very similar in magnitude to the differences encountered by
several publications comparing absorbed dose calculations103,111,135

Previous work in external beam and sealed source brachytherapy has found
minimal differences between ATTILA and other transport codes. Gifford et al12 scored
photon KERMA in a plane around an ovoid containing a

137Cs

source and found

differences between ATTILA and MCNPX to be on the order of 2-5%. The same study
compared ATTILA with EGS4 for an 18 MV percent depth dose curve in a
heterogeneous phantom and found the largest difference was ATTILA overestimating
the EGS4 values by only 2.2%. An additional study by Gifford et al13 compared ATTILA
with MCNPX photon KERMA around an 192Ir source and found 98% of voxels to be
within 5% of MCNPX, although there were localized differences of -7% beyond the
source tip and differences over +5% near the source shown graphically. Vassiliev et
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al14 compared ATTILA with EGSnrc for clinical patient cases treated with 6 MV photon
beams and reported >98% of voxels had passing gamma indices110 for 3%/3 mm.
Previous publications with the GBBS focused on external beam and high energy
sealed source brachytherapy. In this work, we found that differences exist between MC
and GBBS in the nuclear medicine energy regime. Gifford et al12 suggested that
differences in cross sections used by the GBBS and MC over the energy range of
interest in external beam and high energy brachytherapy were minimal. Our results
suggest that the differences in cross sections become noticeable at lower electron
energies including the nuclear medicine energy regime.
We hypothesize that these differences manifest in the energy reaction rate cross
sections, which are used to convert the local electron spectra to absorbed dose,
calculated by ZERKON/CEPXS. Comparing both KERMA and absorbed dose GBBS
calculations with MC absorbed doses for low energy photon sources (0.1 MeV, 0.01
MeV) (where KERMA is a good approximation to dose) showed that the KERMA
reaction rate agreed within 3.3% for the MC absorbed dose, but the GBBS absorbed
doses, using the energy reaction rate cross section, produced lower absorbed doses
with larger magnitude differences. To determine whether the differences in absorbed
dose were from transport or the energy reaction rate cross sections, we ran ATTILA
simulations with electron transport energy cutoff > max energy in the problem (i.e., no
transport performed) for mono-energetic electrons of 1 MeV, 0.1 MeV, and 0.01 MeV;
for these simulations we expected the energy deposited in the source voxel to equal
the mono-energetic electron energy. However, the observed differences without
transport were -6.5%, -7.5%, and -13.5% for 1 MeV, 0.1 MeV, and 0.01 MeV,
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respectively. The differences persisted without transport, providing additional evidence
that the energy reaction rate cross sections may be the reason for differences, but
further investigation is required to reconcile the differences.
Convergence and bias are two separate, but related phenomena. A process can
converge and still have bias. Bias implies that the process converged to a different
value from the truth. For example, having differences in cross sections will lead to such
biases for both deterministic and stochastic transport codes. At such low energies and
at such small scales it is difficult to have an absolute truth. Given EGSnrc’s extensive
benchmarking and reputation for accurate condensed history electron transport, we
chose it as the standard, but differences will still exist among modern radiation
transport codes103,105,136.
Similar to MC, convergence with the GBBS is not constant throughout space.
GBBS absorbed doses converge “faster” closer to the source as can be seen in Figure
7a and Table 3 where there is little change between the coarsest and finest
discretizations – this change decreases further at lower energies. Taking MC as the
truth, GBBS biases increase in magnitude in the source voxel at lower energies. To
achieve an identical level of convergence as the source voxel in a voxel far away from
the source, MC requires the simulation of many more source particles to achieve
similar convergence. Similarly, the GBBS requires additional angular discretization or a
first-scattered distributed source with ray-tracing to achieve convergence. When
moving to patient-specific calculations, the discretization at distance, and
corresponding ray effects, will be less important because the source will be distributed
spatially and the absorbed dose in a voxel will be dominated by the local activity.
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Yoriyaz et al 105 investigated absorbed dose fractions for spheres of material and
found maximum differences between MCNP and GEANT4 to be 5% for photons and
10% for electrons – their geometry is approximately equivalent to the source voxel in
this work. Our GBBS results in the source voxel, for the full 90Y and 131I spectra listed in
Table 5, are similar to the differences they reported. Pacilio et al103 estimated
differences on the order of 5% in the source voxel and much larger in surrounding
voxels. It is important to note that the uncertainties in cross sections increase at lower
energies, so different models can give quite different results. The magnitude can seem
alarming to those with backgrounds in radiation oncology transport for megavoltage
photon beams, but one has to interpret these differences in the proper context, which
we have tried to provide by reporting differences between other modern radiation
transport codes in the nuclear medicine energy regime.
Voxel-S-values are typically calculated once and then used in a convolution. As
such, these are reference values and their computation time is irrelevant. We
calculated voxel-S-values with GBBS because voxel-S-values are widely understood in
the nuclear medicine community and the results are often tabulated, which enables
quantitative comparisons. We want to emphasize that the purpose of this work was to
perform a low-level benchmark of the GBBS against MC in the therapeutic nuclear
medicine energy regime. We have previously shown clinically feasible calculation times
with adaptive tetrahedral meshing on patient scans137, but this is a separate issue and
will be addressed Chapter 3. We are of the opinion that matching voxel boundaries by
forcing at least 6 tetrahedrons per voxel is not an efficient use of tetrahedrons. This
was done to ensure the benchmarking elucidated differences underlying the transport
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and cross-sections used in the GBBS and not differences due to mismatched source
and scoring geometries.
The purpose of this chapter was to benchmark the GBBS against MC using
voxel-S-values. It should be noted that by matching the voxel boundaries, the GBBS
calculates absorbed dose at a level finer than the voxel – in addition to the linear
variation across a tetrahedron there exist multiple tetrahedrons (>= 6) in each voxel.
This allows one to investigate the spatial distribution within each voxel. We did not
investigate intra-voxel distributions here, but want to point out that the additional
runtime incurred by finer meshes delivers additional information not found in the MC
simulations. Similarly, intra-voxel information could be obtained with MC by decreasing
the scoring voxel sizes at the expense of calculation time and memory requirements.
We found only one study104 in the literature that provided tabulated voxel-Svalues in a material other than soft tissue. As nuclear medicine continues to adopt
voxel-level dosimetry, the use of multiple material-based kernels may provide a
reasonable intermediate step towards full-transport solutions; this could have an
immediate impact on 90Y microsphere therapy or 131I therapy of metastatic lung
nodules, where lung and liver or lung and tumor are, respectively, the regions of
interest. Such kernels may also be important for bone-seeking radiopharmaceuticals
with bone and soft tissue interfaces. Believing that differences in material and density
will play a role moving forward we compared the GBBS with MC at multiple interfaces
(lungsoft tissue, soft tissuelung, bonesoft tissue, soft tissuebone) to capture
the aforementioned clinical uses. In addition, we supplied tabulated mono-energetics
(10 keV, 100 keV, 1 MeV) and individual components (auger + IC, beta, x-ray +
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gammas) of 153Sm, 131I, 177Lu, and 99mTc for MC, adding to the tabulated data available
to researchers.
One strength of our study is that we matched scoring geometry between
transport codes. This was essential for evaluating voxel-S-values for nuclear medicine
sources where the absorbed dose gradients are very large; previous studies of the
GBBS did not follow such a methodology. Furthermore, we ensured the source voxel
was sufficiently converged by comparing multiple phase-space variable discretizations.
An important distinction of this work relevant to nuclear medicine is that previous
studies exclusively used photon sources with either KERMA reaction rates for sealed
sources or energy deposition reaction rates for megavoltage photon beams with partialcoupling (photonselectrons), but in this work we investigated both electron and
photon sources with full-coupling.
In this work, we made sure to sufficiently capture source spectral shapes and
significant discrete radiations through the energy group discretizations. It should be
noted that previous studies of GBBS for radiotherapy used much coarser energy group
structures then we did and reported excellent agreement. This suggests that
optimization of group structure (minimizing number of energy groups) may lead to good
agreement with MC, but it is unclear if such solutions will be converged in the energy
discretization variable. It may also be possible to combine all the sources (gamma + xray, beta, auger + IC electrons) into a single source for use with the GBBS when
simulations are performed with full-coupling. This would be accomplished by mapping
the corresponding emission to the correct energy group and applying normalization
factors to account for branching ratios.
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The purpose of this work was not to report on speed, but one potential
advantage of the GBBS in radiation oncology is its speed and accuracy. Providing
voxel-level absorbed dose maps from nuclear medicine tomographic scans in a timely
matter will help the adoption of voxel-level dosimetry for nuclear medicine departments.
Our GBBS calculation times on a 24-core (two 12-core AMD 6174) machine ranged
from ≈2 minutes for the coarsest discretizations to ≈20 minutes for the intermediate
discretizations, and up to a few days for the finest. The coarsest calculations required a
couple gigabytes of RAM whereas the finest required around 60 GB of RAM.
A modern deterministic code such as ATTILA has several adaptable (space &
energy) options for controlling levels of discretization. Nuclear medicine absorbed dose
calculations depend on radionuclide spectra and spatial distributions of activity,
material, and density. An advantage of ATTILA is its use of an unstructured tetrahedral
mesh. However, in this work the advantage of accurately approximating general
geometries through unstructured tetrahedral meshing was negated; we forced
tetrahedrons to not cross voxel boundaries to avoid geometric source specification
errors and absorbed dose scoring errors when comparing with MC.
Future work should investigate relaxing the voxel-matching tetrahedral mesh
generation used in this work. Resolving the activity, material, and density in space
through adaptive tetrahedral meshing will be a necessary step for using ATTILA on
patient data sets.
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2.5. Conclusion
We calculated MC voxel-S-values in soft tissue, lung, and bone for 1) monoenergetic electrons and photons and 2) individual radionuclide components (beta,
auger + IC, gamma + x-ray) for 99mTc, 131I, 177Lu, 153Sm, and 90Y. When evaluating
voxel-S-values, it is important to test radionuclides that have significant contributions
from all possible emissions (e.g. 90Y and 131I have negligible to small auger + IC
electron yields, but 177Lu and 153Sm have significant auger+IC electron yields).
A GBBS has been benchmarked against MC in the nuclear medicine regime and
has been shown to be suitable for absorbed dose calculations. Unlike previous
dosimetry studies with the GBBS we 1) removed geometrical errors by decomposing
voxels into tetrahedrons, which was necessary due to the large dose gradients in
nuclear medicine and 2) investigated both electron and photon sources with fullcoupling.
The results of this study lead naturally to several additional areas of
investigation, including the use of GBBS for patient-specific absorbed doses from
unsealed sources. Investigation of GBBS computation time is also warranted and can
include studies of 1) relaxing the tetrahedral mesh to not match voxels exactly; 2)
coarsening energy group structures for each radionuclide; 3) setting energy group
dependent SN and PN; and 4) combining all of the auger + IC electrons, betas, and
gamma + x-ray emissions into a single fully-coupled source.
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Chapter 3: Feasibility of fast and accurate GBBS calculations on clinical data
through adaptive tetrahedral meshing of emission and transmission images

3.1 Introduction
Voxel-level absorbed dose calculations in nuclear medicine have been around
for decades, but their use has primarily been in retrospective research
studies15,42,43,65,115–117,124. Emission image quality continues to improve with better
sensitivity and spatial resolution due to hardware and reconstruction algorithms. The
advancements in targeted pharmaceutical development and radiopharmaceuticals are
occurring in parallel to the improvements in image quality.
Voxel-level dosimetry is not used clinically at most institutions. Instead, the
standard of practice S-values based on reference human stylized phantoms are
typically used. The S-values are more relevant for radiation protection and have known
limitations including 1) assuming a uniform distribution of activity throughout an organ;
2) geometry not accurately representing the patient; and 3) an overly simplistic tumor
model consisting of a sphere that does not contribute/receive energy to/from other
organs. There has been active development of more sophisticated anthropomorophic
phantoms, but these are again for population based protection or diagnostic studies.
Consequently, there is a need for patient-specific voxel-level absorbed dose
calculations in the clinic.
Although Monte Carlo (MC)138 and convolution methods (voxel-S-values or dose
point kernels)15 are prevalent in the nuclear medicine literature for voxel-level absorbed
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doses, other methods exist. Sanchez-Garcia has recently implemented collapsed-cone
calculations, common in external beam, for unsealed sources60,61. The use of complete
local absorption has also been used for pure beta emitters such as 90Y122,123,139. In
Chapter 2 we performed a low-level evaluation of the deterministic grid-based
Boltzmann solver (GBBS) ATTILA (Varian Medical Systems, Palo Alto, CA) showing
that it can be used for voxel-level absorbed doses. However, this was a low-level study
that only investigated two simple sources and scoring geometries: a voxel source in
uniform media and a single source voxel at an interface of two media.
The GBBS spatial discretization requires an unstructured tetrahedral mesh, but
most medical images consist of structured hexahedral meshes (i.e. voxels). In the
previous study we ensured 1) that GBBS geometry matched voxel geometry by not
allowing tetrahedrons to cross voxel boundaries; and 2) that the solution was
converged due to discretization parameters (space, angle, energy) in and around the
source voxel. The GBBS was not designed for use with the structured hexahedral
meshes common to medical imaging; forcing at least 6 tetrahedrons per voxel to avoid
geometric differences in radiation transport between MC and GBBS is neither feasible
nor efficient on patient scans.
The objective of this work is to show that fast and accurate absorbed dose
calculations are possible with the GBBS for patient-specific nuclear medicine dosimetry
at the voxel-level. We accomplish this by 1) calculating our gold standard MC
absorbed dose in each voxel from the SPECT/CT; 2) generating an adaptive
tetrahedral mesh based on the SPECT/CT voxel geometry; 3) calculating absorbed
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dose with the GBBS based on the adaptive mesh; and 4) comparing GBBS absorbed
doses with MC absorbed doses.
3.2 Methods and Materials
3.2.1 Patient Data
Using UT MD Anderson Cancer Center Institutional Review Board protocol
DR09-0025, we retrospectively selected a post-therapy 90Y bremsstrahlung SPECT/CT
for a patient treated with glass microspheres at our institution. Uptake is exhibited
primarily in the liver, and tumor and normal liver were the volumes of interest (VOI). A
pre-therapy Na131ISPECT/CT for a patient treated with Na131I was also selected from
our clinical database. Uptake was seen in metastatic tumors in the lung; both lungs and
the tumors were VOIs.
3.2.2 DOSXYZnrc Monte Carlo (MC)
The EGSnrc128 (v4.2.4.0) user code DOSXYZnrc127 was used as the MC gold
standard for comparisons with the GBBS code. EGSnrc is a general purpose radiation
transport code with improved low energy support compared with EGS4, 129 and
DOSXYZnrc allows scoring in voxel geometry.
3.2.2.1 Transport Parameters
All electrons and photons were tracked down to kinetic energies of 1 keV. The
simulation parameters were set to all the advanced options including bound Compton
scattering, Rayleigh scattering, atomic relaxations, electron impact ionization, XCOM
photon cross sections132, spin effects, exact boundary crossing, and PRESTA-II128,129.
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3.2.2.2 Sources and Spectra
The 90Y and 131I radionuclide spectra were obtained from RADTABS
software.130 The simulated auger component was the collapsed auger electrons listed
in the *.RAD file output by RADTABS. We did not simulate the gamma and x-ray
emissions or auger and conversion electrons for 90Y because their contributions are
negligible for dosimetry.
The sources were decomposed into the following components: 1) discrete
gamma + x-ray, 2) continuous beta, and 3) discrete auger + conversion electrons. A
single MC simulation was performed for each component. The individual MC
simulations were performed using 1E+09 source particles. The total absorbed dose
was calculated by weighting the individual components by their respective branching
ratios.
3.2.2.3 Mapping of CT to Density and Material
CT numbers were mapped to mass density based on a matched peak energy
(130 kVp) CT scan of a CIRS material phantom. The mapped density was used directly
in the MC simulation. Material was determined by mapping the density to one of four
materials: air140 (0.001 to 0.130 g/cc), lung100 (0.130 to 0.605 g/cc), soft tissue131
(0.605 to 1.101 g/cc), and cortical bone100 ( >1.101 g/cc).

3.2.3 GBBS ATTILA
ATTILA® (version 8.0.0) was the GBBS used in this work. ATTILA has been
used to calculate absorbed doses from external megavoltage photon beams12,14, as
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well as high energy gamma emitting sealed sources (137Cs, 192Ir).12,13 ATTILA
discretizes space, angle, and energy to solve the linear Boltzmann Transport equation
for photons and the linear Boltzmann-Fokker-Planck Transport equation for charged
̂)
particles. It solves for the energy and angular dependent particle flux Ψ(𝑟⃗, 𝐸, Ω
throughout space.
3.2.3.1 Adaptive Tetrahedral Mesh Generation
An adaptive mesh must capture the source, material, and density distributions
sufficiently to have minimal effect on the calculated absorbed dose. To meet this goal
our mesh generation is based on both the emission and transmission image.
The computer program TetGen (v1.5.0)141,142 was used to generate tetrahedral
meshes. TetGen has been used by one group to model brachytherapy applicators143
from CAD, but in this work we used it to transform the SPECT/CT into a tetrahedral
mesh. This was accomplished by defining a mesh-sizing function 𝐿(𝑖, 𝑗, 𝑘) at each voxel
centroid of the SPECT/CT. The mesh sizing function returns a target tetrahedral edge
length, and these edge lengths are interrogated by TetGen during its internal mesh
generation and optimization process.
A mesh-sizing function was defined within a bounding box on the SPECT/CT.
The bounding box was selected to encompass the entire patient body on CT. A fine
background mesh with a node at every SPECT/CT voxel centroid was then created.
The background mesh is not used in the GBBS calculation. It is a temporary construct
that enables geometry matching when defining 𝐿(𝑖, 𝑗, 𝑘) for use with TetGen. This
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allows image processing on the SPECT and CT in voxel geometry to drive the
tetrahedral mesh adaptation.
Two mesh-sizing functions were derived from the input MC activity and material
distributions, which were generated from the SPECT/CT. The first, 𝐿𝐴𝐶𝑇 (𝑖, 𝑗, 𝑘), was
derived directly from the activity distribution. Voxels with higher counts or activity are
more important than lower ones. We plotted the normalized cumulative count histogram
weighted by counts; this generates a monotonically increasing curve that is normalized
to the total number of counts. For the initial definition, we then assigned bands (every
10%) of voxels from the cumulative distribution to target tetrahedral lengths ranging
from 0.5 cm (highest activity voxels) to 8.0 cm for the (lowest activity voxels). Figure 14
shows a the normalized cumulative count histogram weighted by counts for the

Fraction of Total Counts

SPECT used to assign 𝐿𝐴𝐶𝑇 (𝑖, 𝑗, 𝑘).
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90Y

Figure 14. Example illustration showing how 𝑳𝑨𝑪𝑻 (𝒊, 𝒋, 𝒌) is determined from the
input activity distribution. I use the fraction of total counts, not fraction of
volume to determine thresholds for assigning tetrahedral edge lengths. 4 mm
and 8 mm are not shown due to space constraints on the graph.
The second mesh-sizing function was based on the material distribution from
MC. First, 𝐿𝑀𝐴𝑇 (𝑖, 𝑗, 𝑘) was set to an edge length based on the material. A pseudogradient magnitude, |∇′𝑀𝐴𝑇(𝑖, 𝑗, 𝑘)|, was calculated from the MC material distribution.
This quantity was based on the 26 neighbors around a voxel; if a neighbor differed from
the central voxel then a value of 1 was added to the pseudo-gradient magnitude. The
corresponding magnitudes ranged from 0 to 26. The pseudo-gradient magnitude was
used to define a multiplicative factor, 𝛼|∇`𝑀𝐴𝑇| (𝑖, 𝑗, 𝑘) to increase sampling at interfaces.
The material specified edge length and multiplicative factor were used to define the CT
based mesh-sizing function as 𝐿𝐶𝑇 (𝑖, 𝑗, 𝑘) = 𝐿𝑀𝐴𝑇 (𝑖, 𝑗, 𝑘) × 𝛼|∇`𝑀𝐴𝑇| (𝑖, 𝑗, 𝑘).
The final mesh-sizing function input to TetGen was defined as 𝐿(𝑖, 𝑗, 𝑘) =
min(𝐿𝐴𝐶𝑇 (𝑖, 𝑗, 𝑘), 𝐿𝐶𝑇 (𝑖, 𝑗, 𝑘)). The output of TetGen was visually compared with the
original SPECT/CT and manual adjustments were made to 𝐿𝐴𝐶𝑇 (𝑖, 𝑗, 𝑘) to reduce the
number of tetrahedra to approximately 70,000. Our previous low-level benchmarking
showed run times of a few minutes with a similar number of tetrahedra, coarse energy
group structure (30 e-, 30 photon), 𝑆4 , and 𝑃0 scatter expansion. The final parameters
used to determine the mesh sizing function are list in Table 7. The only difference
between the two cases was in the 𝐿𝐴𝐶𝑇 (𝑖, 𝑗, 𝑘).
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𝐿𝐴𝐶𝑇 (𝑖, 𝑗, 𝑘) (cm)
131I

𝐿𝐴𝐶𝑇 (𝑖, 𝑗, 𝑘) (cm)
90Y

Normalized
Cumulative
Activity
Band (%)

𝑀𝐴𝑇(𝑖, 𝑗, 𝑘)

𝐿𝑀𝐴𝑇 (𝑖, 𝑗, 𝑘)
(cm)

|∇′𝑀𝐴𝑇(𝑖, 𝑗, 𝑘)|

𝛼|∇`𝑀𝐴𝑇| (𝑖, 𝑗, 𝑘)

0-10

8.0

8.0

Air

8.0

<9

1.0

10-20

8.0

4.0

Lung

4.0

9-16

0.8

20-40

4.0

2.0

Soft Tissue

2.0

> 16

0.6

40-60

2.0

1.0

Bone

1.0

60-80

1.0

0.5

80-100

0.5

0.25

Table 7. Parameters used in determining the final 90Y and 131I mesh-sizing
functions.
3.2.3.2 Mapping of source, material, and density to the tetrahedral mesh
After the mesh generation, each tetrahedron was assigned the counts (source),
material, and density from the nearest voxel in the corresponding MC input distribution.
The shortest distance between tetrahedron centroid and voxel centroid was used to
determine the nearest voxel.
The GBBS, in its current form, requires the user to explicitly list material-density
pairs (e.g. (tissue,0.99), (tissue,1.00), (tissue,1.01),…). For 90Y microspheres, minimal
absorbed dose differences within the liver have been shown when using a nominal
density139,144. Thus we used a single nominal density for each material: air = 0.001
g/cc, lung = 0.26 g/cc, soft tissue = 1.04 g/cc, and bone=1.85 g/cc. For the Na 131I
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SPECT/CT, densities were quantized at every 0.05 g/cc which lead to 42 unique
material-density pairs. For each material-density pair, a region was defined in the
GBBS that included the corresponding tetrahedra.

3.2.3.2 Cross Sections and Energy Groups
ATTILA requires multi-group energy cross sections, which were generated using
ZERKON (Varian Medical Systems, Palo Alto, CA), which is an extension of CEPXS.68
CEPXS has been benchmarked against several other codes suggesting it sufficiently
accounts for electron and photon interactions.69 For cross section generation, fullcoupling was used for both photon and electron sources with a Legendre expansion of
order 7. Cross sections were generated for air, soft tissue, lung, and bone matching the
atomic composition used in the MC simulations. Cross section files were generated for
each radionuclide emission component with approximately 30 energy groups for
electrons and 30 energy groups for photons.
3.2.3.3 Transport parameters
Three GBBS calculations were performed on the adaptive mesh for the

90Y

patient scan summarized in Table 8. Only the beta spectra of the 90Y source was
considered. The electron transport cut-off energy of 200 keV was the same for each
90Y

calculation. The first calculation ConvergenceWithBrem was run until the default

stopping criterion of 10−4 was achieved. The stopping criteria is defined as the change
in the scalar flux from the previous iteration normalized to the current iteration scalar
flux, and the maximum value over all tetrahedrons is used in the evaluation of
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convergence. The WithBrem calculation performs some photon transport, but not to
convergence. Instead, we chose to terminate the simulation after two outer iterations.
The NoBrem calculation only performs one single outer iteration.
𝑺𝑵

Calculation Name

𝑷𝑵

pcut (MeV)

Outer iterations

ConvergenceWithBrem 4

0

0.01

5

WithBrem

4

0

0.01

2*

NoBrem

4

0

2.2

1*

* indicates early termination due to set number of outer iterations being exceeded
Table 8. Summary of the different parameters used for the multiple

90Y

GBBS

calculations.
In practice, the number of outer iterations will be determined by convergence
properties. In this work we forced early termination. The use of early termination means
the GBBS did not converge according to its internal stopping criterion, but the
convergence criterion may be too strict or rigorous and not a good surrogate for clinical
accuracy requirements. It should be noted that early termination is routinely used in
clinical practice when performing iterative reconstructions of emission images.
Five GBBS calculations were performed for the

131I

patient scan. The electron

transport cut energy was set 0.1 MeV and the scatter expansion was isotropic 𝑃0 for all
131I

GBBS simulations. They are listed in Table 9. The Auger+IC calculation was the

auger and internal conversion electron component of the

131I

decay, while the Beta

calculation was for the beta component. Multiple angular quadrature orders were
investigated for the gamma + x-ray component.
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𝑺𝑵

Calculation Name

pcut (MeV)

Outer iterations

Auger+IC

4

0.69

4

Beta

4

0.77

5

Gamma+xray4

4

0.001

4

Gamma+xray8

8

0.001

4

Gamma+xray16

16

0.001

4

Table 9. Summary of the different parameters used for the multiple

131I

GBBS

calculations.
3.2.3.4 Post-processing to calculate absorbed doses for comparison with MC
During post-processing ATTILA computes the energy dependent scalar flux,
̂ ). The GBBS employs a linear discontinuous finite element
Φ(𝑟⃗, 𝐸), from Ψ(𝑟⃗, 𝐸, Ω
method for spatial discretization. Consequently, the solution varies linearly across a
tetrahedron. To make voxel-level comparisons with MC, the GBBS must calculate an
“effective” voxel dose. This was accomplished by reporting absorbed doses at the
centroids specified by the voxels. Absorbed dose point edits in the GBBS calculate the
energy reaction rate at the point in space and then divide the energy deposited by the
mass in a 1 cc sphere with density defined by the tetrahedron in which the point lays.
Further details of calculating reaction rates as post-processing steps are not replicated
here because they have been listed and described in previous publications. 11–14
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3.2.5 Analysis
Adaptive tetrahedral meshes were displayed in Paraview145 and compared to the
corresponding SPECT/CT slice. The percent difference in mean absorbed dose
between GBBS and MC was recorded for all VOIs. A line profile was drawn on an axial
slice through the tumor for the 90Y case and both MC and GBBS dose profiles were
plotted. Qualitative visual comparisons were performed for dose volume histograms.
The GBBS and MC coronal 131I absorbed dose distributions were inspected for notable
differences. Finally, the wall clock time for the GBBS transport was recorded for both
patient scans.
3.3 Results
3.3.1 90Y Tetrahedral Mesh
Figure 15 shows the 90Y SPECT/CT compared with the adaptive tetrahedral
mesh. The mesh contained ≈ 67,000 tetrahedra and the adaptation performed as
expected. The tumor with high uptake has increased sampling. Tetrahedra are larger in
air, and the interfaces are reasonably represented as shown by the lung soft tissue
interfaces, ribs, and spine.
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Tetrahedra Activity

SPECT/CT

Tetrahedra Material

Figure 15. Sample axial and coronal planes of the adaptive tetrahedral mesh
(a,c,d,b) compared with SPECT/CT (b,e) for the 90Y microsphere patient. The
material mapping (a,d) and activity mapping (c,f) have good qualitative
agreement. Material colors blue, cyan, beige, and red were representative of air,
lung, soft tissue, and bone, respectively. The tetrahedral activity mapping is
displayed on a log scale. The dashed line in (b) is plotted as a dose profile in
Figure 16b.
3.3.2 90Y GBBS calculations and comparison with MC
The multiple GBBS calculations yielded results similar to MC, but some GBBS
calcuations took substantially longer than the fastest ones. The NoBrem transport was
fastest and only took 34 seconds whereas the ConvergenceWithBrem took 165
seconds. Results from the NoBrem are shown in the remainder of the manuscript.
Excellent agreement was found between the GBBS and MC as demonstrated by the
dose volume histogram (DVH) and line profile comparison in Figure 16. In addition, the
differences between GBBS and MC for mean absorbed dose to VOIs are within 3.5%
as shown in Table 10.
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Figure 16. Dose volume histograms for the 90Y patient (a) showing excellent
agreement between MC and the GBBS ATTILA in the tumor and normal liver. A
dose line profile (b) also shows excellent agreement of the GBBS with MC across
the tumor.
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VOI

Mean absorbed dose percent
difference. (100*(GBBS-MC)/MC)

Tumor

1.0

Liver

-0.6

Right Lung

-1.0

Left Lung

3.4

Table 10. Summary of percent differences between GBBS and MC for

90Y

patient

tumor and normal tissue VOIs.

3.3.3 131I Tetrahedral Mesh

Figure 17 shows that the 131I tetrahedral mesh had good agreement with the
SPECT/CT. The mesh contained ≈ 69,000 tetrahedra. Tumor nodules in both lungs
had increased sampling with smaller tetrahedra, and the lung-soft tissue interfaces and
bone were well resolved.
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Tetrahedra Material

SPECT/CT
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Figure 17. Coronal plane comparing the 131I tetrahedral mesh with the SPECT/CT.
The material color definitions are the same as those used in Figure 15.
3.3.4 131I GBBS calculations and comparison with MC

The Auger+IC and Beta calculations each took 2 minutes for transport. The
three gamma+xray calculations took 5, 10, and 30 minutes with longer run times for
larger 𝑆𝑁 . All subsequent 131I GBBS analysis was performed using the total absorbed
dose by combing the Auger+IC, Beta, and gamma+xray4 calculations. Mean absorbed
doses to VOIs were within 4.5% of MC (Table 11), and the GBBS dose volume
histograms matched MC well, but they were slightly lower (Figure 18). The GBBS being
slightly lower is consistent with the results from our previous benchmarking in Chapter
2.
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VOI

Mean absorbed dose percent
difference. (100*(GBBS-MC)/MC)

Tumor 1

-4.2

Tumor 2

-3.7

Right Lung

-2.6

Left Lung

-2.3

Table 11. Summary of percent differences between GBBS and MC for

131I

patient

tumor and normal lung VOIs.

Figure 18. MC (solid) curves are slightly higher than the GBBS (dashed) DVH
curves for the 131I patient tumor and normal lung VOIs.
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Differences between GBBS and MC are noted in the coronal plane shown in
Figure 19. The GBBS absorbed dose matches MC well near and around the tumors,
but differences < 25 Gy do exist just outside the patient body. These differences seen
lateral to the spleen and liver and on either side of the neck are likely due to a
combination of differences in material assignment just outside the patient and ray
effects. They have no clinical importance, and could be simply removed by masking
absorbed doses to exist only within the patient’s body.

Figure 19. Qualitative visual comparison of GBBS (a) and MC (b) absorbed dose
distribution for 131I in the coronal plane through tumors and lungs.
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3.4 Discussion
When relaxing the tetrahedral meshing from the exact matching of voxel
geometry, the GBBS can be used to generate fast and accurate absorbed doses for
targeted radionuclide therapies. GBBS DVHs were virtually indistinguishable from MC
DVHs for both the 90Y and 131I patient scans. The percent differences of GBBS from
MC for mean absorbed doses of organs and tumors were also within a few percent.
This is not entirely surprising given that we previously found good agreement for

90Y

and 131I.
A unique contribution of this work lies in its approach to adaptive tetrahedral
mesh generation using a patient’s emission (SPECT or PET) and transmission (CT)
images. The adaptive mesh generation was performed to create a spatial discretization
used by the GBBS that enabled fast and accurate absorbed dose calculations.
Although a more rigorous and in-depth optimization can be performed, we believe this
to be a good starting point that produces excellent quantitative comparisons with MC.
In addition, others interested in radiation transport of unsealed sources in patients will
likely find our adaptive tetrahedral mesh approach useful because both Geant4 and
MCNP have recently implemented support for unstructured tetrahedral meshes.
Our approach for adaptive meshing needs to be further investigated for
automation and robustness. In this work, we customized the activity mapping for both
the 90Y and 131I patient scans. As such, the current method is not automatic and
requires some manual intervention. Nevertheless, we have shown in this work that it is
possible to generate fast and accurate, relative to MC, GBBS absorbed doses.
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Activity, material, and density distributions drove the mesh generation in this
work. However, there is additional information that could be incorporated into the mesh
generation including 1) gradients from the SPECT; 2) error metrics from the GBBS
when performing iterative refinement; and 3) pre-segmented volumes of interest. The
incorporation of additional data should be a future area of study.
Bone marrow and kidneys are typically the dose limiting tissues in nuclear
medicine. We have only shown comparisons of voxel-level absorbed dose. Advances
in imaging and development of models that tie macroscopic images to red marrow
toxicity will be needed to further improve the state of voxel-level dosimetry. However,
the biological effective dose at a macroscopic level has been shown to be useful when
predicting kidney toxicity97,146. Consequently, there is still tremendous value in voxellevel absorbed doses.
3.5 Conclusion
Our implementation of GBBS with adaptive meshing showed that fast and
accurate patient-specific voxel-level absorbed dose calculations are feasible for clinical
nuclear medicine dosimetry.
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Chapter 4: Biases and variability in tumor and non-tumoral absorbed doses from
clinical dosimetry models applied to post-therapy 90Y SPECT/CT
4.1. Introduction
The use of

90Y

microspheres is an established palliative therapy for primary

hepatocellular carcinoma (HCC) and metastatic disease found in the liver (e.g. metastatic
colorectal cancer)147. The standard dosimetry model for both glass and resin

90Y

microsphere devices is extremely coarse80,81; it assumes uniform uptake of microspheres
in the entire target volume including the tumors. There are, however, differences in
dosimetry models between glass and resin microspheres: glass uses the MIRD model 80
(STD) and resin uses the empirical or body surface area (BSA) model81. The dosimetry
is designed to keep mean lung doses below 25-30 Gy and to maintain mean whole liver
doses below a certain threshold 148. Current microsphere dosimetry models are focused
on safety and not on ensuring that targets receive tumorcidal absorbed doses.
Nevertheless, 90Y therapies have shown promising clinical results149–158.
An alternative, but much less frequently used, dosimetry method for resin
microspheres is the partition model159 (PM), where the non-tumoral liver (NT) and tumors
(T) are separated with a fixed concentration of microsphere uptake in each compartment.
The PM is an improvement over STD or BSA, but it also has major limitations. For
patients with multiple tumors, it is unable to account for variable tumor microsphere
concentration and therefore it can only provide an average absorbed dose to all the
tumors – meaning individual tumors may be assigned an incorrect mean absorbed dose.
Even in the best case of a single tumor, the PM assumes uniform uptake within T and
NT and therefore only reports mean absorbed doses to both T and NT; thus the PM is
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unable to account for the heterogeneity of dose within T or NT compartments. When
estimating the T-to-NT ratio (TNR) as required by PM, the NT uptake is often estimated
using a single volume of interest (VOI) placed in either the T, NT, or both on the SPECT
image as opposed to VOIs that represent the entire NT or T. This type of haphazard
sampling increases the uncertainty or variability in reported PM absorbed doses.
From radiation oncology, we expect the minimum absorbed dose to tumor to be
a better predictor of response than the mean absorbed dose, but the PM is not designed
to calculate the minimum. In spite of these limitations, the PM has been used to assess
response to therapy and some studies have shown that when tumors exceeded a mean
absorbed dose threshold, the patients had improved progression free and overall
survivals 150–152,154.
Most 90Y dosimetry and treatment planning studies have been based on the STD
or PM, but recently several groups have investigated voxel-level dosimetry, including
Monte Carlo (MC), for

90Y 60,104,112,122,135,139,160–162.

Transitioning to new dosimetry

models is difficult and requires acquiring a new “clinical intuition.” Thus, comparing
currently accepted dosimetry models with future voxel-based models is a necessary step
towards clinical adaptation and implementation. An important motivation for this work is
to demonstrate the salient concept that 100 Gy as calculated by STD does not equal 100
Gy calculated by PM does not equal 100 Gy by voxel-based dosimetry. All dosimetry
models have biases and uncertainties, and transformations or mappings are necessary
to provide a consistent frame of reference (i.e. “equivalent”) for absorbed doses across
dosimetry models. External beam radiation therapy has progressed through such
growing

pains,

and

sealed

source

brachytherapy
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is

undergoing

a

similar

transformation55. Therefore, there is a critical need to understand both fundamental and
quantitative differences between voxel-level dosimetry models and both STD and PM.
The goal of this work is to highlight limitations of STD and PM in estimating T and
NT absorbed doses by comparing them with MC. We compare mean T and NT absorbed
doses between STD, PM, and MC to elucidate correlations and assess the value of using
STD and PM to predict mean MC dose estimates for an individual patient’s T and NT.
We also quantify variability in PM T and NT absorbed dose due to uncertainty in NT
uptake estimation. We perform a separate subset of analyses for the best case scenario
of a solitary tumor, as well as, the more realistic cases involving multiple tumors.

4.2. Materials and Methods
4.2.1 Patient Data
We retrospectively analyzed imaging data from 19 hepatocellular cancer (HCC)
patients treated with

90Y

glass microspheres. During planning the administered activity

was determined using the STD model described in the device package insert80 to deliver
80-120 Gy to the target volume (mass); this dosimetry model assumes the activity is
uniformly delivered to the entire target mass (whole liver, single lobe, or segment)
excluding the lung shunt fraction (LS). The liver volume used in the planning calculation
was determined from an anatomic diagnostic scan (contrast-enhanced CT or magnetic
resonance image). The planned activity was adjusted to account for LS, which was
obtained from a planar 99mTc MAA imaging study.
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This retrospective study was approved by the UT MD Anderson Cancer Center
Institutional Review Board protocol DR09-0025. The average administered activity was
3.14 ± 1.29 GBq (N=19) and the average target mass was 1.81 ± 0.66 kg (N=19).
Quantitative

90Y

SPECT/CT post-therapy imaging was performed a few hours after the

therapeutic interventional procedure. All dosimetric analysis in this work was performed
using the post-therapy quantitative 90Y SPECT/CT.
Registration and segmentation was performed using MiM Maestro v6.4. The
diagnostic CT or MRI scan was rigidly registered to the CT from the 90Y SPECT/CT scan.
The interventional radiologist segmented up to three tumors on attenuation CT from the
SPECT/CT using information from the registered diagnostic scan as a guide. Each
segmented tumor was required to be greater than 2.5 cm in diameter. The limit on
number of tumors was set arbitrarily as a practical limit; the tumor diameter was chosen
because the spatial resolution of our 90Y SPECT has been measured as 20 mm full-width
half maximum in water.
4.2.2 Dosimetry Models Applied to Post-Therapy Imaging
We applied three dosimetry models to each patient’s treatment based on the posttherapy imaging. The administered activity (A), and T and NT VOIs (and thus masses,
M), were kept constant between the models. STD combines NT with T as a single target
(T+NT) shown in equation [1]. Throughout this chapter all masses, absorbed doses, and
activities have units of kilograms, Grays, and Giga-Becquerels, respectively, unless
stated otherwise. We did not apply a LS correction for this investigation, as the accuracy
of MAA planar LS is questionable163, and in Chapter 5 we show that lung absorbed doses
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are very sensitive to the liver-lung interface139 and likely overestimate the lung absorbed
dose.
[1]

𝐷𝑇+𝑁𝑇 =

49.67 × 𝐴
𝑀𝑇+𝑁𝑇

Unlike STD, PM calculates separate absorbed doses for T and NT. This is
accomplished through the measurement of a TNR from the activity distribution – the
same distribution used for MC. Equations [2] and [3] describe the PM absorbed dose
calculation.

[2]

[3]

𝐷𝑇 =

49.67 × 𝐴 × 𝑇𝑁𝑅
𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅

𝐷𝑁𝑇 =

49.67 × 𝐴
𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅

Voxel-level absorbed doses were obtained using the EGSnrc (v4.2.4.0) user code
DOSXYZnrc, which models radiation transport via MC127,128. Several researchers have
used MC for 90Y voxel-based dosimetry103,104,111,122,139,160.
Voxel-level dosimetry requires calibration of the reconstructed SPECT. In this
work we performed a self-calibration; we exploited the fact that the administered activity
was contained within the SPECT field of view and calculated patient-specific calibration
factors by dividing the administered activity by the total counts in the SPECT. We
multiplied the SPECT by this factor to convert the SPECT to activity. We then assumed
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no biological clearance and converted the activity in a voxel to the total number of
disintegrations assuming a physical half-life of 64.1 h.
4.2.3 Assessing Partition Model variability
PM absorbed doses depend explicitly on TNR estimation, which represents a
source of variability. We assessed variation in the TNR by calculating four different TNRs
for each patient. This was done by varying the estimate of NT uptake (i.e., the
denominator in TNR). We estimated the NT uptake using the entire NT VOI and three
spherical VOIs (d=2.5 cm) that were placed by an interventional radiologist in the NT
compartment. In reality, there is also variability in T uptake (i.e., the numerator in TNR)
depending on if a sphere is used to sample the T uptake, anatomic VOIs are used versus
SPECT thresholding for T delineation, and inclusion or exclusion of necrotic cores. For
simplicity we did not vary T uptake; rather we used the volume-weighted average activity
concentration based on anatomic segmentation including necrotic cores.
Four TNR estimates lead to four PM absorbed doses (PMNT, PMS1, PMS2,
PMS3) for both T and NT. The variation in T and NT absorbed dose for each patient was
shown using a box and whisker plot. We summarized the coefficient of variation (COV)
seen in a given patient’s absorbed dose estimates for the following subsets: all cases,
cases with a single tumor, and cases with multiple tumors. Throughout this Chapter, the
reported PM absorbed doses were calculated using the TNR based on the entire NT
compartment unless stated otherwise.
To provide context for the contributing uncertainties in PM absorbed doses, we
performed an uncertainty analysis for T and NT derived from equations [2] and [3].
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Uncertainties in activity (Δ𝐴), target mass segmentation (Δ𝑀𝑇 ), and non-tumoral liver
mass segmentation (Δ𝑀𝑁𝑇 ) were estimated at the 95% level (e.g., Δ𝐴 = 1.96𝜎𝐴 ) from the
literature. TNR uncertainty was based on the measured average TNR COV across all
patients.
Assuming normally distributed uncertainties and that input variables are
uncorrelated, we estimated PM uncertainty for both tumor absorbed dose (Δ𝑃𝑀𝑇 ) and
non-tumoral liver absorbed dose (Δ𝑃𝑀𝑁𝑇 ). Equations [4] through [8] describe the
formulas and terms used for the PM T absorbed dose uncertainty analysis, while
equations [9] through [13] were used for PM NT analysis. Nominal values of activity,
masses, and TNR from our patient study were used to estimate absolute uncertainty for
an average patient.
[4]

(ΔPMT

)2

∂𝑃𝑀𝑇 2
∂𝑃𝑀𝑇 2
∂𝑃𝑀𝑇 2
∂𝑃𝑀𝑇 2
2
2
2
≈(
) (Δ𝐴) + (
) (Δ𝑀𝑁𝑇 ) + (
) (Δ𝑀𝑇 ) + (
) (Δ𝑇𝑁𝑅)2
∂A
∂MNT
∂MT
∂TNR

[5]

∂𝑃𝑀𝑇
49.67 × 𝑇𝑁𝑅
Δ𝐴 ≈
⋅ Δ𝐴
∂A
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)

[6]

∂𝑃𝑀𝑇
−49.67 × 𝐴 × 𝑇𝑁𝑅
Δ𝑀𝑁𝑇 ≈
⋅ Δ𝑀𝑁𝑇
∂MNT
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)2

[7]

∂𝑃𝑀𝑇
−49.67 × 𝐴 × 𝑇𝑁𝑅 2
Δ𝑀𝑇 ≈
⋅ Δ𝑀𝑇
∂MT
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)2

[8]

∂𝑃𝑀𝑇
−49.67 × 𝐴 × 𝑀𝑁𝑇
Δ𝑇𝑁𝑅 ≈
⋅ Δ𝑇𝑁𝑅
∂TNR
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)2
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[9]

(ΔPMNT )2 ≈ (

∂𝑃𝑀𝑁𝑇 2
∂𝑃𝑀𝑁𝑇 2
∂𝑃𝑀𝑁𝑇 2
∂𝑃𝑀𝑁𝑇 2
) (Δ𝐴)2 + (
) (Δ𝑀𝑁𝑇 )2 + (
) (Δ𝑀𝑇 )2 + (
) (Δ𝑇𝑁𝑅)2
∂A
∂MNT
∂MT
∂TNR

[10]

∂𝑃𝑀𝑁𝑇
49.67
Δ𝐴 ≈
⋅ Δ𝐴
∂A
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)

[11]

∂𝑃𝑀𝑁𝑇
−49.67 × 𝐴
Δ𝑀𝑁𝑇 ≈
⋅ Δ𝑀𝑁𝑇
∂MNT
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)2

[12]

∂𝑃𝑀𝑁𝑇
−49.67 × 𝐴 × 𝑇𝑁𝑅
Δ𝑀𝑇 ≈
⋅ Δ𝑀𝑇
∂MT
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)2

[13]

∂𝑃𝑀𝑁𝑇
−49.67 × 𝐴 × 𝑀𝑇
Δ𝑇𝑁𝑅 ≈
⋅ Δ𝑇𝑁𝑅
∂TNR
(𝑀𝑁𝑇 + 𝑀𝑇 × 𝑇𝑁𝑅)2

4.2.4 Using linear regression to transform Standard and Partition Model
absorbed doses to Monte Carlo absorbed doses
We compared the STD and PM absorbed doses to individual tumors (T) and nontumoral liver (NT) with their corresponding mean MC absorbed doses. Correlations
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between MC and STD and between MC and the four PM absorbed doses were
calculated using the freely available R statistical software (v3.2.1)164.
Using R, we performed bootstrapping165 to empirically estimate the following
parameters associated with linear regressions: mean slope and intercept, 95%
confidence intervals (95%CI) on mean and slope, and 95% prediction intervals (95%PI).
10,000 linear regressions were performed for each study. The 95%PI were calculated by
recording residuals from points that were not selected during a linear regression to
generate a distribution of residuals; percentiles were extracted from the distribution.
For both T and NT on each subset of patients (single tumor, multiple tumor, all),
we performed analysis using four models: Base STD, Base, Base & TNR, Base & 5%
MC, Base & TNR & 5% MC. Base STD is a bootstrapped linear regression of MC vs
STD. The Base calculation is a bootstrapped linear regression of MC vs PMNT. Base &
TNR incorporates TNR variability in PM by bootstrapping linear regressions of MC vs a
random sample PM value from PMNT, PMS1, PMS2, or PMS3. Base & 5% MC is a
bootstrapped linear regression of the MC vs PMNT where the MC value is resampled
from a Gaussian with a mean of the individual MC estimate and a sigma equal to 5% of
the individual MC estimate. 5% was selected because differences in modern radiation
transport codes in nuclear medicine are a few percent
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Base & TNR & 5% MC is a

bootstrapped linear regression that incorporates the variability in both PM and MC.
We report relative differences between the dosimetry models by calculating the
percent difference in mean absorbed dose between STD and MC, and PM and MC for
both T and NT, choosing MC as the reference.
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4.3. Results
4.3.1 STD, PM, and MC mean absorbed doses to tumor and non-tumoral liver
Figure 20 summarizes the absorbed doses for both T and NT calculated using
STD, PM, and MC dosimetry models. The mean and standard deviation of the
distributions in Figure 20 are listed in Table 12. For T, PM reported the highest absorbed
doses and STD reported the lowest. For NT, STD reported the largest absorbed dose
estimates and MC reported the smallest.
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Figure 20. Box and whisker plots summarizing absorbed dose to a) T and b) NT
calculated using STD (orange triangles), PM (purple circles), and average MC
(green circles). The red line is the median. The top and bottom of the box
represent the 1st (Q1) and 3rd quartile (Q3). The whiskers extend to the largest (or
smallest) value within 1.5*(Q3-Q1) + Q3 for largest (Q1 – 1.5*(Q3-Q1) for
smallest). Outliers beyond the whiskers are marked as crosses. Individual data
points are plotted to the left of the boxplots.

97

Subset
ALL

VOI
STD (Gy)
PM (Gy)
MC (Gy)
T
89 ± 27
226 ± 187
120 ± 91 (N=37)
NT
89
± 27
77 ±(N=19)
37 (N=19)
48 ± 22 (N=19)
(N=19)
SINGLE
T
86 ±(N=19)
32 (N=7) 304 ± 246 (N=7) 171 ± 128 (N=7)
NT 86 ± 32 (N=7)
72 ± 45 (N=7)
41 ± 23 (N=7)
MULTI
T
91 ± 24
181 ± 134
108 ± 77 (N=30)
NT
91
±
24
80
±
33
(N=12)
52 ± 21 (N=12)
(N=12)
(N=12)
Table 12. The mean(N=12)
± sd of absorbed doses using STD, PM, and MC for T and NT.

4.3.2 Variability of PM absorbed doses due to TNR variability from NT uptake
estimation
Variability in PM absorbed doses for T and NT is shown in Figure 21. T
absorbed dose ranged from 185 to 538 Gy for case 7, while NT ranged from 31 to 166
Gy for case 4. Table 13 summarizes the variability by reporting the average COV in
TNR and the corresponding average COV in PM T and NT absorbed doses. The COV
was largest for TNR and smallest for NT. On average, the subset of single tumor cases
exhibited higher COV than multiple tumor cases; T exhibited higher COV than NT.
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Figure 21. Boxplots showing variation in the distribution of PM absorbed doses
for a) T and b) NT. The variation is solely due to differences in estimating the NT
activity concentration using full NT or one of three spheres in NT. Indices 1-7
represent single tumor cases, and the remaining (8-19) cases had multiple
tumors. Boxplots are defined as explained in Figure 20.
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Subset

TNR COV

PM NT COV

PM T COV

Single T (N=7)
Multi T (N=12)
All (N=19)

0.58 ± 0.52
0.43 ± 0.18
0.48 ± 0.34

0.17 ± 0.18
0.17 ± 0.18
0.17 ± 0.18

0.30 ± 0.27
0.27 ± 0.16
0.28 ± 0.20

Table 13. The mean ± sd COV over the patients. These are COV values averaged
over the multiple patients in each subset.

Relative 95% uncertainty in parameters used to estimate uncertainty in the PM
calculations were taken from the literature with Δ𝐴 ≈ 10%,166 Δ𝑀𝑇 ≈ 30% − 50%, 167
Δ𝑀𝑁𝑇 ≈ 25%, 168 and Δ𝑇𝑁𝑅 ≈ 1.96 × 48% = 94% which was estimated from Table 13.
Nominal values for uncertainty in 𝑃𝑀𝑇 and 𝑃𝑀𝑁𝑇 , individual components of the total
uncertainty, and total estimated uncertainty are listed in Table 14. The nominal values
were taken from this study and used to calculate an estimate of the PM uncertainty for
an “average” patient.
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Nominal Input &
95% uncertainty
estimate
PM components of
95% uncertainty

Quantity
𝐴 (𝐺𝐵𝑞)
Δ𝐴 (𝐺𝐵𝑞)
𝑀𝑁𝑇 (𝑘𝑔)
Δ𝑀𝑁𝑇 (𝑘𝑔)
𝑀𝑇 (𝑘𝑔)
Δ𝑀𝑇 (𝑘𝑔)
𝑇𝑁𝑅
Δ𝑇𝑁𝑅
∂𝑃𝑀𝑋
Δ𝐴
∂A
∂𝑃𝑀𝑋
Δ𝑀𝑁𝑇
∂MNT
∂𝑃𝑀𝑋
Δ𝑀𝑇
∂MT
∂𝑃𝑀𝑋
Δ𝑇𝑁𝑅
∂TNR
Δ𝑃𝑀𝑋 (𝐺𝑦)

𝑷𝑴𝑻
3
0.3
1.3
0.33
0.4
0.12, 0.2
5
4.7
23

𝑷𝑴𝑵𝑻
3
0.3
1.3
0.33
0.4
0.12, 0.2
5
4.7
5

-23

-5

-42,-70

-8,-13

-83

-26

Total PM
99,113
95%
uncertainty
*𝑃𝑀𝑋 indicates 𝑃𝑀𝑇 or 𝑃𝑀𝑁𝑇 .

28,30

Table 14. Nominal values of activity, mass, and TNR from this study and their
corresponding absolute uncertainties used to estimate uncertainty in PM
absorbed doses. Two values are listed for 𝚫𝑴𝑻 corresponding to 30% and 50%.
Estimates of PM absorbed dose uncertainty are listed for individual components*
and the total in quadrature at the 95% uncertainty level.

4.3.3 Using linear regression to transform individual patient’s Standard and
Partition Model absorbed doses to Monte Carlo absorbed doses
The results of the correlation analyses are listed in Table 15. For T, STD and
MC absorbed doses were not correlated. For the subset of single tumor patients, we
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observed that MC and PMS2 were not correlated for NT. The remaining investigated
correlations in Table 15 were statistically significant (p<0.05). The correlation
coefficient was generally highest for the single tumor subset and higher for NT
compared to T.

All

Multiple

Single

NT
T
Subset Correlating
r (95% CI)
r (95% CI)
MC vs
0.991 (0.935,0.999)
0.996 (0.973,0.999)
MC vs
0.943 (0.658,0.992)
0.931 (0.594,0.990)
PMNT
MC
vs
0.518* (-0.386,0.914)
0.981 (0.870,0.997)
PMS1
MC
vs
0.970 (0.805,0.996)
0.884 (0.391,0.983)
MCPMS2
vs STD
0.868 (0.331,0.980)
0.635* (-0.226,0.939)
PMS3
MC vs
0.942 (0.803,0.984)
0.823 (0.658,0.913)
MC vs
0.910 (0.704,0.975)
0.688 (0.435,0.840)
PMNT
MC
vs
0.915 (0.719,0.976)
0.699 (0.452,0.846)
PMS1
MC
vs
0.945 (0.810,0.985)
0.775 (0.575,0.887)
MCPMS2
vs STD
0.830 (0.490,0.951)
-0.024* (-0.381,0.339)
PMS3
MC vs
0.951 (0.875,0.981)
0.898 (0.810,0.947)
MC vs
0.903 (0.762,0.963)
0.803 (0.647,0.894)
PMNT
MC
vs
0.769 (0.484,0.907)
0.763 (0.583,0.872)
PMS1
MC
vs
0.930 (0.823,0.973)
0.803 (0.647,0.894)
MCPMS2
vs STD
0.836 (0.616,0.935)
0.162* (-0.171,0.462)
PMS3
*indicates that p value of correlation was not statistically significant at the level of 0.05.
Table 15. Correlations of MC absorbed dose with PM and STD for multiple
subsets for both T and NT.
Linear regressions for MC as a function of PM and STD were evaluated for the
three subsets of patients (single, multiple, all). MC and the four PM absorbed doses are
plotted in Figure 22 with two selected linear regressions: the best case single tumor
subset (BASE), and the full variability for multiple tumor subset (BASE & TNR & 5%
MC). For clarity, the others were not plotted, but their results are included in Table 16.
Figure 22 shows that for tumors there was a large change in bias (slope, intercept) and
uncertainty (95%PI) when going from the best case single tumor BASE regression to
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the more realistic multiple tumor case BASE & TNR & 5% MC.
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Figure 22. Linear regressions of the mean MC absorbed doses as a function of
PM for a) T absorbed doses and b) NT absorbed doses. We plotted the linear fits
for the following cases: BASE for the subset of single tumor patients (red) and
BASE & TNR & 5% MC for the subset of multiple tumor patients (blue). The four
symbols represent the multiple PM absorbed dose calculations and the lines
correspond to fits and their 95%PI.
Table 16 shows the slope and intercept of the linear correlation together with the
95%CI of the linear transformation of absorbed dose estimates for STD to MC and PM
to MC. For no scenario is the slope near unity, which implies that the absorbed dose
estimates are drastically different between models. For T the BASE STD calculation is
a useless model for predicting MC absorbed doses due to the large 95%CI in model
parameters and correspondingly large 95%PI; this is in agreement with the fact that no
correlations were found between STD and MC for T. For NT, the BASE STD is
marginally meaningful due to the large 95%CI and 95%PI relative to the corresponding
transformed PM absorbed doses.
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Bias
Subset

Single
Tumor

Tumors

(N=7)
Multi
Tumor
(PMN=12,
All Tumor
MCN=30)
(PMN=19,
MCN=37)
Single

Non-tumoral Liver

Tumor
(N=7)
Multi
Tumor
(N=12)
All Tumor
(N=19)

Uncertainty

Bootstrapped linear regression

Slope ± 95%

Intercept ±

model for predicting MC

CI (MC/PM)

95% CI (Gy)

2.10±3.28
0.51±0.09
0.48±0.13
0.51±0.10
0.48±0.13
-0.10±0.97
0.56±0.22
0.34±0.10
0.56±0.21
0.34±0.11
0.59±1.39
0.53±0.06
0.39±0.09
0.53±0.07
0.39±0.09
0.67±0.40
0.51±0.05
0.40±0.10
0.52±0.09
0.41±0.12
0.78±0.51
0.60±0.16
0.53±0.06
0.60±0.17
0.53±0.08
0.70±0.25
0.57±0.09
0.47±0.05
0.56±0.10
0.47±0.06

-19±218
14±19
18±25
14±24
18±27
117±106
9±32
36±17
9±33
36±17
66±125
13±17
29±15
13±18
29±16
-17±31
4±5
13±11
3±7
13±12
-19±47
4±11
11±7
4±11
11±7
-15±21
4±6
13±6
5±7
13±6

Base STD
Base
Base & TNR
Base & 5% MC
Base & TNR & 5% MC
Base STD
Base
Base & TNR
Base & 5% MC
Base & TNR & 5% MC
Base STD
Base
Base & TNR
Base & 5% MC
Base & TNR & 5% MC
Base STD
Base
Base & TNR
Base & 5% MC
Base & TNR & 5% MC
Base STD
Base
Base & TNR
Base & 5% MC
Base & TNR & 5% MC
Base STD
Base
Base & TNR
Base & 5% MC
Base & TNR & 5% MC
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95% PI (Gy)

±290
±46
±133
±52
±132
±192
±95
±140
±98
±138
±230
±77
±126
±79
±128
±34
±8
±17
±10
±18
±28
±17
±15
±19
±16
±23
±15
±18
±16
±18

Table 16. Bootstrapped linear regressions for five models showing the bias
(slope and intercept) with 95%CI and uncertainty in transforming STD or PM to
MC.
The BASE for single tumor subsets had the smallest 95%PI of 46 Gy; this was
expected to be the best case when comparing MC with PM. For T, moving to the BASE
for multiple tumor subsets showed an increase of slope by around 10% compared to the
single tumor subset, and more importantly the 95%PI increased to 95 Gy – this increase
was expected since the PM is not designed to properly account for multiple tumors.
TNR variability found in the BASE & TNR and BASE & TNR & 5% MC T
regressions is responsible for the large increases in uncertainty or the 95%PI; 95%PI
increases from 46 Gy to 133 Gy and 95 Gy to 140 Gy for the single tumor and multiple
tumor subsets, respectively. TNR variability also causes a large change in bias for T in
multiple tumor subsets because the slope changes from 0.56 to 0.34, a difference of 40%.
For NT, the BASE for single tumor subsets had the smallest 95%PI of 8 Gy; the
BASE for multiple tumor subsets had a 95%PI of 17 Gy. TNR variability has less effect
on NT with 95%PI of approximately 17 Gy, and slopes changing from 0.51 to 0.41 and
0.60 to 0.53 for single and multiple tumor subsets, respectively.
Table 17 shows PM and STD absorbed doses relative to MC values. PM
absorbed doses on average overestimated MC by ≈ 70% for single tumor cases and ≈
100% for multiple tumor cases. The standard deviation of the PM vs MC differences
was ≈ 25% and ≈ 120% for T absorbed doses for single and multiple tumor cases,
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respectively. PM NT average differences were ≈ 70% for single tumors and ≈ 50% for

STD vs MC

PM vs MC

multiple tumor cases; the standard deviation of these differences stayed around 25%.

Single Tumor Cases

Multiple Tumor Cases

All Cases

T

69.6% ± 24.3% (N=7)

104.2% ± 118.8% (N=30)

97.6% ± 107.9% (N=37)

NT

70.9% ± 26.3% (N=7)

55.7% ± 22.8% (N=12)

61.3% ± 24.6% (N=19)

T

-22.6% ± 68.7% (N=7)

29.7% ± 98.3% (N=30)

19.8% ± 94.9% (N=37)

NT

144.6% ± 85.2% (N=7)

95.6% ± 71.5% (N=12)

113.7% ± 78.3% (N=19)

Table 17. The mean ± sd of percent differences from MC for STD and PM.
For STD vs MC, the T average differences were ≈ -20% for single T and ≈ 30%
for multiple T, but they had large standard deviations of 70% and 100% respectively. For
STD vs MC, NT average differences were ≈ 150% for single tumors and ≈ 100% for
multiple tumors; the corresponding standard deviations of 85% and 70%, respectively
indicated large individual differences from MC.
4.4. Discussion
This work represents the first investigation on comparing both STD and PM with
MC voxel-level dosimetry from post-therapy

90Y

SPECT/CT imaging using anatomic

VOIs registered from diagnostic CT scans. This work is important because it highlights
differences in clinically relevant

90Y

microsphere dosimetry models. Strengths of our
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study include the use of post-therapy imaging, identical VOIs were used for all dosimetry
models, MC absorbed doses, and subset analyses for patients with single tumor and
multiple tumors.
In this work we have demonstrated a critical aspect of 90Y microsphere dosimetry,
i.e., that using different dosimetry models (STD, PM, and MC) on the same input image
with matched VOIs can result in substantial differences in absorbed dose estimates. In
this work we transformed PM and STD absorbed doses to a common frame of reference
-- MC. The biases and uncertainties that result in the transformed absorbed doses are
largely a result of limitations inherent in the models: STD does not separate T and NT
while PM depends on TNR and doesn’t handle multiple tumors with varying TNRs well.
When viewing the transformed PM and STD results in Table 16, we consider the
slope and intercept as bias and the 95%PI as uncertainty. The table represents a
mapping of the PM and STD to a common dosimetry model – voxel-level MC. If the
95%CI is large on the slope and intercept, then the transformation is unreliable; this
can be seen with STD for tumors. For 90Y microsphere therapy, we are interested in
individual absorbed doses; thus the resulting 95%PI of the transformation is important.
Interpreting the transformations in this manner leads to the following observations: STD
is not useful for tumor dosimetry, PM performs better than STD, PM single tumor
performs better than PM multiple tumor, and TNR variability adds substantial
uncertainty in absorbed doses. Different dosimetry models output dramatically different
absorbed dose estimates; consequently caution is warranted when comparing tumor
dose response or toxicity data between studies that use different models. One possible
explanation for the large differences between PM and MC is calibration. PM and STD
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have an implicit calibration based on the delineated total volume T + NT. Thus, all
activity (excluding the LS contribution if modeled) is forced to be in the VOIs. Modifying
VOIs will change this implicit calibration which is problematic – the absorbed dose
calculation should be separate from and not dependent on T + NT segmentation.
The eventual goal is to estimate absolute true absorbed doses. However, the
reported absorbed doses also depend on factors other than the dosimetry model. There
may be additional biases and uncertainties stemming from image quality and registration;
for example, finite spatial resolution, noise, motion, and scatter and attenuation
compensation introduce errors. SPECT self-calibration also has limitations where
insufficient scatter compensation may lead to biases. We have matched the imaging and
VOI definition in this analysis to focus on differences in dosimetry models.
Using published data and results from our patient study, we estimated PM
uncertainty for an average patient. The analysis showed that TNR variability is currently
the dominant factor, even when assuming 50% variability in tumor masses. However,
Chiesa et al162 showed differences of ~200% in tumor masses between SPECT and
anatomical tumor delineation. An additional complicating factor is that the uncertainties
in T and NT will be coupled with TNR. This coupling results from a limitation that PM,
similar to STD, uses the segmentation to explicitly calculate the absorbed dose whereas
voxel-level dosimetry requires segmentation for reporting of absorbed doses.
The wide range of tumor response absorbed doses reported for glass
microspheres summarized by Cremonesi et al161 is due to several factors. Clinical
endpoint, MAA distributions not matching

90Y

distributions, SPECT versus CT

delineation, dosimetry model, and other factors affect the response modelling. Our
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results quantify a portion of the variability due to PM when using spheres to estimate NT.
However, it is clear that much more work is required to quantify biases and variability to
refine methodology and improve the consistency of reporting. Such consistency may not
be important for palliative intent, but for 90Y microsphere therapy to move towards a local
control or curative intent, it will be essential to understand and reduce biases and
variability.
4.5. Conclusion
Moving from STD or PM to voxel-based dosimetry models will require careful
interpretation and understanding of differences between the models. Most importantly,
physicists and clinicians should be aware that in practice 100 Gy STD, 100 Gy PM, and
100 Gy MC are not equivalent. Although voxel dosimetry based on

90Y

SPECT/CT has

limitations, at present it may be the most appropriate model to calculate tumor and nontumoral absorbed doses. All dosimetry models have biases and uncertainties, and
transformations or mappings must be implemented to provide a consistent frame of
reference when comparing absorbed doses across dosimetry models.
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Chapter 5: Comparing voxel-based absorbed dosimetry methods in tumors, liver,
lung, and at the liver-lung interface for 90Y microsphere selective internal
radiation therapy.

This chapter is based upon the following publication: Justin K. Mikell, Armeen
Mahvash, Wendy Siman, Firas Mourtada, and S. Cheenu Kappadath. Comparing
voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung
interface for 90Y microsphere selective internal radiation therapy. EJNMMI Physics
(2015) 2:16 DOI 10.1186/s40658-015-0119-y139. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly
credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated.
5.1 Introduction
Liver-directed selective internal radiation therapy (SIRT) has experienced clinical
growth in recent years for the management of both hepatocellular carcinomas and
metastatic disease from colorectal cancer, breast cancer, and neuro-endocrine tumors.
Methods to calculate the administered activity for SIRT rely on body surface area and
the assumption that activity is distributed uniformly throughout the liver, while the
absorbed dose to the lung is based on the lung shunt (LS) 80,81. A major limitation of
these models is that they do not separate tumors from normal liver (NL) and are more
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accurately characterized as “safety planning” methods rather than “treatment planning.”
The partition model 159 offers an improvement in that it separates tumors from NL, but it
simplistically models all tumors as a single entity having a singular uptake fraction and
assumes uniform activity distribution throughout the tumor and NL compartments.
Recent progress in post-therapy quantitative 90Y imaging with SPECT/CT and
PET/CT has facilitated voxel-level absorbed dose calculations. Voxel-based absorbed
dose calculations are affected by the 90Y image quality in terms of quantitative
accuracy and spatial resolution. Unlike other models, voxel-based absorbed dose
calculations do not require tumor burden, tumor segmentation or tumor uptake fraction
as inputs for estimating absorbed dose at each voxel. Organ-at-risk and tumor
segmentation are still necessary in voxel-based dosimetry, but segmentation is
performed to report on the calculated absorbed doses and not to explicitly calculate the
absorbed dose. Voxel-based dosimetry methods (VBDM) allow the absorbed dose
calculation to be independent of the tumor and organ-at-risk segmentation.
There are several methods to calculate voxel-based absorbed doses for SIRT.
However, little has been published in the literature comparing different VBDM, and the
comparisons have been confined to the liver 144. Lung dosimetry is of importance for
SIRT because absorbed dose to lung often limits the deliverable activity. The lung
shunt fraction can be estimated using 99mTc MAA with planar (or sometimes SPECT)
imaging169,170. In some instances, 99mTC-MAA SPECT/CT is performed to assess
extra-hepatic uptake and these can in principle be used for therapy planning

155

. 99mTc

MAA SPECT scans have superior image quality compared to post-therapy
bremsstrahlung 90Y SPECT scans, but there are studies showing MAA does not
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reliably predict the distribution of delivered 90Y microspheres

171

. To our knowledge,

no previous study has reported the use of VBDM for determining absorbed dose to lung
and explored the implications of different VBDM in the liver-lung interface region 172,173.
Both the EANM 169 and AAPM 170 provide guidance for clinical standard of practice 90Y
microsphere therapy, but neither document addresses the effect of different voxelbased dosimetry methods which are under investigation.
In this study, we investigated differences among four VBDM for tumor, liver, and
lung absorbed doses based on 90Y bremsstrahlung SPECT/CT imaging. Accuracy of
the different methods at the liver-lung interface was estimated for different spatial
resolutions and LS. Patient data was analyzed to determine the sensitivity of NL, right
̅̅̅̅) to the liver-lung interface.
lung (RL), and total liver mean absorbed dose (𝐴𝐷
5.2 Methods and Materials
5.2.1 Patient Data
Patient data were processed to assess the impact of the different VBDM on
absorbed dose calculations under realistic clinical situations. Accurate comparisons
between dosimetry models can be achieved by using the same input patient data
(administered activity and SPECT/CT images) into all of the VBDM. A total of 17 posttherapy 90Y SPECT/CT scans were selected for this study using a UT MD Anderson
Cancer Center Institutional Review Board approved retrospective chart review protocol
(DR09-0025), and informed consent requirement was waived. The mean administered
activity was 2.81 ± 1.04 GBq (range 1.13 to 5.21 GBq). The administered activities
were based on the package insert for the treatment device: ~120 Gy to treatment
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volume for glass microspheres. Adjustments were made to the activity based on the LS
fraction that was estimated by the 99mTc MAA scans. Diagnostic CT or magnetic
resonance images were manually registered to the SPECT/CT to aid in tumor
delineation. A single interventional radiologist segmented the liver and tumors for all
patients using the co-registered CT and/or magnetic resonance images. NL was
generated by subtracting the tumor contours from the liver contour. RL was segmented
using region growing in MIM Maestro v6.2 (MIM Software); RL was then inspected and
manually adjusted by a physicist.
The 90Y SPECT/CT scans were acquired on a Symbia T16 (Siemens Medical
Solutions) with medium-energy low-penetration collimation. SPECT data were
acquired with a 90-125 keV primary window and 312-413 keV scatter window for 128
views over 360 degrees with 28 s/view. A three-dimensional (3D) ordered-subset
expectation maximization (Flash3D, Siemens Medical Solutions) SPECT reconstruction
was performed using 4 iterations and 8 subsets and a 9.6 mm FWHM Gaussian postfilter. The reconstructed isotropic voxel size was 4.8 mm. The reconstruction modeled
geometric collimator response, CT-based attenuation correction using effective energy
of the primary energy window width, and an energy window-based scatter correction
174

. The spatial resolution of the reconstruction was estimated to be 20 mm FWHM

using an 90YCl2 line source in cold background.
Activity in each voxel (𝐴𝑖𝑗𝑘 ) was calculated by converting reconstructed SPECT
counts to activity through a self-calibration factor defined as 𝐴𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦/
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑢𝑛𝑡𝑠. We have assumed that all administered activity was within the SPECT
field of view because most of the lung was included in the SPECT field of view; no
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correction for LS was applied. The 𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑢𝑛𝑡𝑠 = ∑ 𝐶𝑖𝑗𝑘 where 𝐶𝑖𝑗𝑘 represents the
reconstructed counts in a voxel and the summation is over the entire SPECT volume.
Absorbed dose volume histograms of tumor, NL, and RL were generated for
each patient and each VBDM. Correlations of ̅̅̅̅
𝐴𝐷 from local deposition (LD), soft-tissue
kernel (SK), and soft-tissue kernel with density correction (SKD) with Monte Carlo (MC)
were investigated for tumor, NL, and RL. A qualitative evaluation of differences in the
isodose distributions was also performed.
5.2.2 Voxel-Based Dosimetry Methods Investigated: Monte Carlo (MC), Softtissue kernel with density correction (SKD), soft-tissue kernel (SK), and local
deposition (LD)
Four VBDM were investigated to calculate voxel-based absorbed doses for
SIRT: Monte Carlo (MC), soft-tissue kernel with density correction (SKD), soft-tissue
kernel (SK), and local deposition (LD). MC was performed with the EGSnrc
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code DOSXYZnrc 127. All electrons and photons were tracked down to kinetic energies
of 1 keV. The simulation parameters included bound Compton scattering, Rayleigh
scattering, atomic relaxations, Beithe-Heiler bremsstrahlung cross sections, simple
bremsstrahlung angular sampling, spin effects, exact boundary crossing, and PRESTAII128,129. Voxel-level material (𝑀𝑖𝑗𝑘 ), activity (𝐴𝑖𝑗𝑘 ), and density (𝜌𝑖𝑗𝑘 ) distributions were
derived from quantitative 90Y bremsstrahlung SPECT/CT. 𝜌𝑖𝑗𝑘 was determined from the
CT using a scanner- and technique-specific linear lookup table based on electron
density phantom scans. 𝑀𝑖𝑗𝑘 was generated by mapping 𝜌𝑖𝑗𝑘 to one of four materials (air
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, lung 100, soft tissue 131, or bone 100) based on density ranges.
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We assume that 90Y microspheres have no biological clearance, so the total
𝑇

1/2
number of disintegrations in a voxel is given by 𝑁𝑖𝑗𝑘 = 𝐴𝑖𝑗𝑘 ⋅ ln(2)
where 𝑇1/2 is the

physical half-life of 90Y (64.1 h). The 90Y 𝛽 − emission has a maximum energy of 2.28
MeV, corresponding to a maximum range of 11 mm in soft tissue 130, but the range
increases to 44 mm in lung with density 0.26 g/cc.
Table 18 summarizes the different VBDM investigated in this work. Absorbed
doses calculated using MC are a function of material, total number of disintegrations,
density, and the energy spectra of the beta particle emitted. Patient MC simulations
were performed using 109 histories. LD requires only the average energy of the beta
particle and mass of each voxel. For SK and SKD, the absorbed dose soft tissue kernel
was generated from MC simulations in an infinite soft-tissue medium with density of
1.04 g/cc using 2x109 histories; it was validated by comparing with Lanconelli et al.
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The simulation yielded statistical uncertainty ≤ 0.002% in the source voxel and ≤ 2.5%
at 40 mm. The kernel had isotropic voxel size of 4.8 mm matching the reconstructed
SPECT. SK and SKD were calculated by convolving the total number of disintegrations
with the kernel; convolutions were performed in IDL v8.2 (Exelis Visual Information
Solutions). SKD was then scaled by the ratio of kernel density to voxel density
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.

VBDM

Functional Form

Monte Carlo (MC)

𝐹(𝑀𝑖𝑗𝑘 , 𝑁𝑖𝑗𝑘 , 𝜌𝑖𝑗𝑘 , 𝐸90𝑌 )

Notes
𝐸90𝑌 is the beta energy spectra
per disintegration
𝐸𝑎𝑣𝑔 (0.937 𝑀𝑒𝑉) is the average

Local Deposition

𝑁𝑖𝑗𝑘 ⋅

(LD)

𝐸𝑎𝑣𝑔
𝜌𝑖𝑗𝑘 ⋅ Δ𝑉

energy of the beta particle per
disintegration. Δ𝑉 is the volume
of a voxel.
𝐾𝑖′𝑗′𝑘′ is obtained from a MC

Soft-tissue Kernel

simulation of infinite uniform soft-

𝑁𝑖𝑗𝑘 ⊗ 𝐾𝑖′𝑗′𝑘′

(SK)

tissue material with density of
1.04 g/cc.

Soft-tissue Kernel
with Density

(𝑁𝑖𝑗𝑘 ⊗ 𝐾𝑖 ′ 𝑗′ 𝑘 ′ ) ⋅

1.04
𝜌𝑖𝑗𝑘

Assumes 𝜌𝑖𝑗𝑘 is in units of g/cc

Correction (SKD)
*⊗denotes convolution.
Table 18. Characteristics of the different VBDM investigated.
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5.2.3 Assessing sensitivity of non-tumoral liver (NL), right lung (RL), and total
liver mean absorbed dose to the liver-lung interface
To assess sensitivity of NL, RL, and total liver ̅̅̅̅
𝐴𝐷 to the liver-lung interface in
patient data, we generated remainder VOI for total liver, NL, and RL by excluding
regions extending 1, 2, or 3 cm from the liver-lung interface into both the liver and lung.
The sensitivity of ̅̅̅̅
𝐴𝐷 on segmentation was analyzed in Excel by plotting the ̅̅̅̅
𝐴𝐷 to the
original VOI as a function of the ̅̅̅̅
𝐴𝐷 to the remainder VOIs, and fitting a line to the data.
Figure 23 shows an example of how the remainder VOIs were determined.
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Figure 23. Sagittal view through liver and RL illustrating excluded regions from
the liver-lung interface. Remainder RL (red), excluded RL (yellow), excluded liver
(blue), and remainder liver (pink).

5.2.4 Simulation to estimate the impact of spatial resolution and lung shunt (LS)
on the accuracy of voxel-based dosimetry method (VBDM) at the liver-lung
interface
Simulations were performed to estimate errors in the absorbed dose calculations
around the liver-lung interface for the different VBDM as a function of spatial resolution
and LS. We used a slab geometry with multiple spatial resolutions and LS; this simple
simulation had two compartments (liver and lung) shown in Figure 24 and did not use
119

patient data. We placed a uniform amount of activity in the liver compartment
representing a true activity distribution. To simulate limited spatial resolution, the
activity in the liver was convolved with a Gaussian FWHM of 10 or 20 mm causing
count spill-out of the liver and spill-in to the lung; spill-out from the lung into the liver
also occurs for non-zero LS fractions. MC, SK, SKD, and LD voxel-level absorbed
doses were then calculated on the three activity distributions (0, 10, 20 mm FWHM)
and were normalized to the input activity. A similar process was carried out for the lung.

Figure 24. Schematic geometry of the simulations for the liver-lung interface with
uniform activity in the slab representing either the liver (a) or lung (b). Arbitrary
lung shunt fractions (LS) were achieved through superposition of individual
voxel-based dosimetry methods (VBDM) for both liver and lung. Finite spatial
resolution was modeled through Gaussian blurring. Data were averaged in the
orange region to generate 1D absorbed dose profiles along the dashed line.
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The density of soft tissue and lung was set to 1.04 g/cc
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and 0.26 g/cc 100,

respectively. A newer ICRP report 176 lists the density of lung as 0.25 g/cc, but we do
not expect results to change significantly due to a 0.01 g/cc difference in density. The
simulation volume consisted of 61 × 61 × 61 4.8 mm isotropic voxels. These voxels
were padded such that the total dimensions were 200 × 200 × 200 cm3 approximating
an infinite phantom. One-dimensional (1D) line profiles along the z axis were generated
by averaging the central 7 × 7 voxels in each x-y plane.
For the three spatial resolutions, the liver and lung VBDM absorbed doses were
combined via superposition by weighting the lung component by LS and the liver by 1LS. We investigated LS of 1, 10, and 20%. For quantitative comparison between
VBDM, we defined the true absorbed dose distribution as the MC profile of 0 mm
FWHM for a given LS; specifically, distance intervals along the 1D profile for which the
different calculations agreed within ±10% of the truth are reported.
5.3 Results
5.3.1 Comparing soft-tissue kernel with density correction (SKD), soft-tissue
kernel (SK), and local deposition (LD) with Monte Carlo (MC) for patients
Figure 25 illustrates the salient differences in the apparent absorbed dose
distribution stemming from the four VBDM; it shows the different absorbed dose
calculations throughout the RL and liver on a coronal CT slice for a patient. The
isodose curves deep within the liver were nearly identical for all four methods. The 20
Gy line extended furthest in the lung for SKD and LD followed by MC and then SK
(least penetration into lung). The LD isodose distribution was very similar to the SKD
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distribution. There was an unequivocal qualitative difference in the lung absorbed dose
distribution when SK was compared with MC, LD, or SKD, owing to the fact that SK
assumes soft-tissue density of 1.04 g/cc regardless of the true density and material
composition.
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Figure 25. A coronal plane through the RL and liver illustrating salient
differences between the four different voxel-based dosimetry methods (VBDM):
(a) Monte Carlo (MC) (b) local deposition (LD) (c) soft-tissue kernel (SK) (d) soft123

tissue kernel with density correction (SKD). The tumor (shaded in cyan) is 5.2 cm
in length in the cranial-caudal direction.

The correlations in absorbed dose as estimated using LD, SK, and SKD in
relation to the true values from MC are shown in Figure 26. All the correlations had
𝑅 2 > 0.975. Slopes of the fit lines ranged from 0.98 to 1.00 for tumors and NL. For RL
̅̅̅̅, the slopes were 0.88, 0.90, and 2.32 for SKD, LD, and SK respectively. The
𝐴𝐷
summary of percent differences relative to MC are listed in Table 19. ̅̅̅̅
𝐴𝐷 to tumors and
NL using LD, SK, and SKD were within 5% of MC . For ̅̅̅̅
𝐴𝐷 to RL, LD had the best
agreement (17% on average) with MC, whereas SK had the poorest agreement (-60%
on average).
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Figure 26. The correlation of patient absorbed doses from Monte Carlo (MC) with
those from local deposition (LD) (green triangles), soft-tissue kernel (SK) (red
squares), and soft-tissue kernel with density correction (SKD) (blue diamonds)
̅̅̅̅ (N=31) , (b) non-tumoral liver (NL) 𝑨𝑫
̅̅̅̅ (N=17) , and (c) right lung
for (a) tumor 𝑨𝑫
̅̅̅̅ (N=17) shown together with their linear fits. The gray dashed line
(RL) 𝑨𝑫
represents the line of equivalence.
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SKD vs. MC

SK vs. MC

LD vs. MC

-0.2% ± 0.3%,

1.6% ± 1.2%,

0.9% ± 1.2%,

[-1.7%, 0.0%]

[-2.6%, 3.1%]

[-0.4%, 4.7%]

-0.3% ± 0.1%,

1.5% ± 0.7%,

-0.1% ± 0.5%,

[-0.5%, -0.1%]

[-0.6%, 2.3%]

[-1.3%, 0.6%]

19.6% ± 9.9%,

-60.2% ± 3.7%,

17.4% ± 9.4%,

[7.3%, 48.3%]

[-65.8%, -52.7%]

[6.5%, 45.1%]

̅̅̅̅
tumor 𝐴𝐷

̅̅̅̅
NL 𝐴𝐷

RL ̅̅̅̅
𝐴𝐷

*𝜇 ± 𝜎, [𝑚𝑖𝑛, 𝑚𝑎𝑥] of (100×(calculation – MC)/MC)
Table 19. Percent differences in ̅̅̅̅
𝑨𝑫 when using SKD, SK, and LD compared with
MC.

5.3.2 Sensitivity of total liver, non-tumoral liver (NL), and right lung (RL) mean
doses to the liver-lung interface
̅̅̅̅ to the RL when regions extending 1, 2, or 3 cm
Figure 27 shows the MC 𝐴𝐷
from the liver-lung interface were excluded from both the liver and lung VOIs. The
sensitivity was similar for all VBDM. For total liver the slopes were 0.94, 0.87, and 0.74
when excluding 1, 2, and 3 cm from the interface, respectively; NL was less sensitive
with slopes of 0.97, 0.94, and 0.92 respectively, and RL was the most sensitive with
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slopes of 1.43, 1.89, and 2.14, respectively. The RL ̅̅̅̅
𝐴𝐷 sensitivity to the liver-lung
interface was seen as a strong departure from the line of equivalence (Figure 27).
Excluding up to 3 cm of the liver-lung interface for the total liver and NL resulted in
average differences of 4.1% and 6.9%, respectively, from the original ̅̅̅̅
𝐴𝐷 to VOIs
(without excluded regions), suggesting relative insensitivity to the interface region. On
the contrary, excluding up to 3 cm of the interface for the RL led to an average
difference of -48.4% from the original ̅̅̅̅
𝐴𝐷, suggesting that RL ̅̅̅̅
𝐴𝐷 is very sensitive to the
interface region.

Figure 27. The MC ̅̅̅̅
𝑨𝑫 to the patients’ right lung (RL) (N=17) when regions
extending 1 cm (blue circle), 2 cm (red x), or 3 cm (green pentagon) from the
liver-lung interface were excluded from the original RL VOI, shown together with
the linear fit. The gray dashed line represents the line of equivalence.
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5.3.3 Effect of spatial resolution and lung shunt (LS) on accuracy of the voxelbased dosimetry method (VBDM) at the liver-lung interface
Figure 28 shows the percent differences of the different absorbed dose
calculations relative to the truth (MC of true activity distributions) for different LS and
different FWHM. LD is not displayed since the differences were similar to SKD. Errors
on the liver side of the interface were generally within 30% and approached 0 as the
blurring decreased to 0 and moved away from the interface deeper into the liver. Near
the lung interface, errors for 20 mm FWHM blurring and 1% LS were within 20% when
using SK compared to errors over 200% for MC and SKD. Table 20 lists the distance
intervals where agreement with MC was within 10%; on the liver side, agreement to
within 10% for all methods was found beyond 4, 6, and 12 mm from the interface for 0,
10, and 20 mm FWHM blurring, respectively, and a LS from 1% to 20%. For MC, LD,
and SKD in the lung, agreement was found beyond 26, 31, and 39 mm for 0, 10, and
20 mm FWHM blurring, respectively.
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Figure 28. 1D profiles from VBDM simulations with different spatial resolution (20
mm FWHM (blue), 10 mm FWHM (red), 0 mm FWHM (orange)) at the liver-lung
interface, showing percentage differences from MC without blurring. Local
deposition (LD) is omitted since it was similar to Soft-tissue kernel with density
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correction (SKD). LS is 1% in (a) Monte Carlo (MC), (b)SKD, and (c) soft-tissue
kernel (SK). Lung shunt (LS) is 20% in (d) MC, (e) SKD, and (f) SK.
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VBDM

LS

Blurring FWHM (mm)

(%)

MC

LD

SKD

SK

0

10

20

1

(-∞, ∞ )

(-∞,-4) U (31,∞)

(-∞,-12) U (39, ∞)

10

(-∞, ∞ )

(-∞, -3) U (-2, -1) U (17, ∞)

(-∞ ,-11) U (-2,-1) U (26, ∞)

20

(-∞, ∞ )

(-∞, 0) U (11, ∞)

(-∞, -10) U (-2,-1) U (21,∞ )

1

(-∞, -4) U (-2,-1) U (26, ∞)

(-∞,-4) U (-2,-1) U (7,8) U(26, ∞)

(-∞,-11) U (-2,-1) U (24, ∞)

10

(-∞, 0) U (11,∞)

(-∞, -5) U (-2,-1) U (7, ∞)

(-∞,-11) U (-2,-1) U (19, ∞)

20

(-∞, ∞)

(-∞ ,-5) U (-2,-1) U (8,∞)

(∞,-9) U (-2,-1) U (16, ∞ )

1

(-∞,-2) U (4,5) U (23,∞)

(-∞,-6) U (-2,-1) U (10,11) U (23, ∞)

(-∞, -11) U (-2,-1) U (29,∞)

10

(-∞, -1) U (6, ∞)

(-∞,-6) U(-2,-1) U(11,∞)

(-∞,-11) U (-2,-1) U (23,∞)

20

(-∞, -1) U (7,∞)

(-∞, -6) U (-2,-1) U (11, ∞)

(-∞,-10) U (-2,-1) U (21, ∞)

1

(-∞, -2)

(-∞, -6)

(-∞, -11) U (-0.5, 2) U (9, 13)

10

(-∞, -2)

(-∞, -6)

(-∞, -11)

20

(-∞, -2)

(-∞, -6)

(-∞, -10)

*The true absorbed dose distribution was MC with FHWM=0. We employed interval
notation (e.g. (𝑥1, 𝑥2) ⋃ (𝑥3, 𝑥4).
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Table 20. Intervals in millimeters where the VBDM were accurate to within 10% as
a function of lung shunt (LS) and FWHM, where positions ≤ 0 represents liver,
positions > 0 represents lung, and 0 represents the liver-lung interface.
SK approximated the true absorbed dose near the lung interface well for 1% LS
with blurring of 10 mm and 20 mm, but significantly underestimated the absorbed dose
at the lung interface and deep into the lung for the higher LS. MC matched the true lung
absorbed dose better for the higher LS and lower blurring. SKD and LD overestimated
near the lung interface compared to MC, but they both approached the true value deep
(>39 mm) within lung.
LD, SK, SKD, and MC approached the same value deep (>12 mm) within the
liver, and they were all similar on the liver side of the interface, with MC performing
slightly better than the others given a larger FWHM. On the liver side of the interface,
LD, SK, and SKD all underestimated the absorbed dose similarly when the activity
distribution was blurred.
Figure 29 provides context for the relative differences in Figure 28 by showing
line profiles of absorbed dose in arbitrary units for the VBDM with different lung shunt
fractions and spatial resolutions. Figure 29 can be used to estimate absolute errors in
the absorbed dose near the interface. For example, if one assumes the absorbed dose
within the liver far from the interface is 80 Gy , then the SKD absorbed dose in the lung
at 7 mm from the interface for LS = 1% and FWHM = 20 mm, would be ≈ 9.4E15/1.1E-14 * 80 Gy ≈ 68 Gy whereas the true value would be ≈ 1.9E-15/1.1E-14 * 80
Gy = 14 Gy.
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Figure 29. 1D dose distributions at the liver-lung interface to compare the four
VBDMs for different spatial resolution and LS. LS is 1% in (a) 0 mm FWHM, (b) 10
mm FWHM, and (c) 20 mm FWHM, while LS is 20% in (d) 0 mm FWHM, (e) 10 mm
FWHM, and (f) 20 mm FWHM. * A.U. = Arbitrary Units.
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5.4 Discussion
Our NL and tumor absorbed dose results are similar to those reported by
Dieudonne et al. 144; both studies showed better agreement with MC when using SKD
instead of SK. Our work adds to the body of knowledge on

90Y

dosimetry in part by

assessing absorbed dose differences in patient data due to differences in methodology.
We also included LD voxel-based estimates in our comparison; these estimates are
relevant since investigators have recently begun using LD in voxel-based absorbed
dose calculations following SIRT

123,177

. Lung dosimetry is also of central importance in

SIRT because lung absorbed dose limits the administered activity of

90Y

and can

prevent patients from receiving adequate therapeutic tumor absorbed doses. However,
to date, no work has compared VBDM for the lung and in the liver-lung interface based
on 90Y bremsstrahlung SPECT/CT imaging.
The correlations of local deposition (LD), soft-tissue kernel (SK), and soft-tissue
kernel with density correction (SKD) with Monte Carlo (MC) for mean absorbed dose to
tumors, NL, and RL could potentially be used to convert mean absorbed doses
between the different voxel-based dosimetry methods (VBDM) for our image
acquisition protocol.
Regarding absorbed doses in the lung, SKD and LD both overestimate the lung
dose by 15-20% relative to MC, while SK underestimates by 60%. The reason for the
underestimation by SK is that SK never truly encounters lung tissue - everything,
including the lung, is treated as 1.04 g/cc soft tissue. Consequently, the isodose curves
are significantly contracted in the lung because they see a density and mass four times
that of lung on average; this effectively reduces spatial transport and the local absorbed
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doses. For activity placed in the lung or near the liver-lung interface, MC will transport
the betas. Due to the lower density of lung, the transport distance can be significant on the order of a few cm. Thus, MC will transport the electron and the corresponding
energy deposition will occur over several centimeters. In contrast, LD assumes all the
electron energy is deposited locally within the voxel. Because the electrons and their
energy are not being spread out spatially with LD, the local energy density increases
which causes the absorbed dose to increase; this explains why LD is greater than MC
in the lung. A similar explanation holds for SKD; the only difference being that the
energy is spread out over a spatial kernel corresponding to 1.04 g/cc soft-tissue which
will be a smaller region (~1 cm) than MC will transport the electron and its energy in
lung (~ 4 cm).
̅̅̅̅ to the liver-lung
The sensitivity of the patients’ RL, NL, and total liver 𝐴𝐷
interface agrees with the trend that larger distances from the interface are required in
̅̅̅̅ decreased by
lung (relative to liver) to reach accurate absorbed doses. The RL 𝐴𝐷
~50% (8.8 ± 5.4 Gy to 4.2 ± 2.3 Gy) when 3 cm of the interface was excluded, whereas
̅̅̅̅ only increased by ~3% (45.1 ± 12.7 Gy to 46.6 ± 15.0 Gy) for a similar
the total liver 𝐴𝐷
̅̅̅̅
interface exclusion. From a clinical perspective, this finding highlights that the liver 𝐴𝐷
is not sensitive to the interface region, but RL ̅̅̅̅
𝐴𝐷 is sensitive to the interface and the
community needs to establish standards and guidelines for lung segmentation to
ensure proper reporting of lung absorbed doses when using VBDM. These findings call
for careful consideration of lung dose based on post-therapy Y90 imaging (and to a
lesser degree pre-therapy 99mTc-MAA) for cumulative lung dose calculation as part of
repeat treatments where cumulative lung dose is not to exceed 50 Gy. Patient
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respiratory motion further degrades the effective spatial resolution at the liver-lung
interface because motion correction techniques are not available in commercial
SPECT/CT systems.
The simulated estimates of accuracy for MC, LD, SK, and SKD around the liverlung interface as a function of LS and spatial resolution FWHM showed that all four
VBDM investigated are within 10% of the true liver absorbed dose when deeper than
12 mm from the liver-lung interface; this distance is expected to increase for larger
FWHM and lower LS. Using MC, LD, or SKD, a similar accuracy was achieved in the
lung when deeper than 39 mm from the interface. SK is not suitable for estimating
accurate deep lung absorbed doses, but in the special case where LS is small and
FWHM is large, SK may provide accurate estimates in close proximity to the liver-lung
interface; this transient accuracy occurs due to SK errors in lung dosimetry cancelling
errors due to count spill-in/out at the interface.
For the clinical results (tumors, NL, and RL), we have only investigated
differences among VBDM in this work. Although we estimated accuracy of VBDM at the
liver-lung interface through simulations, we have not performed such simulations for
patient data. Future work should include the use of virtual phantoms where the true
activity distribution is known followed by imaging simulation and application of VBDM to
estimate true accuracy of such methods in patients.
Some have argued that LD may be preferable to transport (SK, SKD, or MC)
for pure-beta emitters such as 90Y 122; radiation transport spreads 90Y beta energy
deposition locally at ~5 mm scale in soft-tissue. Their rationale is that the finite spatial
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resolution of the imaging system (typically >10 mm in emission imaging) can account
for beta radiation transport. However realistic particle transport will depend on tissue
type and density (e.g., soft tissue vs. lung). Although not discussed here, the collapsed
cone convolution is another VBDM that is accurate at the lung-soft tissue interface for
SIRT 60.
Our results on accuracy suggest that if one uses VBDM, then to reduce errors in
absorbed dose estimates at the interface, the effective spatial resolution (physical
spatial resolution and motion blurring) at the liver-lung interface should be minimized.
Improvements in SPECT image quality would provide improved voxel-based activity
distribution, especially at the liver-lung interface.
One limitation of our study stems from the use of a free-breathing CT scan as
part of the SPECT/CT scan. Consequently, the contoured liver/lung interface could be
from any point of the respiratory cycle. In the analysis of the interface on patient data,
the results must be viewed critically since there is not a straightforward method to
determine the correct spatial location or a reference volume for the lung. We have only
estimated errors in 1D absorbed doses for misplaced activity at the lung-liver interface
due to effective spatial resolution, not the change in activity due to incorrect attenuation
correction at the interface. Future work could involve analysis with some respiratory
motion management such as breath hold, average CT, or 4D-CT. There was also
uncertainty in the delineation of the tumor, liver, and lung and registration errors
between the diagnostic contrast scan and the attenuation scan from the SPECT. Our
RL segmentation methodology was similar to that of Busse et al., who reported that
region growing resulted in an average error of 7% for lung mass estimates based on
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free-breathing CT scans of the thorax 178. We would like to point out that the patient
data analysis was based on a single SPECT/CT model and customized imaging
protocol and segmentation by a single physician using data from our institution.
There are limitations to all imaging acquisition and reconstruction protocols.
Differences at the liver-lung interface depend on several parameters including spatial
resolution, respiratory motion, activity distribution near the interface, free-breathing CT
vs average CT vs breath-hold CT, and the corresponding scatter and attenuation
compensations during reconstruction. Consequently, the magnitude of the sensitivity of
right lung, total liver, and non-tumoral liver absorbed dose to the liver-lung interface
may change if PET/CT or a different SPECT/CT acquisition protocol or reconstruction
algorithm such as Rong et al. 179 is used. In this work we have investigated differences
among four VBDM for tumor, liver, and lung absorbed doses based on a given 90Y
bremsstrahlung SPECT/CT imaging technique; the magnitude of the clinical findings in
this work may change with different acquisition or reconstruction protocols, but the
trends in sensitivity to the interface should hold. Thus, these findings are not restricted
to any one specific Y90 image generation technique.
SPECT calibration is important for reconstructing quantitative images. We
estimated the 95% confidence interval in our self-calibration to be ~10%, based on 25
different patient scans. The purpose of this work was to investigate differences
between VBDM, and thus by design the administered activity and total SPECT counts
were the same between different VBDM. Therefore, the results of this work are not
sensitive to the uncertainties in SPECT self-calibration.

138

5.5 Conclusion
Voxel-based dosimetry was performed using post-therapy 90Y bremsstrahlung
SPECT/CT. Multiple VBDM (MC, LD, SKD, SK) were investigated and compared to MC
̅̅̅̅ for tumor, NL, and RL. Differences were equivalent (<5%) for tumor and NL 𝐴𝐷
̅̅̅̅,
for 𝐴𝐷
with SKD agreeing best with MC. Larger differences were found for the RL ̅̅̅̅
𝐴𝐷, with LD
agreeing best with MC and SK producing dramatically incorrect values deep in the
lung. Simulations of the liver-lung interface for multiple effective spatial resolutions and
LS were used to estimate nominal distance from the liver-lung interface where
accuracy within 10% was achieved deep within the liver, and deep within the lung.
̅̅̅̅ estimates to be sensitive to the
Finite spatial resolution was shown to cause RL 𝐴𝐷
liver-lung interface region.
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Chapter 6: Absorbed dose response for hepatocellular carcinoma (HCC) tumors
based on post-therapy 90Y SPECT/CT
6.1 Introduction
Liver cancer accounts for 748,000 new cancer cases every year making it the
6th most diagnosed cancer throughout the world71,72. It is almost always fatal, with
survival rates on the order of a few percent; liver cancers are estimated to cause
696,000 deaths per year globally - trailing only the number of deaths from lung
(1,380,000) and stomach (738,000) cancers.72 Consequently, investigations to improve
the efficacy of liver-directed therapies is of the utmost importance for the global
population.
Radioembolization is currently a promising palliative therapy for both
hepatocellular carcinoma (HCC) and metastatic colorectal cancer in the
liver149,154,155,180. Unfortunately, package insert dosimetry models used clinically (body
surface area (BSA), single compartment MIRD (STD), and three compartment partition
model MIRD (PM)) are very simplistic and have several limitations. The limitations
range from not being patient specific for BSA to not separating tumor and non-tumoral
liver for STD, and the PM’s inability to handle multiple tumors with variable tumor to
normal liver uptake ratios.
Voxel-level dosimetry overcomes many of the limitations in current clinical
dosimetry models. Furthermore, linear quadratic radiobiological modeling that
incorporates dose rate effects, repair kinetics, and radiosensitivity may be applied to
compute a biological effective dose (BED)46,121,161,181 from 90Y microsphere absorbed
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dose. The BED can then be transformed to an equivalent 2 Gy per fraction absorbed
dose (EQD2)182, which is the fractionation scheme for the majority of published
radiation therapy tumor and normal tissue response data. Such transformations may
yield additional insight into differences between radioembolization and external beam;
the BED or EQD2, in theory, will enable clinicians to use the large amount of response
data generated in radiation oncology.
99mTc

MAA is not a perfect surrogate for 90Y microspheres, and the concordance

rate between the 99mTc MAA treatment planning SPECT and the post therapy 90Y
SPECT or PET scan has been investigated by several authors121,171,183–185. The lack of
concordance may be due to several factors, including: changes in the tumor
vasculature; flow dynamics during delivery; catheter positions; the size, shape, and
number of MAA relative to microspheres; and the biological breakdown of MAA once
infused. Given the potential lack of concordance, tumor dose response should be
investigated using an estimate of the therapeutic activity distribution based on posttherapy imaging and not pre-therapy planning images.
The objective of this work was to retrospectively investigate HCC tumor dose
response on patients treated with glass microspheres with voxel-level dosimetry based
on post-therapy 90Y bremsstrahlung SPECT/CT. To accomplish the objective, response
criteria (RECIST, WHO, modified RECIST) were modeled as a univariate function of a
single dosimetric quantity for each of the following: mean voxel-level absorbed dose,
multiple dose volume histogram (DVH) coverage parameters, mean voxel-level BED,
and multiple BED DVH coverage parameters.
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6.2 Methods & Materials
6.2.1 Patient Data
This retrospective study was approved by the University of Texas MD Anderson
Cancer Center Institutional Review Board (protocol DR09-0025). Twenty-one patients
with HCC were treated with glass microspheres using package insert STD
dosimetry186. The average ± standard deviation of administered activity was 3.15 ± 1.22
GBq with a minimum of 1.13 GBq and maximum of 7.47 GBq.
Post-therapy imaging was performed using quantitative bremsstrahlung
SPECT/CT on a Siemens Symbia T6 with attenuation, scatter, and geometric
resolution compensations, and self-calibration174. All registration and segmentation was
performed using MiM Maestro v6.5. The CT portion of the post-therapy SPECT/CT was
rigidly registered with a diagnostic contrast enhanced CT or MRI. An interventional
radiologist segmented the total liver and right and left lobe volumes of interest (VOI),
using the CT from the post-therapy SPECT/CT; up to three tumors were delineated
using the registered diagnostic scan to aid tumor localization on the CT from posttherapy SPECT/CT. In total, 37 tumors were segmented. Normal liver was segmented
by subtraction of the tumors from the total liver. Normal left or normal right lobe was
created in a similar manner.
6.2.2 Response Criteria
Follow-up diagnostic scans were performed every 3 months after therapy.
Response was assessed on the 3 or 6 month scans. The following criteria were used to
determine response: 1) response evaluation criteria in solid tumors (RECIST)187,188; 2)
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world health organization (WHO)189; and 3) modified RECIST (mRECIST)190. RECIST
looks at changes in the longest diameter (1D), whereas WHO is the product of the
longest diameter and corresponding perpendicular diameter (2D). RECIST and WHO
are both anatomic morphological response metrics based on size. mRECIST
incorporates necrosis, which appears as non-enhancing portions of the HCC tumor on
follow-up contrast CT imaging, into the evaluation of response. Differences between
RECIST and WHO are shown graphically in Figure 1 in the review by Suzuki et al191,
and the difference between RECIST and mRECIST for HCC is clearly demonstrated in
Figure 1 of Lencioni and Llovet190. The European Association for the Study of the Liver
(EASL) response criteria192 was not investigated in this study; it is a two-dimensional
(similar to WHO) measurement that accounts for necrosis, non-enhancing HCC tumor
regions on follow-up contrast CT imaging.
Tumor response was initially classified as either progressive disease (PD),
stable disease (SD), partial response (PR), or complete response (CR). Due to the low
number of tumors investigated, the classifications were coarsened to non-responders
(NR = PD+SD) and responders (R = PR + CR).
6.2.3 Dosimetric Quantities
6.2.3.1 Voxel-level absorbed dose and biological effective dose

Voxel-level dose calculations were carried out with the EGSnrc128 user code
DOSXYZnrc127. Previous work139 by our group describes the process in more detail.
The voxel-level absorbed doses were converted to BED assuming continuous
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𝛼

irradiation (𝜏1𝑒𝑓𝑓 = 64.1 h) for the linear quadratic model, with 𝛽 of 15 Gy and 2.5 Gy
2

and repair half-lives (𝜏1𝑟𝑒𝑝𝑎𝑖𝑟 ) of 1.5 h and 2.5 h for HCC tumors and normal liver
2

tissues, respectively. The BED formalism detailed by Prideaux et al 46 was followed in
this work, and the radiobiological parameters for HCC were taken from Tai et al 193. The
average absorbed dose and average BED were reported for each tumor.
6.2.3.2 DVH and BEDVH metrics
Cumulative absorbed dose volume histograms (DVH) and cumulative BED DVH
(BEDVH) were calculated from the corresponding voxel-level distributions. In addition
to the mean absorbed dose (mean D) and mean BED, coverage metrics from both
were extracted: D70, D90, BED70, and BED90. DXX and BEDXX should be interpreted
as the absorbed dose or BED that covers XX percent of the given VOI volume. For
example, D0 is the maximum absorbed dose, and D100 is the minimum absorbed
dose. D90 represents the absorbed dose that encompasses 90% of the VOI volume.
6.2.4 Data Analysis
6.2.4.1 Summary data
All analysis was performed in the R statistical computing environment 164 version
3.2.2. The number of responders for each response criteria were tabulated.
Distributions of responders and non-responders were summarized in box plots. A twotailed t-test with unequal variance ($ output <- t.test(dose_responder,dose_ nonresponder)) was applied to test if the mean of responder and non-responder
distributions were different at a 0.05 level of significance; multiple dosimetric quantities
were investigated.
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6.2.4.2 Logistic Regression
Univariate logistic regression was applied to generate HCC tumor dose
response curves and included 95% confidence intervals. Odds ratios, 95% confidence
interval for odds ratios, Wald test p-values, and the p-values from likelihood ratio tests
were performed. Statistical significance at the 0.05 level is assumed. In addition, the
dosimetric value that yielded 50% chance of response (𝑑50% ) and the normalized doseresponse gradient (𝛾50%) were also reported, as these are common in the doseresponse literature194,195. Further explanation of logistic regression is contained in the
appendix.
Tabulated values were calculated according to the following R code:
$ output <- glm(response~dose, family=binomial(link=”logit”))
$ OR_95CI <- exp(cbind(OR=coef(output), confint(output)))
$ OR_95CI <- OR_95CI["xi",]
$ WaldPVal <- (summary(output))$coefficients["xi","Pr(>|z|)"]
$ LLRpvalue <- with(output, pchisq(null.deviance - deviance, df.null - df.residual,
lower.tail = FALSE))
The variable response is a vector consisting of the values ‘R’ or ‘NR’, and it has a length equal
to the number of tumors. The variable dose is a vector the same length of response and
contains the dosimetric value for each tumor. This process was repeated for different
dosimetric values. As a result, the dose variable would contain corresponding mean D, D70,
D90, mean BED, BED70, or BED90.

Fit curves and 95% confidence bands were generated based on the values
output by the following R code:
$ output <- glm(response~dose, family=binomial(link="logit"))
$ x <- seq(minDose,maxDose,1)
$ pmodel <- predict(output, list(response=x), type="link", se.fit=TRUE)
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$ y <- plogis(pmodel$fit)
$ yLL <- plogis(pmodel$fit - (1.96 * pmodel$se.fit))
$ yUL <- plogis(pmodel$fit + (1.96 * pmodel$se.fit))

6.2.4.3 Receiver operating curve
Receiver operating curves were generated using the pROC196 library in R. Area
under the curve and its 95% confidence interval were calculated for each response
metric for the dosimetric quantities. A “best” threshold dosimetric quantity was also
selected and the corresponding specificity and sensitivity was tabulated.
The ROC values were generated with the following R code:
$ rocobj <- roc(response,dose, percent = TRUE)
$ aucArr <- ci.auc(rocobj)
$ aucLL <- aucArr[1]
$ auc <- aucArr[2]
$ aucUL <- aucArr[3]
$ bestThresh <- coords(rocobj, "best")
$ thresh <- bestThresh[1]
$ SP <- bestThresh[2]
$ SE <- bestThresh[3]

6.3 Results
6.3.1 Box plots, t-tests, and summary of dosimetric quantities
Figure 30 shows the responders and non-responders in boxplots for mean, 90%
coverage, and 70% coverage for both absorbed dose and BED. In general, WHO and
RECIST produced similar distributions. Compared to mRECIST, WHO and RECIST
have non-responders with larger values for dosimetric quantities; these can be seen as
points beyond the whiskers on the box plots. For the response metrics shown, the
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responder median dosimetric quantity was greater than the corresponding nonresponder distribution.
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Figure 30. Boxplots summarizing the mRECIST, WHO, and RECIST tumor
responders (R) and non-responders (NR) for mean absorbed dose (a), mean BED
(b), D90 (c), BED90 (d), D70 (e), and BED70 (f).

The summary of responder and non-responder, and corresponding p-value from
the t-test are listed in Table 21. The results show that only mRECIST criteria provided
statistically significant different means in the responder and non-responder for all the
voxel-level dosimetric quantities investigated (both absorbed dose and BED). The
mean of the responder distribution was greater than the non-responder distribution for
all response criteria investigated. BED values were always larger in magnitude than the
corresponding absorbed dose values.
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Responder Distribution (Gy)

(Gy)

p-value

Response criteria

Dosimetric quantity

Non-responder Distribution

sd

min

max

mean

sd

min

Max

Dmean

177.8

109.6

35.1

383.7

80.1

29.5

26.7

128.5

0.003

D90

91.2

55.3

11.4

207.2

43.5

24.5

6.3

84.2

0.005

131.4

79.2

17.7

286.4

59.2

26.5

11.4

108.7

0.003

254.8

193.8

37.9

639.5

93.4

37.7

27.9

155.3

0.005

108.1

72.5

11.5

727.6

47.2

28.0

6.4

95.0

0.005

BED70

166.6

114.9

18.2

411.4

65.5

31.1

11.6

126.6

0.003

Dmean

152.3

107.5

35.1

348.6

113.8

82.2

26.7

383.7

0.345

D90

79.7

46.1

11.4

125.9

61.0

47.0

6.3

207.2

0.31

D70

114.2

72.1

17.7

216.3

84.5

63.3

11.4

286.4

0.29

213.5

187.4

37.9

596.3

148.3

138.6

27.9

639.5

0.356

BED90

92.2

55.3

11.5

149.9

69.9

31.2

6.4

272.6

0.321

BED70

141.0

96.8

18.2

287.5

101.2

91.2

11.6

411.4

0.296

Dmean

152.7

114.9

35.1

348.6

115.0

80.9

26.7

383.7

0.407

D90

77.1

48.5

11.4

125.9

62.4

46.8

6.3

207.2

0.463

112.8

76.9

17.7

216.3

85.9

62.6

11.4

286.4

0.384

217.1

200.0

38.0

596.3

149.6

136.3

27.9

639.5

0.392

BED90

89.2

52.8

11.5

149.9

71.5

60.8

6.4

272.6

0.468

BED70

140.1

103.4

18.2

287.5

102.8

90.0

11.6

411.4

0.376

BED90

BEDmean

D70
BEDmean

WHO

BEDmean

RECIST

D70

mRECIST

mean
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Table 21. Summary of the dosimetric quantity responder and non-responder
distributions and the corresponding p-value of t-test between the two
distributions for mRECIST, WHO, and RECIST response criteria.

6.3.2 Logistic Regression
The summary of the logistic regression is listed in Table 22. The odds ratios for
all regressions were greater than unity, indicating that a unit increase of the dosimetric
quantity results in an increase of the odds by a constant factor, but statistical
significance was only found for mRECIST response criteria.
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97.5% Odds Ratio

Wald p-value

Likelihood ratio p-value

2.5% Odds Ratio

1.026

1.009

1.053

0.019

<0.001

D90

1.031

1.011

1.060

0.009

0.001

1.029

1.011

1.058

0.013

<0.001

1.019

1.006

1.040

0.025

<0.001

BED90

1.027

1.009

1.051

0.010

0.001

BED70

1.023

1.008

1.047

0.017

<0.001

Dmean

1.005

0.996

1.013

0.266

0.271

D90

1.008

0.992

1.025

0.302

0.303

1.006

0.995

1.018

0.246

0.248

BEDmean

1.003

0.998

1.007

0.272

0.279

BED90

1.006

0.993

1.019

0.335

0.339

BED70

1.004

0.996

1.012

0.272

0.276

Dmean

1.004

0.996

1.013

0.295

0.304

D90

1.006

0.990

1.023

0.434

0.439

1.006

0.994

1.018

0.309

0.316

1.003

0.998

1.007

0.275

0.286

BED90

1.005

0.991

1.018

0.461

0.468

BED70

1.004

0.996

1.012

0.322

0.330

D70

D70
BEDmean

mRECIST
WHO

BEDmean

RECIST

D70

Response criteria

Odds Ratio

Dosimetric quantity
Dmean
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Table 22. Summary of logistic regressions for predicting response criteria from
dosimetric quantities.
The logistic regression fits with corresponding 95% confidence intervals are
plotted in Figure 31. Plots with WHO criteria were omitted because they are similar to
the RECIST plots shown. The other coverage metrics were not shown because they
are also similar to the mean plots shown. To achieve a 50% chance of mRECIST
response, the mean absorbed dose is 115 Gy, while the mean BED is 175 Gy. The
probability of a 50% chance of RECIST response doesn’t change much over the range
of mean absorbed dose or mean BED, and this is consistent with not finding statistically
significant regressions as determined by the likelihood ratio.
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Figure 31. Logistic Regressions for the mean absorbed dose (a) & (b) and mean
BED (c) & (d) for mRECIST response criteria (a) & (c) and RECIST (b) & (d). The
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dashed line represents the fit from the regression. The shaded area represents
the 95% confidence interval. Responders are jittered as points near the top of the
plots, while non-responders are near the bottom. Both RECIST and WHO did not
have statistically significant regressions with dosimetric quantities investigated.
6.3.3 Receiver Operating Curve
Table 23 summarizes the ROC analysis performed. Excluding the threshold
values, ROC results for the mean absorbed dose, D90, and D70 are match the
corresponding BED quantities well. Using the dosimetric quantities with mRECIST,
specificity approaches 100% while the sensitivity is approximately 70% for the
thresholds chosen. The AUC for mRECIST is higher than both WHO and RECIST. The
AUC for WHO and RECIST were very similar. Figure 32 shows the ROC curves,
including thresholds, for the same quantities depicted in Figure 31.
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“best”Threshold (Gy)

Threshold specificity

Threshold sensitivity

130.2

100.0

68.8

76.0

58.1

93.8

92.1

100.0

56.3

80.3

63.7

96.9

88.1

89.5

68.8

80.9

63.9

98.0

159.1

100.0

68.8

76.0

58.1

93.8

105.0

100.0

56.3

80.3

63.7

96.9

99.8

89.5

68.8

62.7

36.2

89.2

135.9

82.1

66.7

63.5

36.3

90.6

100.6

89.3

66.7

63.9

36.9

90.9

124.2

89.3

66.7

62.3

35.5

89.1

166.9

82.1

66.7

63.5

36.3

90.6

115.9

89.3

66.7

63.9

36.9

90.9

147.6

89.3

66.7

59.1

30.3

87.8

135.9

79.3

62.5

60.3

30.7

90.0

101.5

89.7

62.5

60.8

31.2

90.3

125.5

89.7

62.5

58.6

29.5

87.7

166.9

79.3

62.5

60.3

30.7

90.0

117.2

89.7

62.5

60.8

31.2

90.3

149.4

89.7

62.5

97.5% AUC
98.0

2.5% AUC
63.9

AUC

Response criteria

Dosimetric quantity

80.9

D90
D70
BEDmean

mRECIST

Dmean

BED90
BED70
Dmean

D70

WHO

D90

BEDmean
BED90
BED70
Dmean

D70
BEDmean

RECIST

D90

BED90
BED70
Table 23. Summary of ROC analysis for the response and dosimetric quantities
investigated.
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Figure 32. ROC curves for the mean absorbed dose (a) & (b) and mean BED (c) &
(d) for mRECIST response criteria (a) & (c) and RECIST (b) & (d). The solid line
represent the ROC. The shaded region represents the 95% confidence interval
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for the ROC. The area under the curve is indicated on the plots, and the “best”
threshold is circled with corresponding specificity and sensitivity. Both RECIST
and WHO shapes were similar with large confidence intervals.

6.4 Discussion
In this retrospective study we have compiled data showing that disease specific
response criteria mRECIST can be used to separate responders and non-responders
according to voxel-level absorbed doses or biological effective doses. This is not
entirely surprising given that mRECIST, relative to WHO and RECIST, has shown
better correlation with overall survival and progression-free survival in HCC patients
treated with transarterial chemoembolization197–201. Thus, the fact that statistically
significant correlations of absorbed dose with mRECIST were found is encouraging,
because from basic radiobiology we expect the probability of tumor response to
increase as the absorbed dose increases. More specifically, this is one of the first
works to generate absorbed dose-response curves for HCC treated with glass spheres
using post-therapy 90Y bremsstrahlung SPECT/CT. The majority of the response
literature to date has been performed using the planned

99mTc

MAA

SPECT/CT150,152,155,156,161.
Emission image quality, primarily driven by spatial resolution, patient motion
near the liver dome, and imperfect scatter corrections, is currently the limiting factor in
voxel-level dosimetry. Due to such limitations, it is unlikely that a voxel-level absorbed
dose calculated on a post-therapy SPECT or PET would equal a pre-therapy voxel157

level absorbed dose. Although image quality will continue to improve, in the interim the
community needs to further investigate and determine appropriate methods for
mapping voxel-level dosimetric quantities between bremsstrahlung, PET, and MAA
99mTc.

The dose response curves generated in this work are likely specific to our posttherapy imaging protocol due to the image quality limitations. However, such curves
may still be very useful to clinicians and patients. Given that the current clinical
standard of practice requires prescribing based on rudimentary package insert
dosimetry models, the use of post-therapy dosimetry with prediction of tumor response
may be beneficial to a select number of patients and change their management. For
example, if a tumor is judged not likely to respond then an additional therapeutic
procedure could be suggested or performed. Furthermore, in the context of valuebased medicine, predicted response probabilities based on post-therapy imaging could
be used as a quality metric.
The distribution of responders ( jitter points near top of the plots in Figure 31)
and distribution of non-responders (jitter points near bottom of the plots in Figure 31)
aren’t that different between mRECIST and RECIST; the only noticeable difference is a
few non-responders with large mean absorbed dose or BED compared to mRECIST.
Given that tabulated data were trending towards RECIST and WHO being predictive or
response, it is possible that a larger sample size will demonstrate statistical
significance. It is encouraging for mRECIST response criteria that the higher absorbed
doses were assigned as responders taking into consideration that larger absorbed
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doses should provide more tumor cell killing which can lead to necrosis with the
breakdown of peripheral vasculature.
In addition to the dose-response curves, the ROC analysis in this work was
performed to investigate how well (specificity, sensitivity) various thresholds separate
responders from non-responders for a given dosimetric quantity. The corresponding
AUC values can be useful in determining the dosimetric quantity that best discriminates
between responder and non-responder. There is no discernible difference between
using an absorbed dose metric or a biological effective dose metric for gauging any of
the response criteria. In other words, it doesn’t appear that biological effective dose has
an advantage for predicting mRECIST, WHO, or RECIST relative to physical absorbed
dose. However, the BED may be prove to be more useful in fractionated
administrations, combinations of radiotherapy161, or comparing external beam with 90Y
microsphere therapy.
This was a retrospective study based on a limited sample size. Future work
should increase the number of patients and tumors evaluated. Only univariate
regressions were performed, but there is additional information (demographics,
pathology, functional imaging, etc.) that may be incorporated to create an improved
response model.
6.5 Conclusion
Both absorbed dose and biological effective dosimetric quantities were able to predict
mRECIST response. Dose response curves were generated for HCC tumors. These
curves are likely specific to our institution and imaging protocol. Thus future work
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should increase the number of tumors and test the robustness of the dose response
curves.
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Chapter 7: Discussion
7.1 Summary
This work had two main goals: 1) to demonstrate that a deterministic grid-based
Boltzmann solver (GBBS) can be used for voxel-level absorbed dose calculations with
accuracy comparable to Monte Carlo (MC) and 2) to assess the value of voxel-level
absorbed dose calculations for 90Y microsphere patients.

The first goal was tested using specific aims one (Chapter 2) and two (Chapter
3). Specific aim one matched scoring geometry (voxels) between the GBBS and MC in
soft-tissue, lung, and bone. Classic voxel-S-value geometry was extended to interface
geometry where absorbed dose differences were comparable to those in uniform
media, which were approximately 6% between GBBS and Monte Carlo for

90Y

and 131I.

Specific aim 2 showed that the use of adaptive tetrahedral meshing, decreasing
angular quadrature order, and increasing electron energy transport cuts for the GBBS
on 90Y microsphere and 131I patient SPECT/CT’s enabled fast (<10 minutes) and
accurate (mean absorbed doses within 5% of MC and cumulative GBBS DVHs overlaid
MC DVHs) absorbed dose calculations on a desktop computer. Adaptive meshing was
necessary to reduce the GBBS’s memory requirements, as using ≥ 6 tetrahedrons per
voxel throughout the entire scan led to unacceptable memory requirements and
computation times.

The clinical value of voxel-level absorbed doses for 90Y microspheres was
investigated in specific aim 3 in Chapters 4, 5, and 6. Chapter 4 quantified differences
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between single compartment MIRD (STD), three compartment partition model MIRD
(PM), and Monte Carlo voxel-level absorbed doses (MC). This was on performed on
post-therapy 90Y bremsstrahlung SPECT/CT using identical volumes of interest as
input to each dosimetry model for each patient. Bootstrapped linear regressions were
performed to empirically quantify bias (slope & intercept) and uncertainty (95%
prediction intervals) in transforming the STD and PM absorbed doses to mean MC
voxel-level absorbed doses. The STD was unable to predict MC tumor doses.
Uncertainties in predicted MC tumor absorbed doses from PM ranged from ± 46 Gy for
single tumor cases with no TNR variability to ± 140 Gy for multiple tumor cases with
TNR variability. Both STD and PM were able to predict non-tumoral liver absorbed
doses with uncertainties in the predicted MC absorbed dose of ± 23 Gy and ± 18 Gy,
respectively. PM TNR variability caused a large change in the bias as indicated by the
slope changing from 0.56 to 0.34 when mapping PM to MC for multiple tumors.

Chapter 5 investigated multiple voxel-level dosimetry methods for 90Y
microsphere therapy. Differences in absorbed doses to tumors, liver, and at the liverlung interface between MC, soft tissue kernel (SK), soft tissue kernel with density
correction (SKD), and local deposition (LD) were reported. SKD, SK, and LD were
within 5% of MC for tumor and non-tumoral liver mean absorbed doses. LD and SKD
overestimated right lung absorbed dose compared to MC on average by 17% and 20%,
respectively. SK underestimated the right lung absorbed dose on average by -60% due
to the assumption of soft tissue density in lung. An interesting result of the study
suggests that the community needs to be very careful about interpreting lung absorbed
doses, which can often limit the amount of administered activity. The absorbed dose to
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lung was sensitive to lung segmentation near the liver-lung interface. Excluding 1, 2,
and 3 cm of the right lung near the liver-lung interface changed the resulting mean right
lung absorbed dose by -22%, -38%, and -48% respectively.

In Chapter 6, an interventional radiologist (AM) segmented multiple
hepatocellular carcinoma (HCC) tumors on post-therapy 90Y bremsstrahlung
SPECT/CT with the aid of a registered diagnostic scan. Tumor response was assessed
using RECIST, WHO, and modified RECIST criteria. Logistic regressions were
performed to generate HCC tumor-response curves as a function of mean MC voxellevel absorbed doses, DVH metrics (D0,D10,…D90,D100), mean MC biological
effective dose (BED), and BED DVH metrics (BEDVH0, BEDVH10,…BEDVH90,
BEDVH100). The results showed that MC mean, BED mean, DVH metrics, and
BEDVH metrics all could be used to predict modified RECIST response. This is an
important contribution because it 1) provides an absorbed dose that can be
transformed into a planning target absorbed dose for a given probability of tumor
response and 2) it provides a mechanism to predict tumor response the day after
therapy, and this enables the physician to prescribed other treatment options if
probability of response is deemed too low.

The hypothesis of this work was a deterministic grid-based Boltzmann solver
can calculate voxel-level absorbed doses for nuclear medicine applications within 5%
of Monte Carlo. Data obtained from the low-level benchmarking in aim 1 do not support
the hypothesis. Differences between the GBBS and MC were slightly outside the 5%
range; they were 6% for 90Y and 131I and slightly larger (7% to 15%) for monoenergetics
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with decreasing energy. To decrease this to within 5%, further investigation of the
energy reaction rate calculated by the cross-section generating code is suggested.
Data obtained from patient calculations in specific aim 2 support the hypothesis with
mean voxel-level absorbed doses agreeing within 5% and differences between dose
volume histograms metrics agreeing within 5%. The value of voxel-level absorbed
doses for 90Y microspheres was demonstrated by 1) highlighting limitations, including
large inherent variability, in current clinical dosimetry models, 2) showing small
differences between voxel-level absorbed dosimetry methods in the liver, and 3)
generating dose response curves for hepatocellular carcinoma tumors.

7.2 Listed Contributions of this Dissertation
7.2.1 Physics Contributions

1) Identification of missing auger and conversion electron emissions in freely available
voxel-S-values.

2) Low-level benchmarking of GBBS in nuclear medicine regime.

3) Methodology for adaptive tetrahedral meshing based on SPECT/CT to enable fast
and accurate GBBS absorbed doses in patients.
7.2.2 Clinical Contributions
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1) Demonstration of large potential differences (factor of 2) between clinical dosimetry
models and voxel-level absorbed doses. The partition model was shown to have large
variability based on single sphere sampling of normal liver for TNR estimation, and the
single compartment model was not predictive of tumor absorbed doses.

2) MC, SKD, SK, and LD were all equivalent in the liver, but large differences can exist
in the lung. Furthermore, we quantified sensitivity of lung absorbed dose to the liverlung interface. Specifically, the mean right lung absorbed dose can changes by up to 48% when excluding 3 cm of the lung near the interface.

3) Absorbed dose response curves were generated for HCC tumors using post-therapy
90Y

bremsstrahlung imaging.

7.3 Future Directions
7.3.1 Opportunities for the GBBS unique to radioembolization and nuclear
medicine
Much value has been added to radiation oncology through the use of more
accurate radiation transport. Furthermore, having the ability to harness accurate
transport in a clinically feasible time frame is important for practical applications. This
will likely also be the case for radioembolization and nuclear medicine.
The main goal of this work was to introduce the GBBS to the nuclear medicine
community. Consequently, there are several optimization opportunities that have not
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been fully or rigorously explored. First, a more rigorous optimization for runtime and
accuracy for each radionuclide can be performed by varying energy group structure
(bin edges, bin widths), energy and spatially dependent angular quadrature order (S N)
and scattering order (PN), and tetrahedral meshing. Second, combining all electron
sources (Auger, conversion electrons, betas) and photon sources (gammas, x-rays)
into a single source compatible with the GBBS should be implemented to improve
calculation times.
Given that the benchmarking study of the GBBS compared to MC showed
absorbed dose differences up to approximately 15% at low energies (10 keV),
investigation of the cross-section generating code ZERKON and CEPXS68 is
warranted. Specifically, the energy reaction rates used to convert scalar flux to
absorbed doses should be studied.
The deterministic GBBS does not have to be used alone. Instead, a hybrid
deterministic-stochastic transport approach can be taken to solve problems. One
example of such a hybrid approach is using the GBBS to generate weight windows for
variance reduction in MC for both absorbed dose calculations and imaging simulations.
This dissertation applied the GBBS to reconstructed patient scans, but the
GBBS can be applied even earlier in the process. Thus, using the GBBS as a forward
projector during reconstruction should enable more accurate scatter estimates and
allow for absorbed dose rate calculations simultaneously because the GBBS solves for
the angular flux throughout space. For example, the GBBS has recently shown such
improvements in scatter modeling when incorporated into cone beam CT
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reconstructions202. In addition, there is much concern over absorbed doses from
diagnostic scans, and returning an absorbed dose map with the reconstructed image
would 1) show physicians and patients their spatial absorbed dose estimates and 2) aid
in the long term study of radiation induced cancers by providing more accurate
absorbed dose maps that can be accumulated over time.
Biological effective doses depend on absorbed dose rate. The GBBS is an
iterative solver, and this may be advantageous with multi-time point data. There is likely
to be some spatial correlation between multiple time points when acquiring emission
scans to determine kinetics for therapeutic procedures. Thus, the GBBS may be used
to calculate absorbed dose rates at the multiple time points using an initial solution
based on the solved angular flux from the previous time point. Such an approach may
yield faster computations for later time points.
Another area of investigation should include the use of the GBBS for pairedtransport techniques to improve modeling of response. The GBBS solves for the
angular flux throughout space. The energy spectra at a given spatial location can be
coupled to a lower-level model. For example, in bone, mapping the spectra to a marrow
source and trabecular bone surface source203,204 may offer some improvements in
modeling hematological toxicities.
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7.3.2 Continued translation of Radiation Oncology methods to radioembolization
and nuclear medicine

The work in this dissertation can be broadly described as translating radiation
oncology methods to 90Y microspheres and nuclear medicine. It makes sense to
generate dose-response curves for both tumor and normal liver with the uncertainty in
concordance between MAA and 90Y scans removed, but providing a useful and
predictive planning tool could benefit patients tremendously. This work only
investigated results from post-therapy bremsstrahlung SPECT/CT. Closing the
feedback loop and producing correlations with treatment planned

99Tc

MAA

SPECT/CTs need to be studied to make a more useful tool for clinicians. Specifically,
absorbed dose response curves generated with post-therapy imaging should be
transformed to the planned absorbed doses based on MAA.
One of the largest uncertainties in radiation oncology is tumor segmentation. It is
likely that such uncertainties will also be important for 90Y microsphere therapies when
implementing an anatomic segmentation on contrast CT or MRI. The sensitivity of
reported absorbed doses to segmentation uncertainties (inter and intra user variability)
needs to investigated. Absorbed dose gradients, compared to external beam, are larger
in 90Y microspheres and nuclear medicine, so the effect may be quite large.
Simple methods from radiation oncology can be applied to 90Y microspheres.
For example, minimizing the time between planning SPECT/CT and administration.
There are logistics involved requiring the ordering of microspheres depending on glass
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or resin. Similar to sealed source LDR brachytherapy, real-time planning and
administration may be possible.
The use of image registration to objectively reproduce catheter tip position
between the MAA and administration of microspheres may increase the concordance
rate of MAA and 90Y distributions. Registration of planned and treatment-day
fluoroscopic images or cone beam CT may be aided by implanting a radiopaque
fiducial in the hepatic artery during planning.
Current SPECT and PET image acquisitions are 20 minutes to 1 h in duration.
This means there is 1) anatomic mismatch between the single time point CT used in
the iterative reconstructions, and 2) the activity concentration is blurred out in the liverlung interface dependent on the magnitude of the motion. Being able to deconvolve this
motion blurring will help provide more accurate quantitative inputs. Applying respiratory
management techniques (4DCT, cineCT, etc) from Radiation Oncology to SPECT and
PET acquisitions should be investigated.
Voxel-level absorbed doses from either 90Y microspheres or therapeutic nuclear
medicine procedures may allow for combinations with external beam or sealed source
brachytherapy from radiation oncology. Generating biological effective doses and
corresponding equivalent absorbed dose in 2 Gy per fraction for tumors and normal
liver will aid in implementing such a method. In such a treatment combination, the
microspheres can be administered and then post-therapy imaging can be used to
determine if tumors were undertreated or had a low probability of response. Given this
information, a boost from radiation oncology can be planned. In theory, this is possible
because the 90Y therapy has 1) decreased the effective target size and 2) decreased
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the amount of absorbed dose that needs to be delivered. Investigating the feasibility of
this approach needs to be studied.
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Appendix
A1: Estimating the in-vivo accuracy of local deposition approximation and Monte
Carlo for 90Y absorbed dose calculations in tissue as a function of voxel size
and spatial resolution.

A1.1 Introduction
In the current state of emission imaging for both PET and SPECT, several
authors have shown that the complete local deposition (LD) of energy in the voxel
divided by the mass of the voxel is an excellent approximation to Monte Carlo (MC)
absorbed doses in the liver or soft-tissue. The accuracy of the approximation will
depend on 1) the voxel size, with smaller voxel sizes allowing more betas from the 90Y
to escape, and 2) the spatial resolution used to image the in-vivo activity distribution,
which “transports” activity outside the source voxel also known as partial volume effect.
In uniform distributions, voxels that are more than 1.28 × FWHM from an edge will be in
equilibrium and not suffer from partial volume or misplacing of the activity.
A1.2 Methods & Materials
For the 1, 2, 4, 8, 16, 32, and 64 mm voxel sizes we performed the following steps:
1) A blank activity volume was generated matching the voxel size selected
2) 90Y was uniformly distributed in the central voxel
3) DOSXYZnrc MC simulation was performed in soft tissue and the resulting absorbed
dose in the source voxel was taken as the true absorbed dose (MC_0).
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4) Local Deposition was calculated in the source voxel (LD_0).
5) For 1, 2, 5, 10, and 20 mm FWHM the following was performed:
5a) Apply a Gaussian blur with FWHM to the activity distribution in 2 above to
generate a blurred distribution.
5b) Perform MC simulation and record absorbed dose in source voxel on the
blurred distribution to obtain MC_FWHM.
5c) Calculate LD using the blurred distribution to obtain LD_FWHM

Percent difference curves were then plotted by calculating:

100 ×

(𝑋−𝑀𝐶_0)
𝑀𝐶_0

where X=LD_FWHM or MC_FWHM.
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A1.3 Results

The percent difference curve is plotted in Figure 33. For large spatial resolutions
LD and MC track each other very closely over all voxel sizes investigated. The
difference between LD and MC becomes more pronounced at smaller voxel sizes and
smaller FHWM. LD eventually overestimates the absorbed dose by 40% for 8 mm
voxels with a 1 mm FWHM, the error becomes even more positive for smaller voxel
sizes. For clinical PET imaging, perhaps a voxel size of 2 mm is used with a FWHM of
5 mm. In this regime, errors are dominated by the spatial resolution. LD_5 does
marginally improve the agreement from -90% to -80%. Results are similar for MAA
SPECT imaging with a voxel size of 4 mm and FWHM of 10 mm. It is important to note
that this analysis is only for the source voxel in a single unrealistic geometry.
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Figure 33. Absolute percent differences from the truth for local deposition (solid
curves) and MC (dashed) are plotted for multiple spatial resolutions (FWHM=1
mm (green), 5 mm (red), 10 mm (orange), and 20 mm (purple)). The percent
difference for each calculation is relative to the corresponding voxel size MC
simulation with no spatial blurring. MC_0 is not shown because it is the truth.
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A2: Explanation for the rationale, implementation strategy, and interpretation of
logistic regression parameters for dose-response curve.
In Chapter 6 of this dissertation, I used univariate logistic regression to predict
HCC tumor response (1=response, 0=no response) as a function of an individual
dosimetric quantity (mean absorbed dose (D), D70, D90, mean BED, BED70, BED90)
associated with the tumor. Linear regression would be the simplest first choice for
predicting the response, and the linear regression of mRECIST response as a function
of mean D is shown below in Figure 34.

Figure 34. Linear regression of mRECIST tumor response as a function of mean
tumor absorbed dose. Notice how the line does not fit the tumor response data
well. In addition, the line continues to +/- infinity whereas the response is
bounded between 0 (non-responder) and 1 (responder).
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Linear regression is intended for predicting a continuous dependent variable,
and not a discrete (binary in this case) dependent variable. If we now bin the data to
estimate the probability of response (R/(NR+R)) in each bin and perform a linear
regression of the probability of response as a function of mean D at the center of each
bin (Figure 35), then the corresponding linear regression will be more appropriate
because we are now predicting a continuous variable (probability of response). The
slope from the resulting linear regression shows that a unit increase in mean D causes
a constant increase of the probability of response. However, the predicted probability
still goes beyond the accepted limits of 0 and 1. An additional limitation of this
approach is a binning scheme must be employed and the corresponding estimated
probabilities may be sensitive to the binning.

Figure 35. Linear regression of the binned (5 bins) probability of mRECIST tumor
response as a function of mean tumor absorbed dose. Unfortunately, using
linear regression still causes the predicted probability to extend beyond 0 and 1;
the selection and sensitivity of bin edges to determine the fraction of responders
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is also problematic. Notice how the linear fit performs better on the probability of
response from binned data compared to the pure binary response data shown in
Figure 34.

There are several functions that follow a sigmoidal shape and can be used to
model response including Poisson, logistic, and probit195. In this work, I employed the
logistic function, shown below, which has the following properties:
𝑒𝑥
1
𝑝(𝑥) =
=
1 + 𝑒 𝑥 1 + 𝑒 −𝑥
1) lim 𝑝(𝑥) = 1
𝑥→+∞

2) lim 𝑝(𝑥) = 0
𝑥→−∞

3) 𝑝(𝑥) 𝜖 [0,1] ∀ 𝑥 𝜖 (−∞, +∞)
When modeling a binary response probability as a function of continuous
variable, the logistic function transforms/maps the continuous input variable, x, to a
continuous probability that ranges from 0 to 1. Notice how using the logistic function
solves the issue encountered with linear regression of binned probabilities:
mapped/transformed probabilities no longer go below 0 or above 1.
The next step is to find the coefficients (𝛽0 , 𝛽1 ) that make the pairs of mean D
and response the most likely to have occurred. This is done through maximum
likelihood estimation. The maximum likelihood estimation provides values of 𝛽0 and 𝛽1
given the pairs of data, and the resulting logistic function is shown below:

𝑝(𝑑) =

1
1 + 𝑒 −(β0 +𝛽1 𝑑)
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Regarding interpretation of the 𝛽0 and 𝛽1 obtained from maximum likelihood
𝛽

estimation, we start with the realization that the absorbed dose given by − 𝛽0
1

corresponds to a 50% probability of response.

𝑝 (−

𝛽0
)=
𝛽1

1
1+

𝛽
−(β +𝛽 ⋅− 0 )
𝑒 0 1 𝛽1

=

1
= 0.5
1 + 𝑒0

Next, I derive the odds, log odds, and their corresponding ratios starting from the
logistic function:
𝑝(𝑑) =

1
1+

𝑒 −(β0 +𝛽1 𝑑)

(1 + 𝑒 −(β0 +𝛽1 𝑑) ) × 𝑝(𝑑) = 1
(𝑒 −(β0 +𝛽1𝑑) ) × 𝑝(𝑑) = 1 − 𝑝(𝑑)
𝑒 −(β0 +𝛽1 𝑑) =
𝑒 (β0 +𝛽1𝑑) = 𝑒 𝛽0 𝑒 𝛽1 𝑑 =

1 − 𝑝(𝑑)
𝑝(𝑑)

𝑝(𝑑)
= 𝑂𝐷𝐷𝑆(𝑑)
1 − 𝑝(𝑑)

This last equation represents the odds: the ratio of the probability of response (𝑝(𝑑)) to
the probability of no response (1 − 𝑝(𝑑)). The log odds is calculated by taking the
logarithm of both sides:

𝛽0 + 𝛽1 𝑑 = ln (

𝑝(𝑑)
) = ln(𝑂𝐷𝐷𝑆(𝑑))
1 − 𝑝(𝑑)

To get to the log odds ratio, I start with the difference between the log odds at d+1 and
the log odds at d, and then show the interpretation for 𝛽1:
(𝛽0 + 𝛽1 (𝑑 + 1)) − (𝛽0 + 𝛽1 𝑑) = ln(𝑂𝐷𝐷𝑆(𝑑 + 1)) − ln(𝑂𝐷𝐷𝑆(𝑑))
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ln(𝑂𝐷𝐷𝑆(𝑑)) + 𝛽1 = ln(𝑂𝐷𝐷𝑆(𝑑 + 1))
𝛽1 = ln (

𝑂𝐷𝐷𝑆(𝑑 + 1)
)
𝑂𝐷𝐷𝑆(𝑑)

This expression shows that the coefficient, 𝛽1 , from the logistic regression is equal to
𝑝(𝑑+1)

𝑝(𝑑)

the log of the ratio of the odds at d+1, 1−𝑝(𝑑+1), to the odds at d, 1−𝑝(𝑑). This is known as
the log odds ratio. The equation preceding it shows that increasing the dose by a single
unit, regardless of the dose level, changes the log odds by a constant, 𝛽1.
Exponentiating each side of the equation yields:

𝑒 𝛽1 =

𝑂𝐷𝐷𝑆(𝑑 + 1)
𝑂𝐷𝐷𝑆(𝑑)

𝑂𝐷𝐷𝑆(𝑑) ⋅ 𝑒 𝛽1 = 𝑂𝐷𝐷𝑆(𝑑 + 1)

The factor 𝑒 𝛽1 represents the odds ratio which is the ratio of the odds at d+1 to
the odds at d. Thus, for a single unit increase of d, irrespective of the current dose
level, the odds at d+1 will differ from the odds at d by the constant factor 𝑒 𝛽1 .
In the dose response literature195, dose corresponding to 50% response and a measure
of steepness of the curve is often reported. I previously showed the absorbed dose
𝛽

corresponding to 50% chance of response was (𝑑50% = − 𝛽0). Now, I derive the
1

maximum slope of the regression.

𝑝(𝑑) =

1
1+

𝑒 −(β0 +𝛽1 𝑑)

𝛽1 ⋅ 𝑒 −(𝛽0 +𝛽1 𝑑)
𝑝′(𝑑) =
(1 + 𝑒 −(β0 +𝛽1𝑑) )2
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𝑝′′(𝑑) =

−𝛽12 ⋅ 𝑒 −(𝛽0 +𝛽1 𝑑)
[1 − 𝑒 −(𝛽0 +𝛽1 𝑑) ]
(1 + 𝑒 −(β0 +𝛽1 𝑑) )3

𝑝′′ (𝑑) = 0 → [1 − 𝑒 −(𝛽0 +𝛽1𝑑) ] = 0
𝑒 −(𝛽0 +𝛽1𝑑) = 1
𝑑=−

𝛽0
𝛽1

𝛽

The slope is maximum at 𝑑 = 𝑑50% = − 𝛽0, and it has a value of
1

𝛽1
4

. The normalized

dose-response gradient, 𝛾 = 𝑑 ⋅ 𝑝′(𝑑), is used frequently in the response literature194,195
to represent the steepness of the curve. It is the product of slope and dose, and it
represents the increase in response given a 1% increase in dose194,195. At 𝑑50% ,
𝛽

𝛾50% = 𝑑50% ⋅ 𝑝′ (𝑑50% ) = − 𝛽0 ⋅
1

𝛽1
4

=−

𝛽0
4

.

Now, we can recast the logistic function in terms of 𝑑50% and 𝛾50%.

𝑝(𝑑) =

1
1 + 𝑒 −(β0 +𝛽1 𝑑)
1

𝑝(𝑑) =
1+𝑒

𝛽
−𝛽0 (1+ 1 ⋅𝑑)
𝛽0

1

𝑝(𝑑) =
1+𝑒

−𝛽0 (1−

𝑑
)
𝑑50%

1

𝑝(𝑑) =
1+𝑒

4𝛾50% (1−

𝑑
)
𝑑50%

This parameterization described by Bentzen and Tucker195 for the logistic regression
coefficients (𝛽0 , 𝛽1) yields a more intuitive interpretation. 𝑑50% represents the absorbed
dose level for a 50% chance of response, and 𝛾50% describes the steepness of the
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response curve at 𝑑50% . Thus, 𝑑50% shifts the curve left and right, while 𝛾50% controls
how quickly it changes from non-responder to responder; the influence of these
parameters is shown in Figure 36.

Figure 36. Example logistic functions that have been parameterized by different
values of 𝒅𝟓𝟎% and 𝜸𝟓𝟎% ; solid (𝒅𝟓𝟎% = 200 Gy, 𝜸𝟓𝟎% = 4), dashed (𝒅𝟓𝟎% = 200 Gy,
𝜸𝟓𝟎% = 1), dotted (𝒅𝟓𝟎% = 100 Gy, 𝜸𝟓𝟎% = 4), dot-dash (𝒅𝟓𝟎% = 100 Gy, 𝜸𝟓𝟎% = 1).
Notice how 𝒅𝟓𝟎% controls the inflection point location of the sigmoidal curve
while 𝜸𝟓𝟎% controls the steepness, or how rapidly it changes from 0 to 1.

Figure 37 below shows the dose-response curve for mean absorbed obtained through
logistic regression. Notice how the probabilities are between 0 and 1, and the
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parameterization of 𝛽0 and 𝛽1 as 𝑑50% and 𝛾50% are more intuitive for interpreting the
curve.

Figure 37. The logistic regression for predicting mRECIST given the mean
absorbed dose. 𝜷𝟎 = −𝟑. 𝟎𝟏 [−𝟓. 𝟕𝟖, −𝟏. 𝟏𝟎], 𝜷𝟏 = 𝟎. 𝟎𝟐𝟓𝟔 [𝟎. 𝟎𝟎𝟗, 𝟎. 𝟎𝟓𝟏] yields
𝒅𝟓𝟎% = 𝟏𝟏𝟖 𝑮𝒚 and a normalized dose-response gradient of 𝜸𝟓𝟎% = 𝟎. 𝟕𝟓.
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Appendix A3: Steps to validate dose-response curve
In a retrospective analysis of HCC tumors treated with

90Y

glass microspheres, I

generated a dose-response curve shown in Figure 38. How would one go about
validating this curve? I list an outline of validation steps below and go into more detail
on increasing the sample size after the list. The remainder of items on the list are for
future study and are provided as one potential path for validating the

90Y

dose

response curve.
1) reduce 95% confidence interval on logistic regression by increasing sample size
2) obtain an independent data set to
-validate that a logistic regression using independent data is not statistically
significant from the original regression
-estimate the true predictive accuracy of the original logistic regression
3) test robustness of acquiring the input data
-sensitivity of dosimetric quantity (e.g. mean absorbed dose)
- to segmentation of tumors (inter/intra observer variability)
- to dose calculation method
-assessing response
-inter/intra observer variability
- contrast CT vs MRI
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-90Y SPECT/CT acquisition and reconstruction parameters
-90Y SPECT/CTvs 90Y PET/CT
- minimum tumor size included in study (confounding variables e.g. volume)
- liver and tumor motion due to respiration
4) investigate subsets of patient data, as current patient demographics may be quite
heterogeneous
- cirrhotic vs non-cirrhotic livers
- liver disease stage
-prior therapy
5) To exclude selection bias that is common in a retrospective study, prospectively use
the dose-response curve to assess its prediction accuracy.
6) Perform a two arm prospective clinical trial where patients are randomly assigned to
an additional treatment or control group. Treatment Arm: use the dose-response curve
to administer additional activity to boost tumors that are classified as non-responders,
Control arm: no additional activity is administered. Compare the tumor response rates
between the two arms, with the hope that the treatment arm response rate will be
statistically significantly higher than the control arm.
7) Using biological effective doses compare the dose response curve for HCC obtained
from 90Y post-therapy imaging to one from external beam.
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8) Generate dose-response curves using the planning image from

99mTc

MAA

SPECT/CT and derive a transformation based on physical parameters (spatial
resolution, scatter, etc.) of the MAA absorbed dose to the 90Y SPECT/CT absorbed
dose. If the dose-response is real and you investigate a subset of patients with
concordant MAA and 90Y scans under the assumption that MAA is reliable surrogate for
microspheres, then a transformation based on physical parameters should exist
between the plan and post-therapy scan.
__________________________________________________________________

Notice that the 95% confidence interval is still quite large given our current data,
so the first step would entail reducing that interval. This will be accomplished by
increasing the sample size, which is currently N=35.

Figure 38. Statistically significant linear regression of modified RECIST criteria
as a function of mean absorbed dose.
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To estimate the sample size needed to reduce the 95% confidence interval, I
perform simulations that randomly draw from simulated responder and non-responder
absorbed dose distributions based on my current distributions. From the current data,
responders have a mean of 178 Gy and standard deviation of 110 Gy, while nonresponders have a mean of 80 Gy and standard deviation of 29 Gy. In addition, 45% of
the data are responders and 55% are non-responders.
When I generate a sample, 45% of the time I will select a responder from
Normal(178, 80) and 55% of the time I will select a responder from Normal(80, 29). I
will simulate 20, 40, 100, and 1000 samples and apply the logistic regression to the
resulting data (Figure 39). From the resulting logistic regressions I calculate 𝑑50% =
−𝛽0 /𝛽1 and 𝛾50% = −𝛽0 /4 as described by Bentzen and Tucker.195 I then propagate
the standard errors on 𝛽0 and 𝛽1, through to estimate standard errors for both 𝑑50% and
𝛾50% (Table 24). An alternative to propagating standard errors would have been to
perform thousands of simulations with the same number of samples and estimate
standard errors from histograms of the quantities of interest (𝛽0 , 𝛽1 , 𝑑50% , 𝛾50%).

2

𝑠𝑒(𝛽0 )
𝛽0
𝑠𝑒(𝑑50% ) = √(
) + ( 2 ⋅ 𝑠𝑒(𝛽1 ))
𝛽1
𝛽1

2

𝑠𝑒(𝛽0 )
𝑠𝑒(𝛾50% ) = √(
)
4
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2

Our data shows that a 𝑑50% around 120 Gy is likely. Decreasing the uncertainty,
(standard error), in this value will be important, as currently it is on the order of 50 Gy
which is approximately 40%. Applying clinical intuition, an uncertainty on the order of
10 Gy in mean absorbed dose using voxel-level dosimetry on post-therapy imaging
would seem reasonable and correspond to just under 8% relative uncertainty. Thus, a
future study would require approximately 1000 tumors according to the simulations
studies.

187

Figure 39. Illustration showing how increasing the sample size will decrease the
95% confidence interval in our fit. Clockwise from upper left N=20, 40, 100, and
1000. All data were simulated as described previously.

𝜷𝟎 ± 𝒔𝒆(𝜷𝟎 ) 𝜷𝟏 ± 𝒔𝒆(𝜷𝟏 ) 𝒅𝟓𝟎% ± 𝒔𝒆(𝒅𝟓𝟎% )

N

𝜸𝟓𝟎% ± 𝒔𝒆(𝜸𝟓𝟎% )

20

-8.17 ± 3.53

0.060 ± 0.028

136 ± 87 Gy

2.04 ± 0.88

40

-3.82 ± 1.21

0.034 ± 0.011

113 ± 51 Gy

0.955 ± 0.303

100

-4.24 ±0.79

0.032 ± 0.006

134 ± 37 Gy

1.059 ± 0.198

1000

-3.85 ±0.24

0.031 ± 0.002

124 ± 11 Gy

0.962 ± 0.059

Table 24. Data showing how varying the number of samples affects the standard
errors on the coefficients and the corresponding 𝒅𝟓𝟎% and 𝜸𝟓𝟎% . All data in this
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table were based on simulations described earlier. Notice that to obtain a
standard error of 11 Gy for 𝒅𝟓𝟎% will require the analysis of 1000 tumors.
The clinical goal of generating a dose-response curve is to predict whether a
tumor will respond or not respond. Thus, we can use the 𝑑50% , or any other operating
point we wish, to classify individual tumors as responders or non-responders. For
example, if the mean absorbed dose to a tumor is above 𝑑50% , then we classify it as a
responder. For the N=35 tumors, using 𝑑50% = 118 Gy as a threshold, we classify
responders correctly 83% (29/35) of the time. Of course, this is based on the data
used to generate the curve and will suffer from overfitting, so we expect the
classification rate to decrease, hopefully not by much, when using an independent
dataset.
Using an independent data set we can 1) validate that the dose-response curve
doesn’t change significantly from our current parameters and 2) estimate the true
prediction accuracy.
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